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LIST OF ABBREVIATIONS
ACT actinomycin D
ADAM a disintegrin and metalloproteinase
ANOVA analysis of variance
APPBP2 amyloid beta precursor protein (cytoplasmic tail)
binding protein 2
AR androgen receptor
AUC area under the curve
B2M β-2-microglobulin
BCIP 5-bromo-4-chloro-3-indolyl phosphate
BLAST basic local alignment search tool
BRCA1 breast cancer 1
BRCA2 breast cancer 2
CA cancer antigen
CCNE1 cyclin E1
CCNE2 cyclin E2
CDC42EP4 cell-division cycle 42 effector protein 4
CDK2 cyclin-dependent kinase-2
cDNA copy DNA
CEA carcinoembryonic antigen 
CGH comparative genomic hybridization
CHX cycloheximide
CI confidence interval
CIT colloidal intraductal tumors
CMF cyclophosphamide, methotrexate, 5-fluorouracil
COL1A1 collagen type I alpha 1 
CR complete remission
CRC colorectal cancer
Ct cycle threshold
c.v. coefficient of variation
DCIS ductal carcinoma in situ
DFS disease-free survival
DM distant metastasis
DMFS distant metastasis-free survival
DNA deoxyribonucleic acid
dsDNA double-stranded DNA
DTF desmoid-type fibromatosis
E2 estradiol
E2IG5 E2 induced gene 5
ECM extracellular matrix
EDTA ethylenediaminetetraacetic acid
EGF epidermal growth factor
EIF1 eukaryotic translation initiation factor 1
ELISA, enzyme-linked immunosorbent assay
EMMPRIN extracellular MMP-inducer
ER estrogen receptor
ERBB2 Her-2/neu; erythroblastic leukemia viral
oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog (avian)
ER-α estrogen receptor alpha
ESR1 estrogen receptor 1 (formerly ER-α) gene
ETS c-ets proto-oncogene transcription factor
EZH1 enhancer of zeste (Drosophila) homolog 1
FDA federal drug administration 
FDR false discovery rate 
FFPE formalin-fixed paraffin-embedded
FGF fibroblast growth factor
FISH fluorescence in situ hybridisation
FMNL formin-like
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GGI genomic grade index 
GOBP gene ontology biological process
GRB7 growth factor receptor-bound protein 7 
HE hematoxylin and eosin
HGF hepatocyte growth factor
HK housekeeper
HMBS hydroxymethylbilane synthase (formerly
porphobilinogen deaminase, PBGD)
HOXB13 homeobox B13
HPRT hypoxanthine-guanine phospho-
ribosyltransferase
HR hazard ratio
HRP horseradish peroxidase
HSPG heparan sulphate proteoglycans
IBC inflammatory breast cancer
IDC invasive/infiltrating ductal carcinoma
IGF insulin-like growth factor
IGFBP insulin-like growth factor binding protein
IL17RB interleukin 17 receptor B
ILC infiltrating/invasive lobular cancer
LCIS lobular carcinoma in situ
LMW low molecular weight
LNN lymph node-negative
LNP lymph node-positive
LOE level of evidence 
LRR local-regional relapse
MC medullary carcinomas 
MEC medical ethics committee
MFS metastasis-free survival
MMP matrix metalloproteinase
mRNA messenger RNA
N normal-tissue-derived
NAT9 N-acetyltransferase 9
NBT nitrotetrazolium blue  
NC no change
NCBI national center for biotechnology information
NIH national institute of health 
NPI Nottingham prognostic index 
NR1D1 nuclear receptor subfamily 1, group D,
member 1
OR odds ratio
OS overall survival
p53 tumor suppressor oncoprotein 53
PA plasminogen activator
PAI plasminogen activator inhibitor
PAI-1 plasminogen activator inhibitor 1 
PBGD porphobilinogen deaminase
PBS phosphate buffered saline
PCR polymerase chain reaction
PD progressive disease 
PFM protein- and serum-free medium
PFS progression free survival
PGR progesterone receptor (formerly PgR) gene
PgR progesterone receptor
PR partial remission
PRS post-relapse survival
ps primer set
qPCR quantitative polymerase chain reaction
qRT-PCR quantitative reverse transcriptase polymerase
chain reaction 
RBC recurrent breast cancer
RNA ribonucleic acid 
ROC receiver operating characteristic
rs Spearman rank correlation
RT reverse transcriptase
RT-PCR reverse transcriptase polymerase chain reaction 
SAM significance analysis of microarrays 
SA-β-gal senescence associated β-galactosidase
SD stable disease
SDS sodium dodecyl sulfate
SEER surveillance, epidemiology, and end results 
SFT solitary fibrous tumors 
SMA smooth muscle actin
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SSC sodium chloride / sodium citrate
Strept ABC streptavidin-biotin-peroxidase complex
s-uPAR soluble urokinase plasminogen activator
receptor
T tumor-tissue-derived
TBP tributyl phosphine
TC epithelial tumor cell nuclei
TERC telomerase RNA component
TERT reverse transcriptase enzyme telomerase 
TGF-β transforming growth factor β
TIMP tissue inhibitor of metalloproteinases
TIMP-1 tissue inhibitor of metalloproteinases-1
TIMP1 TIMP metallopeptidase inhibitor 1 gene
TIMP1-v1 TIMP1 full-length variant gene
TIMP1-v2 TIMP1 variant lacking exon 2 gene
TMUGS tumor marker utility grading system 
TNM tumor node metastases 
TNP trinitrophenyl hapten
tPA tissue-type plasminogen activator
TRAP telomerase repeat amplification
TRF2 telomere repeat binding factor 2
TSP-1 thrombospondin 1
UICC union internationale contre le cancer
uPA urokinase plasminogen activator
uPAR urokinase plasminogen activator receptor
VEGF vascular endothelial growth factor
VIM vimentin
VTN vitronectin
XGAL 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside
α-SMA α-smooth muscle actin
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Chapter 1
1. GENERAL INTRODUCTION
This chapter provides a general overview of breast cancer, including the relevance of measuring gene
expression in the primary breast tumor in relation to the progression of the disease and the tumor
response to treatment. To better understand the concept of breast cancer, extra emphasis will be put on
breast cancer subtypes, staging and grading, and the tumor micro-environment that harbors the
epithelial cancer cells. Currently available biomarkers to assess outcome of breast cancer patients in
general (i.e. prognosis) as well as biomarkers currently available to assess patient outcome in response
to therapy (i.e. prediction) will be discussed. After this it should become clear that there is still an urgent
need for new biomarkers. How this search for additional biomarkers can be achieved by measuring
mRNA gene expression in the primary tumor of patients diagnosed with breast cancer, will be explained
in more detail.
1.1 Breast cancer
Epidemiology
In women breast cancer is, after skin cancer, the most common type of cancer and accounts for about
30% of all cancers in women. For women between 35-55 years of age in the well developed countries
it is overall the main cause of death. In the Netherlands the incidence of breast cancer has been rising
from 100 cases per 100,000 women in 1989 to 124 cases per 100,000 women in 2003 (www.vikc.nl).
The age-adjusted approximate lifetime risk to be diagnosed with breast cancer is currently about 11%
(www.kankerregistratie.nl). In the U.S. the probability of developing breast cancer is already as high as
12% (www.seer.cancer.gov). 
The good news is that early detection, new treatment modalities and new insights have improved
survival rates. An initial analysis of data from the National Cancer Institute's Surveillance,
Epidemiology, and End Results (SEER) registries for example, showed that the age-adjusted incidence
rate of breast cancer in women in the United States fell sharply (by 6.7%) in 2003, as compared with
the rate in 2002. This decrease in breast cancer incidence seems to be temporally related to the first
report of the Women's Health Initiative and the ensuing drop in the use of hormone-replacement
therapy among postmenopausal women in the United States [1]. Nowadays, about 88% of the women
diagnosed with breast cancer in the U.S will survive at least 10 years (www.healthcentral.com). 
Figure 1.1.1. Malignant breast cancer incidence (left panel) and breast cancer related death (right panel) at various ages.
This graph of breast cancer incidence shows a steeply rising incidence with increasing age. (Complied from Surveillance,
Epidemiology, and End Results (SEER) 13 registries for 1995-2004, based on the November 2006 submission; www.seer.cancer.gov).  
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Risk factors for breast cancer
Risk factors to get diagnosed with breast cancer can be divided in those that you cannot change (inborn)
and those related to lifestyle [2]. Well acknowledged inborn risk factors are gender, aging (see also
figure 1.1.1), genetic risk factors, family and personal history of breast cancer, race, abnormal breast
biopsy, previous chest radiation and time of menstrual periods. Lifestyle related factors involve not
having children or delayed childbirth, oral contraceptive use, hormone replacement therapy,
breast-feeding and pregnancy, obesity and dietary aspects, especially use of alcohol (www.cancer.org). 
Note however that most women who have one or more breast cancer risk factors may never develop the
disease, while many women who do have breast cancer have no apparent risk factors (other than being
a woman and growing older, figure 1.1.1). With our aging population, especially the age-related
increase in breast cancer incidence needs our attention. One of the reasons for this age-associated
increased risk to get diagnosed with breast cancer (consequences of telomere attrition in stromal cells)
will be discussed in chapter 3 of this thesis.
Once the cancer has developed, evaluation of additional risk factors such as the type of the breast
cancer, the stage and grade at time of diagnosis, and other intrinsic tumor characteristics such as
chromosomal abnormalities, immunological phenotype, cell proliferation index, and levels of
proteins/enzymes and receptors for hormones and growth factors become important [3].
Types of breast cancer
In general, cancers can be classified according to their site of tissue origin, with the majority of human
tumors arising from epithelial cells, i.e., cells that line the walls of cavities and ducts, or in case of skin,
serve as the outside covering of the body. For example carcinomas arise from epithelial cells,
adenocarcinomas from secretory epithelial cells, squamous cell carcinomas from epithelial cells that
line a duct or the skin and that lack secretory function. These epithelial tumors are responsible for more
than 80% of the cancer-related deaths in the Western world. A second class of malignant tumors arises
from non-epithelial tissues throughout the body. This class of non-epithelial tumors comprises the
sarcomas derived from a variety of mesenchymal cell types such as fibroblasts, adipocytes, osteoblasts
and myocytes, the leukemias and lymphomas derived from the blood-forming tissues, and the
neuroectodermal tumors derived from components of the nervous system [4]. In addition to this, breast
cancers are classified according a more
defined site of origin and cell type (see
also figure 1.1.2 and table 1.1.1).
Figure 1.1.2. Carcinoma sites in breast.
Most often breast cancer has only one location in a
single breast, almost half of which originate in the
upper and outer quadrant of the breast. Though
breast cancer has the potential to spread to other
regions of the body first, it most commonly spreads
first to the axillary (underarm) lymph nodes. This is
known as regional spread. From there, the breast
cancer can metastasize (spread) systematically to
other areas of the body (such as the bone, liver, lung,
or brain). Ductal carcinomas comprise about 85%
of breast tumors and originate from the epithelium
of the mammary ducts. The remaining are mainly
lobular carcinomas, which arise from the mammary
lobules. (www.MyBreastCancerNetwork.com).
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Table 1.1.1. Breast cancer morphological taxonomy.
Freely adapted from www.immunerecovery.net, www.healthcentral.com, and [5].
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1.2 Breast cancer staging and grading
Breast cancer is a heterogeneous disease which encompasses several entities with distinct prognosis.
Although a comprehensive breast cancer morphological taxonomy has been developed and usefully
applied to patient management (see also table 1.1.1), it has become clear that tumors classified under
the same descriptive term may have distinct underlying biological features and clinical behavior [7].
Therefore, in addition to histological typing, breast cancer is characterized by stage, grade and 
molecular markers. 
Breast cancer staging
Staging of breast cancer refers to determination of size and location of the disease. There are currently
two staging classifications in use: a breast cancer staging system that divides breast cancers in 5 stages
for most sites, including a stage 0 for non invasive carcinoma in situ, and the more elaborate tumor node
metastases (TNM) system. In the latter system, T describes the size of the tumor, N describes whether
the cancer has spread to the lymph nodes, and M describes whether the cancer has spread to another part
of the body, such as the bone, liver or the lung. In table 1.2.1 the most common breast cancer stages are
described. As depicted in figure 1.2.1, especially metastatic disease is associated with a very poor
overall survival, thus showing the importance of being able to stage breast cancers and stressing the
urgent need for early detection and tumor-specific treatment modalities.
Figure 1.2.1. Relative
survival rates for breast
cancer in females by stage at
diagnosis.
This graph of breast cancer
survival after diagnosis shows
a steeply declining survival
rate in time, especially for the
patients with a distant
metastasis. 
(Complied from Surveillance,
Epidemiology, and End
Results (SEER) 9 registries for
1988-2003, based on the
November 2006 submission:
www.seer.cancer.gov).   
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Table 1.2.1. Breast cancer staging taxonomy.
Freely adapted from www.immunerecovery.net and www.healthcentral.com (review date: 03/14/2007. Reviewed by: Editorial
Team: Greg Juhn, David R. Eltz, Kelli A. Stacy. Previously reviewed by Harvey Simon, M.D., Associate Professor of Medicine,
Harvard Medical School; Physician, Massachusetts General Hospital (10/2/2006).
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Breast cancer grading
While staging of breast cancer refers to determining the size and location of the disease, grading of
breast cancer is a term used to describe how closely a tumor resembles normal tissue and gives an idea
of how quickly the cancer may develop. Based on the histological appearance as assigned by the
pathologist, there are three grades: grade 1 (low-grade), grade 2 (moderate or intermediate grade) and
grade 3 (high-grade). Low-grade means that the cancer cells look very like the normal,
well-differentiated, cells of the breast. They are usually slow growing and are less likely to spread. In 
high-grade tumors the cells are poorly differentiated and look very abnormal. They will probably grow
more quickly and are more likely to spread. 
Other more advanced methods to characterize tumors according established clinical and pathological
criteria are based on guidelines such as the St Gallen [8, 9] and the National Institute of Health
consensus [10], or by making use of specific prognostic tools such as the Nottingham Prognostic Index
(NPI) [11] or Adjuvant-Online algorithm (www.adjuvant-online. com).
Molecular breast cancer markers
Another way of grading primary breast tumors to estimate the risk of cancer progression in aiding the
clinician to construct a patient tailored therapy is to make use of molecular profiling and genomic
grading indices. Microarray based molecular classification of breast tumors or selection of gene
expression panels to improve prediction of risks or treatment outcomes are thought to be theoretically
superior to established clinical and pathological criteria, based on guidelines such as the St Gallen and
National Institute of Health consensus, or guidelines which use specific prognostic tools, such as the
Nottingham Prognostic Index or Adjuvant-Online algorithm [12]. The first well known studies in this
field, aimed at classifying breast carcinomas based on gene expression patterns, are those of Perou and
Sorlie [13-16]. According these studies, breast carcinomas can now, based on patterns of expression of
496 "intrinsic" genes, be distinguished in tumor subclasses with distinct clinical implications: 
1. Luminal-epithelial group (with sub-classification into types A, B and C), characterized by 
expression of the estrogen receptor and genes associated with the estrogenic function, i.e., 
genes that are typically expressed in the luminal epithelium that lines the ducts. 
2. Basal-epithelial group, typically negative for the estrogen and progesterone receptors as well
as the ERBB2 (Her2/neu) oncogene ("triple negative").
3. ERBB2+ group associated with overexpression of the ERBB2 amplicon. 
4. Normal breast-like group.
At the same time, the Genomic Grade Index (GGI), capturing 97 differentially expressed genes, can be
used to reclassify patients with histologic grade 2 tumors into two groups with high versus low risks of
recurrence [17, 18]. 
But with respect to implementing microarray data much debate is going on in the field with most
clinicians still being more comfortable with the classical ways of grading tumors [12, 18-28].
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1.3 The tumor micro-environment
Human breast carcinomas arise via intermediate steps known as precursor or premalignant lesions (see
figure 1.3.1). Because the most malignant aspect of abnormal proliferation (i.e. neoplasia) is
metastasis, recognition of metastatic phenotypes is particularly important [29]. 
As proposed by Hanahan and Weinberg in 2000 [30], the vast catalogue of cancer cell types can be seen
as a manifestation of six essential alterations in cell physiology that dictate malignant growth,
collectively called the 'Hallmarks of cancer': 
- self-sufficiency in growth signals;
- insensitivity to growth-inhibitory signals;
- evasion of programmed cell death (apoptosis);
- limitless replicative potential;
- sustained growth of new blood vessels (angiogenesis);
- tissue invasion and metastasis. 
The players in the tumor micro-environment, i.e. the area in which the tumor cells are nested, are
multiple, and each of them may contribute to these hallmarks of cancer. For example the stroma or the
supportive platform for the epithelial layer, which accounts for more than 80% of the normal breast
volume [31], is composed of fibroblasts, endothelial cells, smooth muscle cells, adipocytes,
inflammatory cells, nerve cells and a macromolecular network of proteoglycans and glycoproteins
collectively termed the extracellular matrix (ECM). Figure 1.3.2 gives two typical examples of
hematoxylin-eosin (HE) stained breast tumor sections; one section with predominantly epithelial cancer
cells and one section where the epithelial cancer cells are nested in a network of stromal cells. 
Figure 1.3.1. Steps in tumor progression.
After neoplastic transformation, cells start proliferating abnormally. Formation of new blood vessels supports the growth and
invasion of the tumor cells in the extracellular matrix. Cells able to enter and survive in the vasculature may extravasate and form a
metastatic lesion. The purpose of molecular breast cancer markers is to recognize and characterize the steps involved in tumor
progression.
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There is now an increasing insight that signals provided by the stroma can induce the genetic alterations
that underlie tumor formation, can stimulate tumor growth and progression, and can dictate both
therapeutic response and ultimate clinical outcome [32-40]. In vitro research results, including those of
our own group [41-51], and in vivo results [52-54] make it clear that non-neoplastic stromal cells,
notably the stromal (myo)fibroblast cells of carcinomas, are indeed active participants in promoting
growth, invasion and metastasis of tumors. Observations of specific genetic alterations in exclusively
the stromal cells present in the tumor environment [55, 56] even extend this heterotypic interplay
concept to the stroma being responsible for tumor formation and maintenance.
In addition to the microarray grading signatures mentioned previously, three grading signatures that
focus on the stromal micro-environment of the epithelial tumor cells have been described. Firstly, a
grading based on characteristic genes found in five cancer tissue categories (epithelial cells, leucocytes,
myoepithelium/myofibroblasts, endothelium and stroma) [52]. Secondly, a signature based on
differences between 2 types of fibroblastic tumors: desmoid-type fibromatosis (DTF) and solitary
fibrous tumors (SFT) [53]. Thirdly, a signature based on gene expression profiles of fibroblasts from ten
anatomic sites [57]. In the latter, a stereotyped gene expression program was identified in response to
serum exposure that appeared to reflect the multifaceted role of fibroblasts in wound healing.
Genes induced in the fibroblast serum-response program are expressed in tumors by the tumor cells
themselves, by tumor-associated fibroblasts, or both. These stromal signatures capturing the reciprocal
interactions between mesenchymal and epithelial cells might also be considered a way of grading
tumors with distinct clinical features [54, 57].
Therefore cancer should be seen as a multicellular program in which the tumor cells themselves, the
tumor-associated fibroblasts, and diverse other cells in the tumor micro-environment are active
participants [57-60]. 
Figure 1.3.2. Examples of hematoxylin-eosin (HE) stained breast tumor sections.
In the left panel a breast cancer that predominantly consists of epithelial cancer cells (visualized by the darker stained nuclei). In the
right panel an example of a breast cancer where the epithelial cancer cells are nested in a network of stromal cells. 
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1.4 Prognostic and predictive markers
It is important for this thesis to understand the difference between a prognostic and a predictive marker.
A prognostic marker predicts disease recurrence or tumor progression, independently of future
treatment effects. A predictive biomarker predicts response or resistance to a specific cancer therapy.
Any change in disease status during treatment should be reflected by a change in the marker status [61].
Prognostic factors, e.g., metastatic disease, lymph node status, tumor size, histologic grade,
proliferation rate, ERBB2, hormone receptors and other biological markers are used to predict the
clinical course of breast cancer at the time of primary treatment. Patients with a poor prognosis are
offered radiotherapy and systemic adjuvant therapy i.e., endocrine, cytotoxic or biological anticancer
therapy following primary surgery for early stage cancer that affects the entire body. Prediction refers
to the likelihood of outcome in response to a specific therapy. For the choice of (systemic) adjuvant
therapy information about prognostic and predictive factors such as size and shape of the tumor,
location of the tumor, proliferation rate and biological markers are useful. 
Biomarkers in breast cancer for diagnostics, prognosis and targeted therapies
A biological marker is an indicator or characteristic trait of a disease that facilitates differential
diagnosis (the process of distinguishing one disorder from other, similar disorders). Biomarkers are
biological substances normally present in small amounts in tumor tissues or body fluids and encompass
a wide variety of molecules, including transcription factors, cell surface receptors, and secreted
proteins. These are measured in the management of breast cancer patients for the following purposes:
(1) early detection, (2) monitoring of advanced breast cancer patients, (3) prediction of disease
recurrence or tumor progression, and (4) prediction of therapeutic response. In general, biomarkers can
be divided in circulating biomarkers that are detected in body fluids and markers detected in tumor
tissue, with one new class of biomarkers, the circulating tumor cells, bridging the two. Examples of
established breast biomarkers are the serum-based cancer antigens CA 15-3, CA 125, CA 27-29 and
carcinoembryonic antigen (CEA), and the tissue-based estrogen and progesterone hormone receptors,
markers measuring DNA-ploidy/ content and/or proliferation, the oncogene ERBB2, the tumor
suppressor gene p53, and the protease urokinase plasminogen activator (uPA) and its inhibitor
plasminogen activator inhibitor 1 (PAI-1) [3, 9, 62, 63]. 
An example of a new (class of) biomarker(s) that require further prospective validation is represented
by the gene expression profiles [9] that classify breast tumors into histological subtypes [18, 23, 26, 28,
52, 53, 64-67], subgroups with different prognosis [26, 54, 57, 68-78], different sites of relapse [79-81],
and different types of response to treatment [82-101]. To evaluate the usefulness of a new biomarker to
monitor disease progression, correlation of levels of the marker with tumor size, disease-free,
metastasis-free, progression-free, and (post-relapse) overall survival are taken into consideration. Thus
a biological prognostic marker refers to a marker that correlates with disease-free, metastasis-free and
overall survival; the term predictive marker indicates a marker that is capable of predicting tumor
sensitivity or resistance to various therapies. But markers may be applicable to both scenarios.
Estrogen receptors for example are weak prognostic indicators and good predictors of response to
endocrine therapy. On the other hand, markers measuring proliferation indices are good indicators of
prognosis, and, in addition, may directly be related to response to chemotherapy and are closely related
to response to endocrine therapy [102]. Ultimately, a useful clinical marker is one that meets two
criteria: it can be measured reproducibly by means of a reliable and widely available assay and it
conveys information about the disease that is meaningful to the physician and patient. 
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The tumor marker utility grading system (TMUGS)
As the field of tumor associated biomarkers has rapidly expanded over the last two decades with a
concomitant increase in published reports, it has become increasingly apparent that a strong need exists
to establish consensus guidelines for the development and use of established as well as novel tumor
associated markers [61]. For this purpose, the TMUGS has been introduced as a framework tool
consisting of two parts: one part to classify the tumor markers and another part to evaluate the clinical
utility of the tumor markers [103]. 
In the first part the precise characteristics of the marker is clarified. These characteristics include the
marker designation, the molecule and/or substance and the relevant alteration from normalcy, the assay
format and reagents, the specimen type, and the neoplastic disease for which the marker is being
evaluated. In the second part the clinical utility of the marker is evaluated and scaled with respect to risk
assessment, screening, differential diagnosis, prognosis with respect to prediction of relapse/
progression, prognosis with respect to response to therapy, and monitoring clinical course. Finally, to
define the quality of data that exist, the marker is scaled by placing the available data into one or
several levels of evidence (LOE-5 to LOE-1) (table 1.4.1). 
Although it seems cumbersome at first, application of this system by expert reviewers should help
to separate those markers for which clinical utility clearly exists from those markers for which either
more data are necessary or for which further consideration can be discarded [104]. 
Table 1.4.1. Tumor marker utility grading system to classify the level of evidence of tumor associated
biomarker studies.*
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1.5 Available techniques to study biomarkers in the genomics era
The techniques to search for new biomarkers, to validate their usefulness, and assign biological
functions has made great progress in this computerized era of proteomics to study proteins and
genomics to study genes. In the last three decades, techniques for the evaluation of gene expression
have progressed from methods developed for the analysis of single, specific genes (e.g., Northern, slot,
and dot blotting; semi-quantitative and quantitative reverse transcription and PCR; and nuclease
protection assays) to gene expression profiling techniques focused on identifying all genes that differ in
expression or sequence between or among experimental samples (e.g., subtractive hybridization,
differential display, sequencing of expressed sequence tags, serial analysis of gene expression, and
hybridization to microarrays). With the vast amount of data generated in these experiments, specialized
programs are required to interpret the statistical significance and biological meaning from these data.
Pathway analysis is one hot-topic method to find relationships among genes, cell processes and
diseases.
The following summary merely serves to give a brief overview of the currently widely used methods.
Because this thesis is mainly focused on quantifying gene expression by real-time reverse transcriptase
polymerase chain reaction (real-time RT-PCR or qRT-PCR), special emphasis will be put on this
technique, its basic principle, the potentials and the limitations.
Gene expression profiling
There are two main applications of gene expression profiling; studies unravelling novel breast cancer
classifications and those that aim to identify novel markers for prediction of clinical outcome [20].
Gene expression profiling has for example been applied to classify breast tumors into histological
subtypes [18, 23, 26, 52, 53, 64-67], into subgroups with different prognosis [57, 68-78], different sites
of relapse [79-81, 105], and different types of response to treatment [54, 82-101]. Note however that
gene expression levels cannot always be compared with protein levels. Regulatory mechanisms
affecting protein concentrations, activity, and stability can act at the level of DNA and mRNA
translation, protein folding, glycosylation, phosphorylation, and (proteosomal) protein degradation.
Since it is only the actual protein that is biologically active, a sensitive, protein-based, method is
important to determine the actual biological activity of a marker that has been discovered by gene
analysis. While the great advantage of identifying a large set of differentially expressed genes between
or among experimental samples simultaneously (gene expression profiling) is simply the large number
of genes that are analyzed simultaneously, especially low expressed tags might be adversely biased and
validation at the single gene level by real-time RT-PCR remains essential.
Real-time PCR method
Real-time PCR is a method that enables detection of sequence-specific PCR gene products as they
accumulate in "real-time" during the PCR amplification process. For an example see figure 1.5.1. When
the PCR product of interest is produced during cycling (x-axis), real-time PCR can detect their
accumulation (y-axis) and quantify the number of gene copies present in the initial PCR mixture before
amplification began. With special algorithms the number of copies can be calculated. Real-time PCR
can be applied on genomic DNA sequences or on copy DNA (cDNA) generated from mRNA after a
reverse transcriptase (RT) reaction.The main differences between the variations in the procedure are
found in the fluorophores or dyes to detect the levels. The most sensitive, least expensive, but also least
specific method makes use of double-stranded (ds) DNA dyes such as SYBR Green. The lack of
specificity is due to the fact that dsDNA dyes will bind all dsDNA PCR products, including nonspecific
products such as primer dimers (when two primers used to set up the PCR reaction hybridize). Using
fluorescent reporter probes is the most accurate and most reliable method, but also the most expensive
one. It uses a sequence-specific RNA or DNA-based probe to quantify only the sequence in the gene of
interest matching the probe sequence; thus, use of this probe-based method significantly increases
specificity, and allows quantification even in the presence of some non-specific DNA amplification. If
the necessary precautions are taken, this method potentially allows for multiplexing (assaying for
several genes in the same reaction) by using specific probes with different-colored labels.
Quantitation of PCR products
Relative concentrations of PCR products present during the exponential phase of the reaction are
determined by plotting fluorescence against cycle number on a logarithmic scale (see figure 1.5.1). A
threshold for detection of fluorescence above background is determined. The cycle at which the
fluorescence from a sample crosses the threshold (solid horizontal line in figure 1.5.1) is called the
cycle threshold, Ct. Since the quantity of PCR product doubles every cycle during the exponential
phase, relative amounts of PCR products can be calculated, e.g., a sample whose Ct is 3 cycles earlier
than another sample had 23 = 8 times more initial gene copies. The number of (m)RNA or DNA copies
are then determined by comparing the results to a standard curve produced by RT-PCR of serial
dilutions of a known amount of (m)RNA or DNA copies. 
To accurately quantify gene expression, the measured amount of RNA from the gene of interest is
divided by the amount of RNA from a reference (housekeeping) gene measured in the same sample to
normalize for possible variation in the amount and quality of RNA between different samples. This
normalization permits accurate comparison of expression of the gene of interest between different
samples, provided that the expression of the reference gene used in the normalization is very similar
across all the samples. Choosing a reference gene or set of genes fulfilling this criterion is therefore of
high importance, and often challenging, because only very few genes show equal levels of expression
across a range of different conditions or tissues [106-110]. 
Pathway analysis
As described above, microarray technology has successfully classified breast tumors into histological
subtypes [18, 23, 26, 52, 53, 64-67], subgroups with different prognosis [57, 68-78], different sites of
relapse [79-81, 105], and different types of response to treatment [54, 82-101]. However, it soon
became clear that various gene signatures identified for classifying patients with different subtypes of
breast cancer or with different prognosis had few genes overlapping [75, 111, 112]. This could be due
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Figure 1.5.1.
Real-time PCR amplification plot.
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to the fact that many genes function in the same biological pathway. Therefore, to place potential
suitable biomarkers in a biological context, the biological pathways rather than individual genes related
to patient outcomes should be investigated [112-116]. 
1.6 Tumor tissue, DNA, RNA, and protein bank
A shortage of high-quality human tumor samples might very well be the top barrier to progress in
cancer research. With scientists pinning their hopes for new diagnostics and cures on molecular
biomarkers, they need access to human tissue samples from large numbers of people. For this, biobanks
with stored tissues, body fluids and related products such as DNA, RNA and protein lysates are
essential. A biobank allows formal accreditation of ethics and security procedures, and through a
dedicated management, processing, storage, retrieval, and release structure, can provide selected and
preassembled material and data for research and discovery [117, 118]. Clinical pathology archives are
usually extensive but comprise mostly formalin-fixed paraffin-embedded (FFPE) tissue blocks.
Although recent progress has been made with tumor RNA and DNA analysis in FFPE tissue, the RNA
and DNA fragmentation and chemical modifications that occur with formalin fixation remain
significant barriers to biomarker research. In addition, although FFPE tissue microarrays can be very
suitable for immunological staining, various specific approaches such as those aimed at protein
modifications and mass spectrometry are difficult to apply to formalin-fixed tissue [119]. Therefore the
main request for clinical specimens for biomarker research involves fresh frozen tissue. 
Power of the Rotterdam fresh frozen breast tissue bank for 'omics' research
The opportunity to collect fresh frozen tumor tissue that is suitable for studies on extracted DNA, RNA
and protein has been further reduced by early diagnosis, reduction in surgical extent, and trends towards
preoperative therapies. For ethical reasons, trials of therapy in patients with breast cancer no longer
include an untreated control group. Therefore, retrospective studies involving well-characterized tumor
banks with tumors from untreated patients are necessary to determine whether putative biomarkers are
pure prognostic markers in stead of a predictor for the benefits of systemic therapy. One such well
characterized fresh frozen tissue bank has been established by the department of Medical Oncology,
Erasmus Medical Center, Rotterdam, The Netherlands. 
This fresh frozen breast tumor tissue bank currently contains over 14,000 samples stored in liquid
nitrogen since 1978. Of 5,500 patients a computerized database with updated clinical follow-up is
available. In addition, information on high quality extracts of DNA from 3,000 tissues, RNA from 2,000
tissues, and protein from over 10,000 tissues are stored in accompanying computerized databases.
Because of the uniqueness of this bank, these resources are also extensively used in collaborative
studies with other European and American research groups [18, 75, 80, 81, 94, 120-124], to name only
the 2005-2007 publications that resulted from such collaborative studies. Figure 1 in chapter 6 of this
thesis gives a detailed overview of the RNA collection stored in this bank with sufficient clinical
follow-up for reliable statistical analyses [125]. These RNA samples were the very important source of
clinical samples for the studies included in this thesis [50, 51, 112, 123, 125].
1.7 Aims and outline of this thesis
The aims of this thesis are firstly to gain insight into the interaction between breast tumor cells and the
surrounding stromal fibroblasts. Secondly, this concept of a multi-cellular program in which the tumor
cells, the tumor-associated fibroblasts, and diverse other cells in the tumor micro-environment are
active participants, is integrated in our search for novel prognostic and predictive biomarkers. Finally,
the concept of biomarkers is placed in a larger context by looking at pathways rather then individual
biomarkers. In summary, the more specific subjects discussed in this thesis are: 1) studies on the
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interaction between different biological systems, 2) studies on prognosis, and 3) studies on prediction
to tamoxifen therapy response.
In chapter 2 the role of peri-tumoral fibroblasts in relation to the expression of components of the
plasminogen activator (PA) system and the insulin-like growth factor (IGF) system in normal and
tumor-tissue-derived human breast fibroblasts exposed to various fibroblast growth factors (FGFs) is
discussed [48]. The in vitro data presented propose that of the FGFs studied (FGF-1, -2, -4, -5, and -7),
FGF-2 is the most attractive target for therapeutical strategies aimed at diminishing the contribution of
stromal fibroblasts in the PA-directed breast tumor proteolysis.
With our aging population, especially the age-related increase in breast cancer incidence should worry
us. In chapter 3 the role of peri-tumoral fibroblasts is investigated in relation to this important aspect
[49]. For this, we investigated whether breast fibroblasts aged in vitro through passage in culture
display altered levels of the PA system and growth factors that are known to modulate that system. Our
results show that aging accompanied by telomere loss induces PAI-1 and FGF-1 mRNA expression in
all breast fibroblast strains, increases uPA and decreases IGF-1 mRNA expression in a subset, and
increases MMP-2 protein expression only in tumor-derived breast fibroblasts. Thus, the age-induced
levels of these biomarkers in stromal breast fibroblasts could contribute to breast cancer progression.
In chapter 4 the multi-cellular notion is experienced in the clinical setting. In this chapter we evaluated
the predictive value of the disintegrin and metalloproteinases, ADAM-9, ADAM-10, ADAM-11, and
ADAM-12, and of the matrix metalloproteinases, MMP-2 and MMP-9, in patients with recurrent breast
cancer treated with tamoxifen [50]. The data will show that especially for primary tumors containing a
high proportion of stromal elements, the assessment of mRNA expression levels of ADAM-9 and
ADAM-11 could be useful to identify patients with recurrent breast cancer who are likely to benefit or
fail from tamoxifen therapy.
One of the applications of real-time RT-PCR is validation of putative biomarkers that emerge from
microarray experiments in a larger patient cohort. One such biomarker is cyclin E2 (CCNE2), a gene
that overlaps between our 76-gene prognostic signature [75] and the 70-gene prognostic signature [70].
In chapter 5 we describe the prognostic evaluation of cyclin E with this quantitative method in a large
cohort of 635 lymph node-negative (LNN) breast cancer patients that did not receive systemic adjuvant
therapy [51]. The study shows that both CCNE1 and CCNE2 qualify as independent prognostic
markers for LNN breast cancer patients, and that CCNE1 may provide additional information for
specific subgroups of patients with stroma-enriched primary tumors. 
Another validation study, discussed in chapter 6, concerns the HOXB13-to-IL17BR expression ratio
that was previously identified to predict clinical outcome of breast cancer patients treated with adjuvant
tamoxifen [125]. In this study we demonstrate that, in addition to tamoxifen therapy failure (prediction),
high HOXB13-to-IL17BR ratio expression levels also associate with tumor aggressiveness (prognosis). 
Having discovered and identified two alternatively spliced variants of TIMP1 mRNA in cancer cell
lines and colon cancer tissue [126] (chapter 7), the prognostic value of these variants were tested in
1301 primary breast specimens [123] (chapter 8). Comparing TIMP1 mRNA and protein levels
revealed that concentrations of TIMP1 mRNA and one of its splice variants and TIMP-1 protein were
differentially associated with prognosis in primary breast cancer. It is discussed how such a differential
association might help our understanding of the role of TIMP-1 with respect to breast cancer
progression.  
As shown in chapter 5, published prognostic gene signatures in breast cancer have few genes in
common. In chapter 9 a rationale for this observation is provided by studying the prognostic power and
the underlying biological pathways of different gene signatures [112]. 
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Differential effects of fibroblast growth factors on
expression of genes of the plasminogen activator and
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ABSTRACT
In breast stroma urokinase plasminogen activa-
tor (uPA) is predominantly expressed by fibro-
blasts located in the near vicinity of tumor cells,
and fibroblast-derived insulin-like growth
factor-1 (IGF-1) may be involved in inhibiting
the expression of uPA in these fibroblasts. To
investigate a possible role for fibroblast growth
factors (FGFs), we evaluated the expression of
components of the PA system and the IGF
system in normal and tumor-tissue-derived
human breast fibroblasts exposed to various
FGFs in vitro. mRNA analysis revealed that
FGF-1, FGF-2 and FGF-4 induced the mRNA
expression levels of uPA, tPA, uPAR, PAI-1 and
PAI-2, and reduced those of IGF-1, IGF-1R,
IGF-2R and IGFBP-4, without significantly
affecting the levels of IGFBP-3, IGFBP-5 and
IGFBP-6 mRNA. Concerning the expression of
IGF-2 mRNA, the effects mediated by FGF-1,
FGF-2 and FGF-4 were divergent. In general,
the effects elicited by FGF-1 on the various
mRNA levels studied were rapid and short-
term. Those mediated by FGF-2 overall lagged
behind but were longer-lasting. For FGF-4 an in
between pattern was observed. Blocking tran-
scription and translation demonstrated that a)
both the FGF-1 and FGF-2 induced effects were
the result of altered gene transcription or
mRNA stability, b) the short-term effects medi-
ated by FGF-1 and FGF-2 required de novo pro-
tein synthesis, and c) the long-term effects
elicited by FGF-2 did not depend on de novo
protein synthesis during the first 24 h, but were
triggered by proteins produced or made avail-
able thereafter. The data presented propose that
of the FGFs studied (FGF-1, -2, -4, -5, and -7),
FGF-2 is the most attractive target for therapeu-
tical strategies aimed at diminishing the contri-
bution of stromal fibroblasts in the PA-directed
breast tumor proteolysis.
INTRODUCTION
In breast cancer, peritumoral stromal fibroblast-
like cells have been shown to express proteo-
lytic enzymes such as the metalloproteinases
MMP-2 [1], MMP-11 [1, 2], MMP-13 [3] and
MMP-14 [4] and the urokinase-type plasmino-
gen activator uPA [1, 5, 6]. In particular the uPA
system, constituting uPA, its cell-bound recep-
tor (uPAR), and its main inhibitors plasminogen
activator inhibitors type 1 and 2 (PAI-1 and
PAI-2) have been shown to be involved in the
process of matrix degradation, tumor cell
migration and invasion, and angiogenesis. Upon
binding to its receptor, uPA converts plasmino-
gen into plasmin. Plasmin is able to directly
degrade a variety of extracellular matrix (ECM)
proteins, and can activate several MMPs, which
in turn are also able to dissolve ECM compo-
nents. Tissue-type plasminogen activator (tPA)
on the other hand has been shown to play a
major role in plasmin-directed lysis of fibrin
clots (reviewed in [7]). Many research groups
have reported high breast tumor levels of uPA,
uPAR and PAI-1 to be associated with poor
prognosis (reviewed in [8-10]). Ergo, an under-
standing of the behavior of potential inducers
and modifiers of components of the PA system
may be helpful in designing future therapeutic
strategies.
We have shown previously that out of a panel of
various cytokines and growth factors, the
fibroblast growth factors FGF-1 and FGF-2
were amongst the most potent inducers, and the
insulin-like growth factors IGF-1 and IGF-2
amongst the most potent inhibitors of uPA pro-
tein production by human breast fibroblasts
[11]. Noteworthy in view of the present study is
the detection of FGF-1 protein in peritumoral
stromal cells of breast tumor tissue treated with
protease inhibitors [12], and the significant
association observed between FGF-2 and uPA
staining of peritumoral stromal cells [13].
The FGF family of soluble growth factors is
Keywords: fibroblast growth factors, plasminogen activator system, insulin-like growth factor system,
fibroblasts, human breast cancer.
composed of a large number of structurally
related proteins. Extracellular FGF binds with
low affinity to heparan sulphate proteoglycans
(HSPGs), which protect FGF from degradation
and serve as FGF-reservoirs to promote
longterm availability [14-16], and with high
affinity to one or more of the 4 identified FGF
tyrosine kinase receptors (FGF-Rs) [17]. For
uPA induction by FGF-2, the involvement of
ETS transcription factors has been described
[18-20]. Although FGFs have been shown to
induce expression of components of the PA
system in a direct manner [21, 22], also indirect
pathways have been described. For example,
induction of the PA system by VEGF, another
angiogenic factor capable of inducing the tran-
scription factor ETS, is dependent on the pres-
ence of FGF-2 [23]. There are no published data
available on a possible role for the IGF system
in relation to the FGF-induced up-regulation of
the PA system. This would be of interest to
know, since we have demonstrated that IGF-1
and uPA are inversely related in human breast
fibroblasts, and showed data suggesting that
IGF-1 controls the expression of uPA [24]. Like
FGFs, IGFs interact with their own tyrosine
kinase receptor, the IGF-1R. Although IGF-2
compared with IGF-1 binds with a 2 to 50-fold
lower affinity to the IGF-1R, both ligands can
mediate the same functions via this receptor
[reviewed in [25]]. The mannose-6-phosphate
receptor/IGF-2R, however, binds IGF-2 and not
IGF-1. Furthermore, the activities of both IGF-
1 and IGF-2 are modulated by their association
with six different high affinity IGF binding pro-
teins (IGFBPs) [25-28].
To examine a possible regulation of the PA and
IGF systems by FGFs in human breast fibro-
blasts, and to shed in this respect some light on
the tumor biology of normal versus tumor-
tissue-derived fibroblasts, we analysed in this
study the FGF-induced mRNA expression of
components of the PA system and of the IGF
system in a set of paired cultured normal and
tumor-tissue-derived human breast fibroblasts.
To examine a possible differential regulation of
components of the PA and IGF system by vari-
ous known FGFs, we selected the following
FGF panel for our study: FGF-1 and FGF-2,
being the FGFs present in almost all breast
cancer cases studied, FGF-5 and FGF-7, repre-
senting the group of FGFs with a more
restricted level of expression in breast cancer,
and FGF-4, representing the group of FGFs not
known to play a role in breast cancer [29-31].
MATERIALS AND METHODS
Culture of fibroblast strains
The human fibroblast strains T and N were
established from an invasive ductal breast ade-
nocarcinoma tumor-tissue-derived (T) fragment
and from adjacent normal breast tissue (N) of
the same patient, as described in detail before
[32]. The original tumor tissue and adjacent
normal breast tissue, as well as the resulting T
and N fibroblast populatons isolated from these
two tissues, were characterised using standard
immunocytochemical procedures, as described
[33]. Fibroblasts were propagated in medium
containing 10% foetal calf serum and for
experimentation transferred to protein-free
medium in 6-well tissue culture plates, coated
with the recombinant cell-attachment factor
Pronectin®F (ICN Biomedicals, Cleveland,
OH, USA), as described [11].
Experimental culture conditions
To obtain quiescent fibroblasts, they were cul-
tured for 4 days in protein-free medium. Then
the protein-free medium was replaced by 2 ml
experimental medium, that is, protein-free
medium containing either the relevant vehicle
or one of the human recombinant FGFs (all
obtained from R&D systems, Minneapolis,
MN) at the concentrations indicated in the text.
For neutralisation purposes, the FGF-specific
neutralising antibodies (R&D systems) were
used against their proper isotype-matched con-
trol antibodies (R&D systems) in the absence
and presence of the relevant FGFs according to
the manufacturer's advise. For studying the
effects of the mRNA synthesis inhibitor actino-
mycin D (ACT), quiescent fibroblasts were pre-
incubated for 15 min in protein-free medium
supplemented with 5 µg/ml ACT (Sigma, St.
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Louis, MO) or with the vehicle only (final con-
centration of 0.05% ethanol). After a double
wash with PBS, they were cultured for an addi-
tional 24 h in fresh protein-free medium in the
absence or presence of FGFs. For studying the
effects of the protein synthesis inhibitor cyclo-
heximide (CHX), quiescent fibroblasts were
cultured for up to 48 h in protein-free medium
supplemented with 50 µg/ml cycloheximide
(Sigma) or with the vehicle only (protein-free
medium) in the absence or presence of FGFs. At
the indicated time-points, the amount of uPA
protein released into the culture medium and the
expression levels of the various mRNA tran-
scripts were evaluated (see below for followed
procedures).
Measurement of the amount of uPA by immunoas-
say
Fifty µl of the 2 ml experimental medium was
used to measure uPA antigen by an enzyme-
linked immunosorbent assay (ELISA) involving
4 different polyclonal antibodies, which has
been characterised in detail [34], as described
[11]. We established previously that the levels
of uPA protein released by these quiescent and
growth factor activated fibroblasts into the cul-
ture medium correlate significantly (Spearman
rank correlation rs=+0.96, P<0.001; n=24] with
the functional ability of uPA to convert plas-
minogen into plasmin [11]. 
RNA isolation and first strand cDNA synthesis
To enable measurement of specific mRNA
species from a relatively small number of fibro-
blasts, we quantitated mRNA transcripts by
reverse transcriptase polymerase chain reaction
(RT-PCR). Cellular RNA from fibroblasts, cul-
tured in duplicate for up to 4 days in experimen-
tal protein-free medium, was isolated using the
guanidium salt extraction with RNAzol B
(Campro, Veenendaal, The Netherlands)
according to the manufacturer's instruction. 1.0
µg RNA samples were reverse-transcribed at
37° C for 60 min in a total volume of 80 µl con-
taining Superscript II RNase H-RT, DTT, first-
strand buffer, RNasin, dNTP, oligo(dT) 12-18,
random hexamer primers, and first-strand buffer
(GibcoBRL, Grand Island, NY, USA) according
to the manufacturer's instruction. The resulting
cDNA samples were aliquoted, and stored at
–80° C before PCR amplification.
PCR-amplification of specific mRNA sequences
To enable comparison of the levels of specific
mRNAs in different samples, they were evalu-
ated as a ratio of the medium abundance house-
keeping gene hypoxanthine-guanine phospho-
ribosyltransferase (HPRT). Utilising the primer
sets depicted in Table 1, the specific sequences
in each cDNA sample were amplified by PCR.
The specificities of these intron-spanning
primer sets were verified by sequencing the
PCR products. Because some of the primer sets
interfered with the other primer sets, and to
enable divergence in the number of PCR cycles
between gene-sequences (see Table 1), we
chose to amplify each sequence separately. To
maximise uniformity in this setting, complete
110 µl cDNA PCR mixtures [containing 5%
(v/v) cDNA in a final concentration of 1.5 x Taq
DNA polymerase buffer with 1.5 mM MgCl2
(Promega, Leiden, The Netherlands), 1.5 mM
each dNTP (Amersham Pharmacia Biotech,
Roosendaal, The Netherlands), supplemented
with 2.5 U of Taq DNA polymerase (Promega)]
were equally divided at 20 µl over 5 tubes con-
taining the respective primer sets in 10 µl at a
final concentration of 0.5 µM of each primer. In
each PCR experiment one of the tubes always
contained the HPRT primer set to allow normal-
isation of the other mRNA expression levels.
After an initial denaturation of 4 min at 94° C,
cDNA was amplified in 23-31 PCR cycles, with
denaturation for 45 s at 94° C, annealing for 45
s at 57° C and extension for 45 s at 72° C per
cycle, with an additional extension for 6 min at
72° C after the last cycle. Initial experiments
were performed to establish conditions to
ensure that all genes were amplified linearly in
this experimental setting. Negative controls
included samples without reverse transcriptase
(RNA control), and samples where cDNA was
omitted (water control). Equal volumes of PCR
products were visualised in duplicate against
HPRT on 2% MetaPhor agarose gels (FMC
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Bioproducts, Rockland, ME) stained with ethi-
dium-bromide, and band intensities were meas-
ured by UV scanning using the Scanalytics
ONE-Dscan 1.0 software (Alpha Innotech Cor-
poration, Biozym). Figure 1 shows a representa-
tive example of a gel electrophoresis analysis of
uPA, uPAR, VEGF and HPRT mRNA expres-
sion levels after RT-PCR amplification. For all
individual cDNAs, amplification of each spe-
cific mRNA sequence was performed in at least
3 independently performed PCR experiments.
The inter-assay coefficient of variation (c.v.) for
control samples (cDNA of tumor-derived fibro-
blasts pre-cultured to near confluence in growth
medium, and analysed for specific uPA and
IGF-1 sequences against HPRT), for 12 inde-
pendently performed PCRs over a period of 6
months was 25%. This inter-assay c.v. includes
all prior handling involved in obtaining the PCR
products as well as the variation introduced by
gel electrophoresis.
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Table 1. Primer sets used for amplification of mRNA by RT-PCR.
a All primer sets (top=sense, bottom=anti-sense) were constructed and optimised for a 57°C annealing-temperature, are
intron-spanning, amplify a region within the coding region of the mature peptide, and showed product formation in at least
one fibroblast strain or cell line.
b Initial experiments were performed to establish the optimal number of cycles required in our experimental set-up to certify
that the analysis of the PCR products would occur during the amplification phase, prior to reaching the plateau phase.
c All PCR products were verified by sequence analysis and tested to agree with the expected size.
1 Reverse primer constructed in the reported alternative exon 7 of the uPAR gene to detect the soluble uPA binding protein
(s-uPAR), which arises from an alternative splicing in the middle of the third domain of uPAR, resulting in an alternative
exon 7 lacking the carboxy-terminal membrane attachment [50].
2 Primers constructed in the sequence of the mature peptide of the 18 kDa FGF-2 downstream the initiation sites of the reported
22.5 kDa and 21 kDa high molecular mass forms of FGF-2, and therefore applicable to detect all different FGF-2 mass forms
[51].   
3 Primers constructed to detect both the reported 121 kDa and 165 kDa secreted VEGF forms and the 189 kDa and 206 kDa
VEGF forms that remain cell associated (reviewed in [52]). With isoform specific primers we found that in our fibroblasts the
121 and 165 kDa splice variants were the isoforms most prominently present (data not shown).
4 Primers constructed within the exon 5 to exon 6 region, upstream the reported alternative splicing variant, ETS-1b, lacking
exon 7, therefore constructed to detect both the ETS-1a and ETS-1b variant, and downstream the reported splice variant
lacking exon 4 [53].
5 To detect both the alternatively spliced IGF-1A and IGF-1B precursors, primers were constructed to span intron 2 and 3 [54]. 
6 Used in the presence of 1 M betaine for optimal PCR amplification. 
7 Used in the presence of 2.5 mM MgCl2 for optimal PCR amplification.
Statistical analysis
In all individual cell culture experiments, fac-
tors were tested in duplicate. Results of one rep-
resentative experiment are expressed as means
± SD. Results of more than one independently
performed experiment are expressed as means ±
SEM. To test for differences between 2 groups,
the 2-sided Student's t-test was used, with
P<0.05 considered as statistically significant. 
RESULTS
Basal mRNA levels
To investigate the basal and FGF-induced
capacity of human breast fibroblasts to express
components of the PA and IGF systems in vitro,
we used a protein-free culture system. All
mRNA expression data were obtained from RT-
PCR experiments and normalised against the
housekeeping gene HPRT as shown in Figure 1.
Comparison of various basal steady-state
mRNA levels after normalisation against HPRT
in quiescent normal (N) and tumor-derived (T)
fibroblasts from the same patient are presented
in Figure 2. Although we were able to detect
IGFBP-1 mRNA transcripts in human MDA-
MB-231 breast cancer cells, and IGFBP-2
mRNA transcripts in human MCF7, T47-D,
ZR75.1 and SKBR-3 breast cancer cells (data
not shown), we were unable to detect IGFBP-1
and IGFBP-2 mRNA transcripts in quiescent
and FGF-activated N and T fibroblasts. As
shown in Figure 2 for the other mRNAs studied,
quiescent N and T fibroblasts expressed similar
amounts of tPA, PAI-2, IGF-2R, IGFBP-4,
IGFBP-6, and FGF-2 mRNA transcripts. uPAR,
its soluble form s-uPAR, IGF-2, and ETS-1
mRNA levels were only slightly (less than 1.5-
fold) elevated (P<0.05) and IGF-1R only
slightly decreased (P<0.01) in T fibroblasts
when compared with N fibroblasts. However,
the T fibroblasts expressed over 1.5-fold more
(P<0.01) PAI-1, uPA, IGFBP-3 and VEGF
mRNA transcripts and over 1.5-fold less
(P<0.01) IGF-1 and IGFBP-5 mRNA tran-
scripts when compared with N fibroblasts.
FGF-mediated alterations in mRNA expression and
uPA protein production
Previously we showed that FGF-1 and FGF-2
are able to induce uPA expression by fibroblasts
[11]. In addition, we have shown that IGF-1 and
uPA are inversely related, and that IGF-1, either
directly or indirectly, down-regulates uPA [24].
To further explore these latter findings, we
investigated a possible role for the FGFs in
these processes. To optimise and confirm the
specificity of our experimental approach, we
exposed both N and T fibroblasts for up to 4
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Figure 1. An example of a gel electrophoresis of RT-PCR amplified uPA, uPAR and VEGF mRNA normalised against HPRT
mRNA.
Quiescent fibroblasts were cultured for up to 4 days in experimental protein-free medium in the absence (control) or presence of 10
nM FGF-2. Total RNA was isolated 1, 4, 24, 48, and 96 h after the addition of experimental medium and analysed by RT-PCR to
obtain uPA, uPAR, VEGF, and HPRT mRNA. For each time-point separately, equal volumes of the different products were loaded
together in one gel slot with the corresponding HPRT mRNA product to allow subsequent normalisation of the uPA, uPAR, and VEGF
mRNA expression levels.
days to various concentrations of FGF-1 (0, 1,
2, 3.3, 10, 33 nM), FGF-2 (0, 1, 3.3, 10, 33 nM),
FGF-4 (0, 1, 2, 10 nM), FGF-5 (0, 5, 10, 50
nM), and FGF-7 (0, 1, 10 nM) before measuring
the amount of uPA protein released into the
medium during this time. These experiments
showed that neither FGF-5 nor FGF-7 were able
to significantly affect the amount of uPA protein
produced by these fibroblasts. In addition, as
analysed by RT-PCR 1, 4, 24, 48, and 96 h after
the addition of 10 nM, neither FGF-5 nor FGF-
7 were able to significantly affect any of the
studied mRNA levels (uPA, tPA, uPAR, PAI-1,
PAI-2, IGF-1, IGF-2, IGF-1R, IGF-2R and
FGF-2). Therefore we decided to further focus
our experiments on FGF-1, FGF-2, and FGF-4.
For all three, a time- and dose-dependent induc-
tion of uPA protein and uPA mRNA was
observed, peaking between 24 and 48 h and
reaching a plateau at the 10 nM concentration
(data not shown). The data presented in Figure 3
show that with 10 nM FGF-1, FGF-2, or FGF-4,
the levels of uPA protein released into the cul-
ture medium during 4 days peaked between 24
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Figure 2. Comparison of basal steady-state mRNA expression levels in quiescent N and T human breast fibroblasts.
Quiescent N and T fibroblasts were cultured for up to 4 days in protein-free medium as described in  the materials and methods sec-
tion. Total RNA was isolated 1, 2, and 4 days after the addition of protein-free medium and analysed by RT-PCR to quantify the basal
mRNA expression levels of the PA-, IGF-, and FGF-related genes as described in the materials and methods section. Bars represent
the means ± SEM of the 3 time-points (days 1, 2 and 4), as obtained from 3 independent cell culture experiments, each performed in
duplicate, and are expressed as fold-difference compared with the counter-part fibroblast strain. */** = significantly different from
the counter-part fibroblast strain (P<0.05/P<0.01).
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Figure 3. FGF-1, FGF-2, and FGF-4 induced effects on uPA
mRNA and uPA protein..
Quiescent N fibroblasts were cultured for up to 4 days in experi-
mental protein-free medium in the absence (control: - - -) or pres-
ence of 10 nM FGF-1 (-{-), 10 nM FGF-2 (-z-), or 10 nM FGF-4
(-∆-). Total RNA and conditioned medium were isolated 1, 2, and 4
days after the addition of experimental medium and analysed by
RT-PCR and ELISA to quantify uPA mRNA expression levels (panel
A) and accumulated uPA protein release into the culture medium
(panel B). Data are expressed as ratio treatment/control ± SD of
one cell culture experiment performed in duplicate. Similar results
were obtained in other experiments with T fibroblasts.
Table 2. Neutralisation of FGF-induced effects on uPA and uPAR mRNA.
Culture conditions of T fibroblasts exposed for 48 h to FGFs at the minimal dose required to elicit an uPA-inducing effect (2 nM
FGF-1, 1 nM FGF-2, 1 nM FGF-4, and a high dose of 10 nM FGF-7) in the absence or presence of specific neutralising anti-
bodies to block these FGF-induced effects, were as described in the materials and methods section. For controls, FGFs and anti-
FGFs were replaced for the proper vehicles (rabbit and goat IgG at the same concentrations used for the neutralising antibodies).
RT-PCR analysis of uPA and uPAR mRNA expression was performed as described in the materials and methods section.
Data shown are those of one experiment performed in duplicate, expressed as mean ratio treatment/control ± SD.
* = significantly different from controls cultured in the absence of (anti-)FGF;
 = significantly different from controls cultured in the presence of FGF (P<0.05).
and 48 h (Figure 3B), and mimicked the levels
of uPA mRNA measured in these cultures, that
reached an optimum at 24 h (Figure 3A). 
To verify the specificity of the FGF-induced
effects, we cultured the human breast T fibro-
blasts for 48 h in the absence and presence of
FGFs at the minimal dose required to elicit a
uPA-inducing effect (2 nM FGF-1, 1 nM FGF-
2, 1 nM FGF-4, and as a control a high dose of
10 nM FGF-7), and studied the ability of spe-
cific neutralising antibodies to block these FGF-
induced effects. While neither FGF-7 nor
anti-FGF-7 affected uPA and uPAR mRNA
levels, all other antibodies were able to signifi-
cantly inhibit the 1.7 to 3.7-fold FGF-mediated
increases in uPA and uPAR mRNA levels by 25-
100% (Table 2). Judged by the effects of the
antibodies on the basal uPA mRNA expression
levels in the control cultures (40% inhibition in
uPA mRNA), these fibroblasts expressed basal
uPA-inducing FGF-2 activity.
Differential effects of FGF-1, FGF-2, and FGF-4
Having established the optimal dose of 10 nM
and the specificity of the FGF-1, FGF-2, and
FGF-4 induced effects, we next investigated the
effects of these FGFs on the expression of PA-
and IGF-related mRNA transcripts. Despite the
differences in the basal steady-state mRNA
levels between N and T human breast fibro-
blasts (Figure 2), no differences were observed
between the responses of N fibroblasts to FGFs
compared with those exhibited by the T fibro-
blasts. Therefore, the results of the experiments
with N and T fibroblasts were combined. Figure
4 shows the kinetics of the mRNA expression
levels as a result of incubation with FGF-1 and
FGF-2. These graphs clearly show an inverse
relation between the mRNA expression levels
of the components of the PA system (Figure 4A)
and several of those of the IGF system (Figure
4B) following stimulation with FGF-1 and
FGF-2. A FGF-1- and FGF-2-induced up to 3-
fold up-regulation of mRNA levels of compo-
nents of the PA system was accompanied by an
up to 8-fold down-regulation of IGF-1 and an
up to 2-fold down-regulation of IGF-1R, IGF-
2R, and IGFBP-4 mRNA levels. Interestingly,
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Figure 4. Differential effects of FGF-1 and FGF-2 on PA- and
IGF-related mRNA levels.
Quiescent N and T fibroblasts were cultured for up to 4 days in
experimental protein-free medium in the absence (control: - - -) or
presence of 10 nM FGF-1 (-{-) or 10 nM FGF-2 (-z-). Total RNA
was isolated 1, 2, and 4 days after the addition of experimental
medium and analysed by RT-PCR to quantify the PA-related (panel
A) and IGF-related (panel B) mRNA expression levels. No differ-
ences were observed between the responses of N fibroblasts to
FGFs compared with those exhibited by the T fibroblasts. There-
fore, the results of the experiments with N and T fibroblasts are
combined in these figures. Data are expressed as ratio treat-
ment/control ± SEM of 6 independent cell culture experiments
(n=3 for both N and T fibroblasts), each performed in duplicate.
the effects elicited on IGF-2 mRNA levels
diverged distinctly between FGF-1 and FGF-2
(Figure 4B). Both FGF-1 and FGF-2 were
unable at any of the time-points to elicit a more
then 1.5-fold difference in the mRNA levels of
IGFBP-3, IGFBP-5 and IGFBP-6 compared
with controls (data not shown).
Despite the comparable up- and down-regula-
tions mediated by both FGF-1 and FGF-2, the
curves do show a time-dependent divergence in
the effects elicited by FGF-1 when compared
with those elicited by FGF-2. FGF-1 is able to
induce PA-related mRNA levels within 1 day,
followed by a rapid decrease back to base-line
levels. The FGF-2-induced effects tend to
increase further after the first day where after
they remain relatively stably increased for up to
4 days. Similarly, although both FGF-1 and
FGF-2 reduce IGF-1, IGF-1R, IGF-2R and
IGFBP-4 mRNA levels, these effects are rapid
and short-term when elicited by FGF-1. The
FGF-2-mediated inhibitions on these mRNAs
on the other hand, overall lag behind for one
day before they remain stably reduced for up to
4 days. For FGF-4 an in-between pattern of
time-dependent inductions and reductions
emerged for these mRNAs when compared with
those elicited by FGF-1 and FGF-2 (data not
shown).
Effect of blocking RNA synthesis on FGF-1- and
FGF-2-induced uPA expression
Our results thus far indicate a time-dependent
difference in the effects elicited by FGF-1 com-
pared with those elicited by FGF-2, with the
effects of FGF-1 being rapid and short-term and
those of FGF-2 overall lagging behind but
longer-lasting. This raised the question whether
FGF-1 and FGF-2 utilise different pathways
and/or whether an additional signal-trans-
duction pathway might be involved. To address
this question at the transcriptional level, we pre-
incubated fibroblasts for 15 min with the tran-
scription inhibitor actinomycin D (ACT) or
vehicle control, followed by an additional 24 h
culturing in the absence or presence of FGF-1 or
FGF-2. While ACT did not change the uPA
mRNA stability in unstimulated control cultures
(data not shown), both FGF-1 and FGF-2 com-
pletely lost their ability to stimulate uPA mRNA
synthesis after pre-incubation with ACT (Figure
5A) as well as their full ability to stimulate the
amount of uPA protein released into the culture
medium (Figure 5B). Similarly, all the other
inductions and reductions elicited by FGF-1 and
FGF-2 on the mRNA levels shown in Figure 4
were completely nullified after pre-incubation
with ACT (data not shown). This indicated that
the FGF-1- and FGF-2-mediated short-term
effects investigated in this study were the result
of altered gene transcription or altered mRNA
stability. In our culturing system the fibroblasts
were extremely sensitive to ACT. Once exposed
to ACT, even for only 15 min, we were unable
to culture these fibroblasts for longer than 24 h
without affecting their ability to stay adherent to
the culture surface. Therefore, the prolonged
effects elicited by FGF-2 on the various mRNA
levels compared with the effects elicited by
FGF-1 could as such not be addressed by these
experiments.
Effect of blocking protein synthesis on FGF-1- and
FGF-2-induced uPA expression
To address the existence of possible different
pathways at the translational level, we cultured
quiescent and FGF-activated fibroblasts for up
to 48 h in the absence and presence of the trans-
lation inhibitor cycloheximide (CHX). Adher-
ence to the culture surface only became a
problem for fibroblasts cultured for over 48 h in
the continuous presence of CHX. All FGF-1-
and FGF-2-mediated alterations on the PA- and
IGF-related mRNAs were annulled in cultures
treated for 24 and 48 h with CHX compared
with control cultures. Therefore, all the
observed short-term (24 h) and longer-term (48
h) effects mediated by both FGF-1 and FGF-2
had to be triggered by proteins that required de
novo synthesis. As an example, the results of the
24 h incubation in the presence of CHX on the
expression levels of uPA mRNA are presented
in Figure 6A, and on the amount of uPA protein
released into the culture medium during this 24
h in Figure 6B. However, a difference between
FGF-1- and FGF-2-induced effects emerged for
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Figure 5. FGF-1 and FGF-2 mediated changes in uPA mRNA and protein levels after blocking gene transcription.
Quiescent N and T fibroblasts, pre-incubated for 15 min with 5 µg/ml ACT (black bars) or with the vehicle only (open bars), were
cultured for an additional 24 h in fresh protein-free and ACT-free medium in the absence (control) or presence of 10 nM FGF-1 or
10 nM FGF-2. Total RNA and conditioned medium were isolated 24 h after the addition of experimental medium and analysed by
RT-PCR and ELISA to quantify uPA mRNA expression levels (panel A) and uPA protein release into the culture medium (panel B). No
differences were observed between the responses of N fibroblasts to FGFs compared with those exhibited by the T fibroblasts. There-
fore, the results of the experiments with N and T fibroblasts are combined in these figures. Data are expressed as ratio treatment/con-
trol ± SEM of 5 independent cell culture experiments (n=2 for N and n=3 for T fibroblasts), each performed in duplicate. * =
significantly different from controls cultured in the absence or presence of ACT (P<0.05).
Figure 6. FGF-1 and FGF-2 mediated changes in uPA mRNA and protein levels after blocking mRNA translation.
Quiescent N and T fibroblasts were cultured for 24 h, either in the presence of 50 µg/ml CHX (black bars) or in the presence of the
vehicle only (open bars), in experimental medium in the absence (control) or presence of 10 nM FGF-1 or 10 nM FGF-2. Total RNA
and conditioned medium were isolated 24 h (panels A and B), and 96 h (panels C and D) after the addition of experimental medium.
For the latter, cultures were thoroughly washed with PBS after the 24 h incubation period and subcultured for an additional 72 h in
fresh protein-free medium lacking CHX and FGFs. uPA mRNA levels and uPA protein release into the culture medium were analysed
with RT-PCR and ELISA. No differences were observed between the responses of N fibroblasts to FGFs compared with those exhib-
ited by the T fibroblasts. Therefore, the results of the experiments with N and T fibroblasts are combined in these figures. Data are
expressed as ratio treatment/control ± SEM of 4 independent cell culture experiments (n=2 for N and n=2 for T fibroblasts), each
performed in duplicate. * = significantly different from controls cultured in the absence or presence of CHX (P<0.05).
fibroblasts cultured for 24 h in the presence of
CHX and allowed to recover for an additional 3
days in protein-free medium lacking FGF-1,
FGF-2 and CHX (Figure 6C and 6D). In this
case, despite the inhibition of translation during
the first 24 h, FGF-2 pre-treatment was still able
to induce uPA mRNA and protein expression as
measured 3 days later. Thus, the observed long-
term effects elicited by FGF-2 resulted from
proteins produced or made available during the
72 h recovery period, following the 24 h incu-
bation in the presence of CHX. Similarly, the
long-term effects elicited by FGF-2 on the
mRNA levels of tPA, uPAR, PAI-1, PAI-2, IGF-
1, IGF-2, IGF-1R, IGF-2R, and IGFBP-4 (see
Figure 4) were not significantly affected by the
presence of CHX during the first 24 h.
DISCUSSION
Results only recently published on a ran-
domised prospective study of 556 patients with
lymph node-negative breast cancer [35], con-
firm that uPA and PAI-1 are strong and inde-
pendent prognostic factors for patients with
primary breast cancer and that uPA and PAI-1
measurements are especially useful for risk-
adapted individualized treatment strategies for
patients with node-negative disease. These new
clinically important level of evidence 1 type
studies [36], clearly indicate that a better under-
standing of the regulation of the PA system is
needed to explore these factors as targets for
tumor biology-oriented therapies. Stromal
involvement in tumor progression in general,
and in ECM degradation in particular, is a topic
of increasing interest. An understanding of the
behavior of stromal fibroblasts in the process of
plasminogen activator directed tumor invasion
and angiogenesis might be helpful in designing
future therapeutic strategies. For that purpose
we investigated the FGF-mediated alterations in
the mRNA levels of components related to the
PA- and IGF-systems in human breast fibro-
blasts in vitro.
In the absence of exogenously added FGFs we
noticed distinct mRNA expression profiles in
quiescent N fibroblasts compared with T fibro-
blasts. While N fibroblasts expressed higher
levels of mRNAs related to the IGF-1 system, T
fibroblasts expressed higher levels of mRNAs
related to the PA system, as well as IGFBP-3
and IGF-2. Although FGF-2 mRNA levels did
not differ between N and T fibroblasts, quies-
cent T fibroblasts expressed higher levels of
VEGF and ETS-1 mRNA. These data indicate a
difference between this set of human fibroblasts
established from malignant breast-tumor tissue
(T) and from adjacent normal breast tissue (N)
of the same patient. In vivo, similar differences
in PA-related [1, 5, 6], IGF-1 and IGF-2 [37],
VEGF [38] and ETS-1 [18] mRNA expression
profiles have been observed in fibroblasts in the
near vicinity of the tumor cells compared with
fibroblasts located in histologically normal
breast tissue. This indicates that the cultured N
and T fibroblasts used in this study still dis-
played at large their original and distinct pheno-
types. Notwithstanding, we can not exclude that
other distinct phenotypical differences were not
as well preserved in these cultured fibroblasts
removed from their in vivo environment.
Despite the differences in the basal steady-state
mRNA levels of N and T human breast fibro-
blasts, no differences were observed between
the responses of the N fibroblasts to FGFs com-
pared with those displayed by the T fibroblasts.
Thus, FGFs are able to induce the various
responses described in this study irrespective of
the distinct phenotypes of N and T fibroblasts,
suggesting that also N fibroblasts, once present
in a FGF-rich environment, are at risk of
becoming potent PA-producing cells. Both N
and T fibroblasts exhibited a time-dependent
difference in gene expression alterations elicited
by FGF-1 compared with those induced by
FGF-2, with the effects of FGF-1 being rapid
and short-term and those of FGF-2 overall lag-
ging behind but longerlasting. This raised the
question whether FGF-1 and FGF-2 might use
distinct signaling pathways. To answer this
question, we performed experiments aimed at
blocking transcription and translation. Blocking
transcription and translation demonstrated that
a) both the FGF-1- and FGF-2-induced effects
were the result of altered gene transcription or
mRNA stability, b) the short-term effects medi-
ated by FGF-1 and FGF-2 required de novo pro-
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tein synthesis, and c) even if the stimulus was
removed after a 24 h incubation, the long-term
effects elicited by FGF-2 remained. These data
suggest that accumulated mRNAs (with long
stability), which attribute to the FGF-2 signal-
ing, can induce the prolonged effect after
removal of the protein synthesis blockade.
Alternatively, the long-term effects did not
require the sustained presence of FGF-2
because FGF-2 was stored and released after the
24 h pre-incubation with CHX.
This latter mechanism is likely connected to the
binding-kinetics of FGFs to heparan proteogly-
cans (HSPGs). In 3T3 mouse fibroblasts for
example, active HSPGs have been shown to
contribute to the increased sensitivity of these
cells to FGF-2 compared to FGF-1 [39]. In
MDA-MB-231 human breast cancer cells, a dif-
ferential sensitivity to FGF-1 and FGF-2 has
been shown to be related to their binding-kinet-
ics to HSPG. While for FGF-1 there was only
one high affinity binding site with a fast associ-
ation rate (fast/high HSPG-R), for FGF-2 there
was, in addition to this fast/high HSPG-R, also
a lower affinity binding site with a slow associ-
ation rate [15]. FGF bound to HSPG can be
released by plasmin, which will increase the
availability of biologically active FGF [40, 41].
Since uPA is able to convert inactive plasmino-
gen into active plasmin [7], FGFs are able to
control their own bioavailability through their
action on the PA system. From the literature we
deduce that the binding-kinetics of FGF-4 to
HSPG are in between those of FGF-1 and FGF-
2 [42]. Therefore, the differential binding of
FGFs to fibroblast-associated HSPGs may very
well explain the rapid but transient response to
FGF-1 (one binding site for HSPG), the bi-
phasic sustained response to FGF-2 (two bind-
ing sites for HSPG), and the intermediate
response to FGF-4.
Like we showed previously for human breast
fibroblasts at the level of uPA mRNA, uPA and
PAI-1 protein, and their ability to generate plas-
min [11, 24], uPA activity in the conditioned
medium of osteosarcoma cells decreased signif-
icantly when they were cultured in the presence
of exogenously added IGF-1 [43]. These studies
are in contrast to the study of Dunn et al., which
reported an up-regulation of uPA in the human
breast cancer cell line MDA-MB-231 by IGF-1
[44]. The present study however confirms the
negative correlation between IGF-1 and uPA in
human breast fibroblasts and extends this to all
components of the PA system (uPA, tPA, uPAR,
PAI-1 and PAI-2) being inversely related to
IGF-1, IGF-1R, IGF-2R, and IGFBP-4. The
action of IGF-1 on the PA system may, like dis-
cussed by Lalou and co-workers for osteosar-
coma cells [43], involve a regulatory loop
whereby IGF-1 controls its own bioavailability
through its action on the PA system, which reg-
ulates dissociation of IGF-1 from IGFBPs. At
the cellular level IGFBPs are thought to inhibit
the actions of the IGFs, but under specific cir-
cumstances they may potentiate their metabolic
and mitogenic effects (reviewed in [25-28]). In
this study, of the six IGFBPs examined, only
IGFBP-4 mRNA expression was notably
affected by the presence of FGF-1, FGF-2, and
FGF-4. Therefore, our results do not indicate
that IGFBP mRNA expression levels in general
are greatly affected by FGFs. This does how-
ever not exclude FGF-induced differences in the
regulation at protein level or changes in the
extracellular activities of IGFBPs. Similarly
like described above for FGF-HSPG com-
plexes, plasmin (generated through PA catal-
ysed activation of plasminogen) is able to
increase the availability of biologically active
IGF in the pericellular environment by dissoci-
ation of IGF-IGFBP complexes [43, 45].
Only in case of IGF-2 mRNA expression the
effects mediated by FGF-1 (a short-term 2-fold
down-regulation) and FGF-2 (a 2.5-fold up-
regulation after 3 days) diverged distinctly. In
various studies, high stromal-derived IGF-2
levels have been correlated with increased
tumorigenicity (reviewed in [37, 46]). Our
results implicate FGF-2 as a potential factor
responsible for these high stromal-derived
IGF-2 levels.
Several research groups have examined a possi-
ble correlation between expression levels and
localisation of FGF and prognosis in patients
with breast cancer [13, 29, 30, 47, 48]. Although
these reports show discrepancies, possibly due
to the different techniques used to assess the
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expression levels and localisation of the FGFs,
the overall consensus appears to be that high
levels of FGF-1 and FGF-2 in human breast
carcinoma are associated with good prognostic
features such as low stage and small tumor size.
In the micro-environment, in contrast to IGF-2,
which is also produced by the epithelial tumor
cells, fibroblasts are the main suppliers of IGF-
1, a potent mitogen for epithelial cells [49].
From our mRNA expression data it can be
deduced that FGFs are able to decrease the
levels of mitogenic IGF-1 which otherwise
would have been available for the breast epithe-
lial (tumor) cells. This may be an explanation
for the overall consensus that high levels of
FGF are associated with favorable prognosis in
patients with breast cancer. On the other hand,
we have shown that FGF-2 and, although to a
lesser extent, FGF-1 and FGF-4 are powerful
inducers of the PA system in these fibroblasts,
which would indicate a poor prognosis
(reviewed in [8-10]). This might suggest that
the balance of the FGF-induced effects on the
IGF-system (decrease in production of mito-
gens for tumor cells = good prognosis) and PA-
system (increase in production of factors
associated with migration, invasion, and angio-
genesis = poor prognosis) is of influence on the
overall prognosis.
In conclusion, our data show that FGFs differ-
entially affect the mRNA expression of compo-
nents related to the PA and IGF systems in
human breast fibroblasts. Furthermore, the data
imply that of the FGFs studied, especially FGF-
2 may be an effective target for therapeutical
strategies aimed at diminishing the contribution
of stromal fibroblasts in the PA-directed breast
tumor proteolysis.
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Aging of stromal-derived human breast fibroblasts
might contribute to breast cancer progression
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ABSTRACT
Age is an important factor in the development
and spread of breast cancer. Stromal cells also
contribute to breast cancer growth and metasta-
sis through the production of extracellular
matrix (ECM) modifiers such as urokinase type
plasminogen activator (uPA), its receptor
(uPAR), its inhibitors (PAI-1 and PAI-2), matrix
metalloproteinases (MMPs), and growth fac-
tors, including the fibroblast and insulin-like
growth factors (FGFs and IGFs). In the present
study we have investigated whether breast
fibroblasts aged in vitro through passage in cul-
ture display altered levels of the plasminogen
activator system and growth factors that are
known to modulate that system.
With real-time RT-PCR we found that during
passage human breast fibroblasts, whether
derived from the tumor burden or from matched
adjacent normal breast tissue, exhibited a con-
sistent increase in PAI-1 and FGF-1 and a
decrease in MMP-2 mRNA expression. In addi-
tion, in 5 out of 7 fibroblast strains we observed
an induction of uPA expression in combination
with a reduced IGF-1 expression. Interestingly,
while during aging MMP-2 protein increased in
all tumor-derived fibroblast strains, these pro-
tein levels were reduced in all normal-tissue-
derived fibroblasts. No other clear-cut
age-dependent alterations were found in the all-
together 26 factors investigated. We further-
more demonstrate in one tumor-derived
fibroblast strain that the increases in uPA and
PAI-1 mRNA and MMP-2 protein production
are inversely related to the telomere length.
Artificially increasing telomere length in this
fibroblast strain by expressing human telom-
erase reverse transcriptase (hTERT) prevented
senescence and resulted in late passage cultures
with early passage uPA, PAI-1 and MMP-2
levels.
Our results show that aging accompanied by
telomere loss induces PAI-1 and FGF-1 and
reduces MMP-2 mRNA expression in all breast
fibroblast strains, increases uPA and decreases
IGF-1 mRNA expression in a subset, and
increases MMP-2 protein expression only in
tumor-derived breast fibroblasts. These age-
induced levels of PAI-1, FGF-1, uPA and MMP-
2 in stromal breast fibroblast could contribute to
breast cancer progression. 
INTRODUCTION
ECM modifiers such as uPA, its receptor uPAR
and its inhibitor PAI-1, MMPs, and cathepsins,
are linked to poor prognosis in breast cancer
[1-8]. Interestingly, the expression of these
remodelling proteins is not always increased in
the tumor cells but quite often in the adjacent
stromal tissue [9-14]. Some of those (PAI-1,
uPA, MMP-2, MMP-9, MMP-11 and MMP-13)
are particularly increased in stromal cells that
border the expanding tumor [11-16]. The pi-
votal role of these stromal derived matrix
remodelling proteins in cancer biology is under-
scored in knock out mice models where in the
absence of stromal uPA, PAI-1, MMP-2 or
MMP-9, tumor growth and/or spread to distant
locations is clearly impaired [17-20]. Thus, the
local microenvironment is an important driving
force stimulating the invasive and malignant
behavior of primary tumor cells [21-26].
Age is an important risk factor in many cancers,
including breast cancer, but its role in cancer
has predominantly been linked to the accumula-
tion of DNA damage in the primary tumor [27].
Much less attention has been paid to the role of
stromal cells in this process. In contrast, delayed
wound healing and impaired migration in the
skin as a result of aging has been ascribed to
altered levels of stromal ECM modulators [28].
Furthermore, skin fibroblasts aged in vitro to
senescence secrete increasing amounts of uPA,
PAI-1, MMPs and tissue inhibitors of MMPs
(TIMP) [29-34]. Similar to wound healing and
migration, breast cancer growth and metastasis
require ECM remodelling processes. Thus, age
related changes in the urokinase system might
contribute to metastasis in the breast. The con-
tribution of aging to breast cancer growth and
Keywords: plasminogen activator, breast cancer, aging, stroma, telomerase.
metastasis was recently underlined by demon-
strating that senescent fibroblasts stimulated in
vitro growth of mouse and human mammary
epithelial cells more efficiently when compared
to younger fibroblasts [35]. Similarly, in mice
senescent human fibroblasts stimulated epithe-
lial mammary tumor cell growth more effec-
tively than young fibroblasts [35]. To follow-up
on this work, we studied changes in factors
related to the plasminogen activator system in
aging human breast fibroblasts.
In the past we have isolated different sets of
breast fibroblast strains derived from the pri-
mary tumor and from normal breast tissue adja-
cent to the tumor of the same patient. In these
strains, we determined expression of compo-
nents of the IGF and urokinase system and
showed that the levels of these components can
be modulated by several known growth factors
including FGF-1, -2 and -4, TGF-ß1 and IGF-1
[36-38].
In the present study we have used in vitro pas-
saging of these normal- and tumor-tissue-
derived breast fibroblast strains as a model
system for aging in vivo. For this, early and late
passage cultures were compared. We initially
focussed on uPA but later we extended our
study to other components of the urokinase
system as well as modulatory factors. Since
aging and subsequent senescence in vitro has
been ascribed to telomere attrition in many dif-
ferent stromal cells [39], we determined telom-
ere length decline after passaging in these
strains. In order to revert the aging process, we
extended telomere length in one of the fibro-
blast strains through the introduction of human
telomerase reverse transcriptase.
The results show that upon aging all fibroblast
strains induce PAI-1 and FGF-1 mRNA and
only a subset of the strains uPA mRNA. Fur-
thermore, while in tumor-derived fibroblasts the
levels of MMP-2 protein increase, those meas-
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Table 1. Intron-spanning primers used for quantitative real-time RT-PCR.
* 1 mM MgCl2 added to the final 25 µl PCR mixture.
ured in normal-tissue-derived fibroblasts
decrease with age. In one of the strains we show
that introduction of human telomerase reverse
transcriptase reverts the changes in PAI-1, uPA
and MMP-2, suggesting that telomere attrition
with increasing passages is responsible for these
inductions in this aging tumor-derived human
breast fibroblast strain.
MATERIALS AND METHODS
Tissue culture
Eight different human fibroblast strains
described in detail before [40] were used. The
strains were established from invasive ductal
breast adenocarcinoma tumor-tissue fragments
(T) and from adjacent normal breast tissue (N)
of the same patients. Due to the large size of the
primary tumor, one patient (n° 26) received
chemotherapy (FEC) before the tumor was
removed. The human MDA-MB-231-BAG and
MCF7-BAG breast cancer cell lines (which
contain the LacZ gene, encoding β-galactosi-
dase) were kindly provided by Dr. N. Brünner
(Finsen Laboratory, Copenhagen, Denmark).
Fibroblast strains and epithelial cell lines were
maintained as described [37].
Culture of fibroblast strains in protein-free medium
Different passages and strains of normal and
tumor-derived breast fibroblasts were split one
to three into 162 cm2 culture flasks. To deplete
the cells of exogenous serum-related factors, the
cells were at 90% confluence washed twice
with PBS and placed overnight on serum- and
protein-free medium (PFM) [37]. The next day
the cells were washed again with PBS and
placed on fresh PFM. After 4 days the cells
were harvested for RNA and protein isolation
(see below).
uPA ELISA
For uPA protein production, fibroblasts were
plated in PFM in 6-well Pronectin F coated
tissue culture plates (ICN Biomedicals, Cleve-
land, OH) as described [37]. After 4 days, PFM
was replaced and cells were allowed to accumu-
late uPA protein for four days. After 4 days
medium and cells were harvested and prepared
for measurement of released and cell-bound
uPA by ELISA [37, 41].
RNA isolation, cDNA synthesis and quantification of
specific mRNA species
Total RNA was extracted with RNAzol B
(Campro, Veenendaal, The Netherlands)
according to the manufacturer from fibroblasts
cultured as described above. Total RNA (6 µg)
was reverse-transcribed using oligo(dT)12-18
and random hexamer primers (Superscript
RNAse H- kit, Invitrogen, Breda, The Nether-
lands) according to the manufacturer’s instruc-
tion. Copy DNA samples were treated with
RNase H- (Promega, Leiden, The Netherlands).
Real-time quantitative PCR was performed in
an ABI Prism 7700 apparatus (Applied Biosys-
tems, Foster City, USA) using for each cDNA
quantified the intron-spanning forward and
reverse primer combination (Table 1). The PCR
products were generated in 35-40 cycles of 15 s
denaturing at 95° C, 30 s annealing at 62° C,
20 s extension at 72° C and an additional 20 s
extension at 79° C in a volume of 25 µl contain-
ing 30 ng cDNA, 330 nM forward and reverse
primer and 12.5 µl SYBR-green PCR-master-
mixture (Applied Biosystems). Depending on
the melting temperature of the products, SYBR-
green fluorescent signals were acquired after
each cycle at 72° C or at 79° C. The size of each
PCR product was initially verified as well as the
efficiency of amplification. Each run included a
calibration curve of a serial diluted cDNA pool
of human breast fibroblasts and cell lines. Cycle
threshold (Ct) values were obtained at a fixed
threshold value of 0.02. For all individual
cDNAs, amplification of each specific mRNA
sequence was performed in at least 2 independ-
ently performed PCR experiments. The errors in
duplicates were always less than 25%, else the
PCR was repeated. Target gene levels were cal-
culated as the mean mRNA-level relative to
the housekeeping gene hypoxanthine-guanine
phosphoribosyltransferase (HPRT) using Ct
values
(mRNA target = 2(mean Ct HPRT - mean Ct target)).
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Methylation status of CpG island in the uPA pro-
moter
Genomic DNA from different fibroblast strains,
MDA-MB-231-BAG and MCF7-BAG was iso-
lated as described [42]. Genomic DNA (4 µg)
was digested with Pst I, Pst I/Hpa II, Pst I/Hha
I or Pst I/Msp I, phenol/chloroform extracted
and precipitated. To determine if the CpG island
of the uPA promoter was methylated, a PCR (30
cycles and an annealing temperature of 58° C)
was performed on digested genomic DNA with
primers that flank the CpG island (TGGGC-
GAGGTAGAGAGTCTCCTGTGC and CTG-
CGGTCTCCGACTGTGCTGCG). PCR pro-
ducts were analysed on 2.0% metaphore
agarose gels.
Western blotting and immunostaining
Sub-confluent fibroblasts serum-starved as
described above were washed twice with 10
mM Tris-HCl (pH=7.4), scraped, pelleted and
stored at –80° C until further use. Proteins were
extracted from the cell pellets using the 3-step
extraction protocol (ReadyPrep Sequential
extraction kit; Biorad, Veenendaal, The Nether-
lands). Briefly, cells were resuspended in 40
mM ice-cold Tris base supplemented with 10%
(v/v) of a protease inhibitor cocktail (#P-9599,
Sigma, Zwijndrecht, The Netherlands), 1 mM
PMFS (#P-7626, Sigma), DNAse I (#DNEP,
Sigma), and RNAse A (#R4642, Sigma). Cells
were disrupted by 3 repetitive freeze/thaw
cycles followed by a 10 min ultrasound sonica-
tion. Soluble proteins were separated from the
intermediate soluble and insoluble proteins by
centrifugation. The remaining pellet used in our
analysis was dissolved in 40 mM Tris base con-
taining 8 M urea, 4% (w/v) CHAPS, 0.2% (w/v)
BioLyte 3/10 ampholyte and 20 mM TBP. Sam-
ples (3-5 µg) were separated in denaturing
MOPS/SDS buffer on a 4 to 12 % gradient
NuPAGE Bis-Tris gel (Invitrogen) according to
the manufacturer. Subsequently, proteins were
electroblotted to HyBond-P PVDF membranes.
Membranes blocked overnight in blocking
buffer [3% BSA in 20 mM Tris-HCl (pH=7.4),
150 mM NaCl (TBS) and 0.05% Tween] were
incubated for 1 h at room temperature in block-
ing buffer with primary antibody (anti-hα-SMA
clone 1A4 (Dako, Glostrup, Denmark); anti-
hMMP-2 clone Ab-3 (Oncogene Research prod-
ucts, Boston, USA); anti-hp53 clone DO-1 or
clone Pab-240 (sc-126 and sc-99, respectively,
Santa Cruz Biotechnology, CA, USA),
antipropyl 4-hydroxylase clone 5B5 (M0877,
Dako), anti-vimentin clone V9 (M0725, Dako),
anti-hGAPDH (Chemicon International,
Temecula, USA), or mouse IgG1k (X0931,
DAKO)). Blots were developed with peroxi-
dase labelled rabbit anti-mouse IgG (P0161,
Dako; 1:5000 in blocking buffer) followed by
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Figure 1. uPA protein production and mRNA expression in aging 19N and 19T breast fibroblasts.
Indicated passages of subconfluent (90%) 19T and 19N breast fibroblast were plated, cultured in duplicate and serum-starved for 4
days in PFM in Pronectin F coated plates. After that, uPA accumulation was allowed to proceed for 4 days and the amount of released
(A) and cell-bound (B) uPA was measured by ELISA. Data shown are the means ± SD of duplicate cell cultures. Basal uPA mRNA
levels (C) were determined by quantitative real-time RT-PCR as described in the material and methods. Data shown are expressed
as fold of the levels measured in passage number 13 (expression set at 1.0) and are the means ± SD of two independently performed
PCR reactions.
ECL chemiluminescence (Amersham, Eind-
hoven, The Netherlands). Expected product
sizes were verified with reference proteins
(#161-0318, Biorad). Quantification of the
intensity of the protein bands relative to band of
the housekeeper GAPDH was determined using
Scanalytics ONE-D scan software (Alpha
Innotech Ltd., Cannock, United Kingdom).
Retroviral gene transfer
The retroviral expression construct containing
hTERT, pBabe-hTERT, and the empty retroviral
expression vector pBabe-puro used have been
described [43, 44]. The retroviral packaging cell
line Phoenix-AMPHO was a gift from Dr. Gary
Nolan (Stanford University, Stanford, CA) and
was maintained as described previously
(http://www.stanford.edu/group/nolan/). Retro-
viral gene transfer was performed essentially as
described previously [45]. Briefly, Phoenix-
AMPHO cells were transfected with retroviral
transfer plasmid (4 µg per well) using Fugene-6
reagent (Roche Diagnostics, Indianapolis, IN,
USA). Two days after transfection, the medium
containing the retroviruses was applied to a
fibroblast culture at 40% confluence and infec-
tion was allowed to proceed for 24 h. Then a
second batch of medium containing retroviruses
made as described above was added and infec-
tion was proceeded for another 24 h. Fibroblasts
that had successfully incorporated a retroviral
copy were selected with puromycin (2 µg/ml;
Sigma).
Telomere length measurements, TRAP assay and
senescence associated β-galactosidase staining
For telomere length measurements genomic
DNA was isolated as described above. DNA (3
µg) was digested with Hinf I and Rsa I, sepa-
rated on 0.7% agarose, blotted to Hybond N+
nylon membrane (Amersham) and hybridised
with a 32P-labelled telomeric (CCCTAA)4 probe
as described [46]. The blot was exposed to a
PhosphorImager screen to visualise bound
telomeric probe. To determine telomerase activ-
ity, cell pellets were solubilised and assayed for
telomerase activity by using a PCR-based
telomere repeat amplification protocol assay
[47] according to the manufacturer (TRAPeze
Telomerase detection kit, Intergen, Purchase,
NY, USA). For senescence associated β-galac-
tosidase staining, fibroblasts (50% confluent)
were fixed in 3.7% formadehyde in PBS for 10
min and stained for 3 to 4 days at 37° C with 5-
bromo-4-chloro-3-indolyl-β-D-galactopyra-
noside (XGAL) at pH=6 as described [48].
RESULTS
Cell-bound and secreted uPA accumulation in aging
breast fibroblasts 
The significance of uPA protein production in
breast fibroblasts during passage in vitro as a
model for aging was studied first in one normal
(19N) and one tumor-derived breast fibroblast
strain (19T) that were both obtained from one
patient. Comparison of basal uPA protein pro-
duction in aging fibroblasts is best studied in
serum-starved sub-confluent cultures in culture
plates coated with Pronectin F [29, 30, 38]. In
the tumor-tissue-derived fibroblast strain the
levels of released (Figure 1A) and cell-associ-
ated uPA (Figure 1B) increased with increasing
passage number. The difference was most strik-
ing in the cultures of fibroblasts reaching senes-
cence, which produced 2- to 3-fold more uPA
protein when compared to the earliest passage
studied. In contrast, no such increase in released
(Figure 1A) or cell-bound uPA (Figure 1B) was
seen in the normal fibroblast strain 19N cul-
tured under similar conditions. To determine
whether the upregulation of uPA protein during
passage in vitro was at the protein or at the
mRNA level, we compared uPA mRNA levels
between different passages of serum-starved
19N and 19T fibroblasts that were cultured in
Pronectin F coated plates. Upon passage, the
basal uPA mRNA levels of 19T fibroblast
increased 1.8-fold while those of 19N fibroblast
did not clearly change (Figure 1C). Thus, uPA
protein levels reflect mRNA levels indicating
that the upregulation of uPA protein in 19T
fibroblasts during passage in vitro is at the
mRNA level.
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Methylation of the uPA promoter
Increased expression of the uPA gene in the 19T
breast fibroblast strain during passage in vitro
could be responsible for the increased mRNA
levels. Recently, in the breast cancer cell line
MCF7 the uPA promoter was shown to be
silenced through methylation at the CpG island
present in its promoter [49]. Thus, a relieve of
repression through the loss of methylation of
the CpG island in the uPA promoter might
explain the increase in mRNA levels during
passage. Therefore, the methylation status of the
CpG island in the human uPA promoter was
determined in early and late passage 19T fibro-
blasts. To determine the methylation status of
the CpG island in the uPA promoter we used
methylation sensitive (Hha I and Hpa II) and
insensitive (Msp I) restriction enzymes fol-
lowed by PCR amplification with primers
flanking the CpG island (Figure 2). As controls
we included MCF7 and MDA-MB-231 cells
from which the methylation status has been
studied before [49]. The results show that, sim-
ilar to MDA-MB-231 cells, the promoter of uPA
is hardly methylated in early as well as in late
passage 19T fibroblasts because after digestion
of genomic DNA with both methylation sensi-
tive and insensitive enzymes little PCR product
was generated from the CpG island studied
(Figure 2). Also in other young fibroblast strains
tested (19N, 26T and 26N) the CpG island in
the uPA promoter was not methylated (not
shown). On the other hand, and in line with pre-
vious work [49], the CpG island in MCF7 cells
was methylated. Hence, unlike the breast cancer
cell line MCF7, the transcription of uPA in 19T
fibroblasts is not negatively regulated through
methylation of the CpG island in its promoter.
Therefore, loss of methylation of the CpG
island in the uPA promoter does not explain
increased uPA mRNA levels observed in late
passage 19T fibroblasts.
Quantification of components in aging fibroblasts
that are relevant to breast cancer metastasis
Next, we examined whether the difference in
uPA levels between normal (19N) and tumor-
derived (19T) breast fibroblast strains was
observed in other sets of aging fibroblast
strains. In addition, to get a broader understand-
ing of age related changes in breast fibroblasts
we broadened our analysis and included 26
markers relevant to the role of stromal fibro-
blasts in breast cancer growth and metastasis
[11-16, 36-38, 50]. The study included ECM
proteases and inhibitors (uPA, uPAR and solu-
ble uPAR, PAI-1 and PAI-2, MMP-2 and MMP-
9), growth factors known to modulate ECM
proteases and their inhibitors (TGF-β1, FGFs,
IGFs and IGFBPs, HGF, EMMPRIN, TSP-1
and VEGF), the myofibroblast differentiation
marker α-SMA [51], and the fibroblast markers
5B5 and VIM [52, 53]. In addition, we meas-
ured wild type p53 levels, a marker for senes-
cence [54]. Early and late passages of 4 sets of
matched human breast fibroblasts strains were
compared. Unfortunately, one strain of normal
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Figure 2. Methylation status of the CpG island in the uPA
promoter does not change between young and aged 19T
fibroblasts.
Genomic DNA was isolated from young (passage number 11)
and aged (passage number 20) 19T fibroblasts, from MCF7-
BAG and from MDA-MB-231-BAG cells.The genomic DNA
was digested with Pst I to allow efficient amplification.The
methylation status was determined by digestion with either a
methylation sensitive (Hha I or Hpa II) or a methylation
insensitive enzyme (Msp I), that all recognise the targeted
CpG island, followed by subsequent amplification of the CpG
island with primers flanking the island as described in the
material and methods.To control for amplification, DNA
digested with Pst I alone was included. PCR fragments (330
bp) generated are shown for each different cell line studied.
fibroblasts from one patient could not be
analysed due to lack of late-passage material
(poor growth). Before analysis, the different
passages of the different strains were made qui-
escent by serum-starvation in PFM. The major-
ity of the markers were analysed at the mRNA
level and basal mRNA levels were measured by
quantitative real-time PCR using the house-
keeping gene HPRT as a reference (Table 2). In
some cases basal protein levels were deter-
mined. These were the (myo)fibroblast markers
(SMA, 5B5 and VIM), and MMP-2 and p53
that are well-known to be regulated at the pro-
tein level [55]. Protein levels were measured on
western blots relative to GAPDH protein levels
(Table 2).
From the mRNA’s quantified of the uPA system,
the basal mRNA expression levels of only
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Table 2. Relative basal mRNA and protein expression of 26 markers in aging fibroblasts.1
1 mRNA values (median and range) of 7 late passage breast fibroblasts are expressed relative to the levels measured in early
passage (set at 1.0). All mRNA levels were measured in duplicate by quantative real-time RT-PCR as described in
materials and methods using the housekeeping gene HPRT as standard.
2 Protein levels (median and range) of late passage breast fibroblasts are expressed relative to the levels
measured in early passage. All protein levels were measured in duplicate on Western blots using chemiluminescence as
described in materials and methods. The signals were normalised against the signal obtained from the GAPDH protein.
3 A two-sided paired t-test was used to compare normalised levels of early passage versus late passage fibroblasts.
PAI-1 (P=0.01) correlated positively with
increasing passage number (Table 2). uPA
mRNA showed only a very weak trend
(P=0.18) towards increased expression but a
subset of the strains (19T, 22T, 25N, 25T and
26N) showed a consistent increase (1.2- to 3-
fold). Of the other factors, FGF-1 mRNA corre-
lated positively (P=0.01) and MMP-2 mRNA
negatively (P=0.02) with increasing passage
number. The other mRNA levels did not change
significantly with increasing age of the culture
(Table 2). MMP-9 mRNA levels were too low to
be accurately analysed with SYBR-green (Ct-
values higher than 33). This low expression of
MMP-9 mRNA is in line with previous work on
breast fibroblasts [56].
Interestingly, MMP-2 protein levels in all
normal fibroblast strains tended towards a
decrease (0.62 ± 0.17; P=0.06, n=3, two-sided
paired t-test) and followed the mRNA levels. In
contrast, MMP-2 protein levels in tumor-associ-
ated fibroblast showed a tendency to an increase
(2.43 ± 1.00; P=0.06, n=4, two-sided paired t-
test). The response of tumor-derived fibroblasts
was significantly different from that of normal
fibroblasts (P=0.03, two-sided standard t-test),
suggesting that MMP-2 protein production
downstream of the messenger during aging is
changed in tumor-derived fibroblasts. p53
levels did not change nor did the fibroblast
markers 5B5 and VIM. The levels of α-SMA
showed a wide variation but tended towards an
increase with increasing passage number
(P=0.08).
All fibroblast strains loose telomere length upon
passage in vitro
Many human fibroblast strains become senes-
cent upon extensive passage due to telomere
attrition [57]. We determined telomere length
with increasing passage number in our fibro-
blast strains (Figure 3 and results not shown).
Since telomere length is hard to measure accu-
rately due to large intercellular variation, we
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Figure 4. Telomerase activity is successfully introduced in
19T fibroblasts.
Lysates from 19T fibroblasts (500 cells) infected with empty
vector (19TB) or with a retroviral vector containing hTERT
(19TT) were analysed for telomerase activity using a stan-
dard TRAP assay as described in the materials and methods.
Lysates (500 cells) from MCF7-BAG cells that contain telom-
erase activity [59] as well as a buffer control (1xCHAPS)
were included. Lysates of 19TB and 19TT containing 10,000
cells were also analysed (19TB 20x and 19TT 20x). Heat-
inactivated samples did not show any specific amplification
products.
Telomerase repeats, indicative of telomerase activity, are vis-
ible as a ladder. Note that, due to the increased amplification
efficiency, the smallest repeat is usually most abundant.
When no repeats were observed, as is the case in lysates from
empty vector infected fibroblasts, a short synthetic 36 bp
telomere repeat present in the PCR serves to confirm a suc-
cessful amplification  procedure.
Figure 3. Telomere length declines during passage of breast
fibroblasts.
HinfI and RsaI digested genomic DNA isolated from indicated
passages of indicated fibroblast strains (19T, 22T, 26N and
26T) were separated on 0.7% agarose gels before hybridiza-
tion with a telomeric probe to detect telomere repeat as
described in the materials and methods section.
have included additional passages (i.e. 19T and
22T). All strains showed a decrease in telomere
length with increasing passage number (Figure
3, only 19T, 22T, 26N, and 26T are shown).
Concluding, in all breast fibroblast strains
telomere length declined with increasing pas-
sage number but in some less dramatically than
others. Thus, the strains are ageing due to the
end replication problem resulting in replicative
senescence [58].
Human telomerase reverse transcriptase restores
telomere length loss as well as uPA and PAI-1
mRNA levels and MMP-2 protein levels in 19T fibro-
blasts
To study the direct role of telomere loss on the
induction of uPA and PAI-1 mRNA and MMP-2
protein during passage in vitro, we introduced
human telomerase reverse transcriptase
(hTERT) into the tumor-derived fibroblast strain
19T. This strain showed an increase in PAI-1
and uPA mRNA and MMP-2 protein during pas-
sage. Since fibroblasts are hard to transfect we
introduced hTERT into this fibroblast strain
using a retroviral delivery system [45]. Retro-
viruses were introduced in pre-senescent fibro-
blasts at passage number 16. We generated one
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Figure 6. Telomere length is extended after the introduction
of telomerase in 19T fibroblasts.
HinfI and RsaI digested genomic DNA isolated from a control
breast carcinoma line MDA-MB-231, from 19T fibroblasts
(passage number 10, 16 and 20) and from empty vector
infected 19TB fibroblasts (passage number 19) and from
hTERT-infected 19TT fibroblasts (passage number 20, 32 and
42), was separated on 0.7% agarose gel and blotted to a
nylon membrane.The blot was hybridised with a telomeric
probe to detect telomere repeats as described in Figure 3.
Figure 5. Senescence associated β-galactosidase staining in young and old fibroblasts with or without telomerase.
Subconfluent young (passage number 13; A) and old (passage number 27; B) 19T fibroblast and old 19T fibroblasts (passage number
27) infected with empty vector (C) or hTERT (D) were stained for senescence associated β-galactosidase activity as descibed in
material and methods. Positive stained cells are indicated with an arrow.
fibroblast subculture, 19TB, infected with the
empty retroviral vector pBabe-puro [44] and
another, 19TT, with the retroviral vector con-
taining human telomerase reverse transcriptase
(phTERT) [43]. To test successful delivery we
measured telomerase activity in both subcul-
tures (Figure 4). While in the 19TB subculture
no telomerase activity could be measured using
a standard TRAP assay [47], telomerase activity
was readily detectable in 19TT fibroblasts, indi-
cating that the transduction was successful. The
activity was approximately 5% of that present
in MCF7 cells, a cell line known to have con-
siderable telomerase activity [59]. To further
verify the significance of this amount of telom-
erase, we performed senescence-associated β-
galactosidase staining (SA-β-gal staining) on
19TB and 19TT fibroblasts and in early and late
passage 19T fibroblasts (Figure 5). SA-β-gal
staining is a marker for senescence indicative of
aging fibroblasts [48]. The 19TB fibroblast cells
infected with the empty vector showed SA-β-
gal staining (5-10%; Figure 5C) which was
comparable to the levels observed in the
parental 19T fibroblast strain of similar passage
(Figure 5B). In contrast, less than 1% staining
was seen in the 19TT line that contains hTERT
(Figure 5D). Similar levels were seen in early
passage 19T fibroblasts (Figure 5A). Conclud-
ing, senescence was not observed in the late
passage 19TT fibroblast line. Absence of senes-
cence was further substantiated by successful
passaging of the 19TT line currently beyond
passage number 55. This passage number was
never reached by 19TB fibroblasts nor by the
parental 19T fibroblasts.
Next, we determined telomere length in 19TB
and 19TT fibroblasts (Figure 6). While telomere
length (approx. 6 kb) in 19TB fibroblasts (pas-
sage number 19) was comparable to the parental
fibroblasts of the similar passage, telomeres of
19TT fibroblast were clearly elongated (approx-
imately 10 kb). Telomeres of 19TT fibroblasts
at this passage were even longer than the telom-
ere length of early passage 19T fibroblasts.
Interestingly, upon continued culturing in vitro
of the 19TT strain, telomere length further
increased and reached a length of approx-
imately 12 kb in passage number 32 and 42
(Figure 6). In humans, telomeres of this length
are only seen in germ cells that do contain
telomerase activity [39]. Concluding, loss of
telomeres and occurrence of senescence can be
overcome by the introduction of human telom-
erase reverse transcriptase in this tumor-derived
breast fibroblast strain.
Finally, we determined the levels of uPA and
PAI-1 mRNA and MMP-2 protein in different
passages of hTERT-infected fibroblasts (Figure
7A, 7B and 7C). To study the effect of hTERT
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Figure 7. uPA and PAI-1 mRNA and MPP2 protein levels return to the levels seen in young fibroblasts.
Young and aged 19T breast fibroblast of indicated passage number (open bars), late passage empty vector infected 19TB (passage
number 22) (shaded bars) and different passages of hTERT-infected 19TT fibroblasts (black bars) were all at 90% confluence serum-
starved for 4 days prior to RNA isolation. Basal uPA (A) and PAI-1 (B) mRNA levels were determined by quantitative real-time RT-
PCR as described in the material and methods. Basal MMP-2 protein levels (C) were determined by Western blot as described in the
material and methods.The levels shown in the graph are all relative to levels in early passage 19T fibroblasts (expression set at 1.0).
expression on uPA and PAI-1 mRNA expression
we measured their levels in senescent 19TB
fibroblasts (passage number 22) and in 19TT
fibroblasts from passage number 22 onwards
(Figure 7A and 7B). Similar to a late passage
parental strain (passage number 18), line 19TT
(passage number 22) and near-senescent 19TB
(passage number 22) fibroblasts had approxi-
mately 1.8-fold more uPA mRNA and 2.6-fold
more PAI-1 mRNA levels compared with the
early passage parental 19T fibroblast strain
(passage number 13). The levels of uPA mRNA
declined gradually in the next 10 passages to
return to the levels seen in  early passage 19T
fibroblasts (passage number 13) (Figure 7A).
For PAI-1, mRNA levels also declined, but this
decline took 10 passages more to return to the
levels seen in young fibroblasts (Figure 7B).
MMP-2 protein levels were 1.5- to 1.8-fold
upregulated as well in late passage 19T and
19TB fibroblasts and in 19TT fibroblast of sim-
ilar passage number (Figure 7C). Those levels
also declined gradually with increasing passage
to the levels seen in early passage 19T fibro-
blasts. Thus, in this tumor-derived fibroblast
strain telomere reconstitution results in mRNA
levels of uPA and PAI-1, and protein levels of
MMP-2 comparable to the levels in early pas-
sage 19T fibroblasts. 
DISCUSSION
Breast cancer metastasis requires ECM remod-
elling. Aging of stromal fibroblasts might con-
tribute to this process by increased production
of proteins with metastatic potential. Here, we
studied during aging in human breast fibroblasts
changes in the urokinase system, in MMPs and
in relevant modulating factors. The fibroblast
strains were isolated either from the tumor
burden or from adjacent normal tissue; each set
from one and the same patient. Among the ECM
remodelling proteins studied, only PAI-1
mRNA consistently increased during aging in
all strains. uPA mRNA was increased only in
some of the strains. An increase in PAI-1 and
uPA protein and mRNA during aging has been
observed before in fibroblasts from skin and
lung [30, 34]. PAI-1 protein was also elevated in
endothelial cells aged in vitro [30], suggesting
that age related induction of particularly PAI-1
is a general phenomenon.
Besides changes in the uPA system, we found
that MMP-2 protein levels were upregulated in
aged tumor-derived fibroblast strains. In normal
breast-derived strains, MMP-2 protein levels
followed the decrease in expression of the
mRNA during passage. Upregulation of MMPs
(MMP-1, -2 and -3) as well as of one of their
inhibitors (TIMP-2) has also been observed in
other fibroblast strains aged in vitro [29, 31, 32].
In contrast, MMP-9 expression was unde-
tectable in all strains independent of age. This
contrasts the abundant presence of MMP-9 in
the fibroblasts bordering the tumor burden [12]
suggesting that MMP-9 expression in breast
fibroblast is completely dependent on inducing
factors from the tumor [56].
What is causing the age related changes in ECM
remodelling proteins is poorly understood. It is
clear from previous work that short telomeres
lead, presumably via the release of telomere
binding proteins, to upregulation of proteins
involved in cell cycle arrest such as p16 and in
certain cases p53 [39, 60-62]. p16 and p53
might subsequently upregulate PAI-1, uPA and
MMP-2. p53 has previously been shown to reg-
ulate PAI-1 promoter activity directly through
binding to a p53 response element in the pro-
moter [63]. A similar link of p53 to the induc-
tion of uPA mRNA has not been described. In
the current work we did not find a role for p53
since the levels of p53 protein did not consis-
tently change during passage. Thus, the upregu-
lation of PAI-1 mRNA during passage of breast
fibroblast does not appear to result from
increased levels of p53 protein.
Among the growth factors analysed we only
observed a consistent increase of FGF-1, but
the relatively slight changes in FGF-1 during
aging can probably not explain the larger
changes in PAI-1 mRNA. We have previously
shown that FGF-1 can modestly upregulate PAI-
1 mRNA in 19T and 19N fibroblasts [50]. The
response of uPA to FGF-1 was more pro-
nounced which would be inconsistent with the
current observation made in all the strains.
Besides FGF-1, the modulating factors
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IGFBP3, TSP-1 and VEGF tended towards
increased expression during aging and, there-
fore, these may become statistically significant
if a larger panel is studied. Altered TGF-β
response has been suggested to regulate MMPs
in aging skin fibroblasts [64], yet, TGF-β1
mRNA levels did not change in our breast fibro-
blasts during passage in vitro. Thus, altered
TGF-β1 mRNA levels can not explain increased
levels of PAI-1. Still though, bioavailability
might have changed during passage. Even so,
changing TGF-β activity alone cannot explain
the increase in PAI-1 and uPA levels seen in the
majority of the aging breast fibroblast because
TGF-β generally stimulates PAI-1 expression
[65], while it decreases uPA expression in
human fibroblasts [37].
The inverse correlation between IGF-1 and uPA
in breast fibroblasts that we observed before
[36] is also seen here in all the strains during
aging in vitro. This confirms that IGF-I and uPA
either regulate each other via an autocrine loop
[36, 50] or are co-regulated. Interestingly, the
moderate to large increases  in IGFBP3 seen in
a number of the lines will cooperate with loss of
IGF-1 expression and indicates that most aging
breast fibroblasts are devoid of IGF signalling
similar to other aging fibroblasts [66].
Besides the consistent increase of some mark-
ers, most of them did not change consistent with
increased passage number. Even analysis of all
changes in expression during passage in all
strains did not reveal a clear clustering of fibro-
blasts according to the patient they were derived
from, nor according to whether the fibroblast
were derived from normal or tumor tissue (not
shown). This suggests a large heterogeneity
among the strains. Large heterogeneity is also
observed in fibroblasts from different sources
(e.g. skin versus lung) and from elder donors
[67, 68]. Due to this heterogeneity, the contribu-
tion of age-induced stromal factors to breast
cancer may be very dependent on the individ-
ual.
Recently, it was reported that breast fibroblasts
derived from normal donors could not be
immortalised by expression of hTERT alone
[69]. Our tumor-derived fibroblast strain 19T
was, however, immortalised after the introduc-
tion of hTERT and has now been cultured for
over 55 passages. Our results are more in line
with the view that short telomeres induce senes-
cence in human fibroblasts [39, 57]. However,
our immortalised fibroblast strain was derived
from tumor tissue and may behave different
from fibroblasts derived from normal breast
tissue. Indeed, our tumor-derived strain can be
passaged several population doublings more
than the normal breast-derived fibroblast strain
that was derived at the same time from the same
patient. Also 19N and 19T fibroblasts produce
different amounts of uPA [50]. Furthermore,
during aging MMP-2 levels change differently
in normal compared with tumor-derived fibro-
blasts. From this we can conclude that tumor-
derived breast fibroblasts even upon extensive
passaging in vitro behave different from normal
breast fibroblasts, confirming that breast fibro-
blasts are programmed by the primary tumor.
Not all fibroblast strains seem to arrest at the
same telomere length (Figure 3). The tumor-
derived strain 22T arrests with telomeres of
approximately 6 kb while other strains such
26N and 26T arrest already with telomeres of
around 8 kb. This is in line with the view that
not the average telomere length determines
senescence but rather the number of chromo-
somes that lack telomeres. In addition, telomere
length may not be the only factor that controls
the onset of senescence [61].
Telomere elongation using hTERT in the 19T
strain not only overcomes replicative senes-
cence but it also restores uPA and PAI-1 mRNA
levels and MMP-2 protein levels to the levels of
early passage fibroblasts. This directly implies
that telomere reconstitution by telomerase regu-
lates changes in uPA, PAI-1 and MMP-2 in this
fibroblast strain. However, since the levels of
uPA, PAI-1 and MMP-2 decline only after sev-
eral passages, while telomere reconstitution is
almost instantaneous, the mechanism that is
responsible for the induction of PAI-1, uPA and
MMP-2 must be stable for several passages.
Methylation of the CpG islands as we have
studied for the uPA promoter does not seem
responsible for such programming because the
methylation status of the uPA CpG island was
not altered in aging 19T fibroblasts. The true
61
Expression of ECM modifying factors in aging breast fibroblasts
mechanism underlying this response thus
remains unknown. However, it may be related
to the mechanism that causes replicative senes-
cence itself, a mechanism that is considered
poorly reversible.
Finally, Campisi and coworkers [35] have
recently shown that senescent fibroblasts are
more potent growth promoters of epithelial
tumor cells in vitro and of tumor growth and
metastasis in mice in vivo. An effect that might
be explained by the increased levels of PAI-1
and FGF-1 and possibly uPA and MMP-2 in
senescent breast fibroblasts. Translating these
data to humans, this suggests that increased
stromal levels of PAI-1, uPA and FGF-1 mRNA
and MMP-2 protein could contribute to breast
cancer progression in older women. 
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ABSTRACT
Purpose: To evaluate the predictive value of the
disintegrin and metalloproteinases, ADAM-9,
ADAM-10, ADAM-11, and ADAM-12, and of
the matrix metalloproteinases, MMP-2 and
MMP-9, in patients with recurrent breast cancer
treated with tamoxifen.
Experimental Design: A retrospective study
was done on 259 frozen specimens of estrogen
receptor-positive primary breast carcinomas
from patients who developed recurrent disease
and were treated with tamoxifen as the first line
of therapy. The expression levels of the biologi-
cal factors were assessed by real-time quantita-
tive reverse transcriptase PCR.
Results: Using log-transformed continuous
variables, increasing levels of ADAM-9 (odds
ratio (OR)=1.41; P=0.015) and decreasing
levels of MMP-9 (OR, 0.81; P=0.035) predicted
favorable disease control independent from the
traditional predictive factors. Furthermore,
when tumors were dichotomized at the median
level of 70% epithelial tumor cell nuclei, our
univariate analysis showed particularly strong
results for the group of 153 patients with pri-
mary tumors containing 30% or more stromal
cells. Although estrogen receptor levels lost
their predictive power for this group of patients,
high levels of ADAM-9 (OR,1.59; P=0.007) and
ADAM-11 (OR,1.65; P=0.001) were signifi-
cantly associated with a higher efficacy of
tamoxifen therapy.
Conclusions: Our results show that especially
for primary tumors containing stromal ele-
ments, the assessment of mRNA expression
levels of ADAM-9 and ADAM-11 could be
useful to identify patients with recurrent breast
cancer who are likely to benefit or fail from
tamoxifen therapy.
INTRODUCTION
The ADAMs, which stands for a disintegrin and
metalloproteinase, also known as MDCs, are a
newly discovered family of membrane proteins.
All ADAMs possess some or all of the follow-
ing domains: a signal peptide, a propeptide, a
metalloprotease, a disintegrin, a cysteine-rich
domain, an epidermal growth factor–like
domain, a transmembrane sequence, and a cyto-
plasmic tail. The propeptide might be involved
in latency with activation upon loss, the metal-
loprotease domain in proteolysis, the disintegrin
domain in adhesion, the cysteine-rich domain in
fusion and adhesion, the epidermal growth
factor–like domain in growth factor activity,
and the cytoplasmic tail in cell signaling. The
possession of these multiple domains with their
potential functions makes them likely candi-
dates to play a role in cancer cell invasion and
metastasis. Indeed, some of these ADAMs have
already been linked to various diseases includ-
ing cancer [1–5]. Despite the above findings, a
definite role for any ADAM in either cancer for-
mation, progression, or response to therapy,
remains to be shown.
In recurrent breast cancer, steroid hormone
receptor status is one of the variables often used
to determine the choice of endocrine therapy.
Thus far, tamoxifen is the most extensively used
hormonal treatment, although only 50% to 60%
of the treated patients will benefit [6–8].
Because proteases such as the urokinase-type
plasminogen activator have been shown to be
associated with failure of tamoxifen therapy in
patients with recurrent breast cancer [9, 10], we
hypothesized that specific ADAMs might also
be associated with therapeutic failure.
Thus far, over 30 different ADAMs have been
described, of which 19 appear in humans. For
our study, we selected four ADAMs for which
no pseudogenes have been described and which
have already been shown to be expressed to
some extent in human breast cancer. Of these
four, only ADAM-11, also named MDC, does
not possess an active matrix metalloproteinase
(MMP)–like domain. However, based on its
location within a loss of heterozygosity region
of chromosome 17q21 [11, 12], ADAM-11 has
Keywords: ADAM, breast cancer, tamoxifen, response prediction, real-time RT-PCR.
been proposed to be a candidate tumor suppres-
sor gene for human breast cancer [13, 14] and
was therefore included in our study. The other
three members included in this study, ADAM-9
(MDC9, meltrin-γ), ADAM-10 (Kuz, SUP-17,
MADM), and ADAM-12 (meltrin-α) all possess
an active MMP-like domain, and in addition
have all been reported to be increased in malig-
nant compared with normal breast tissue [3, 15].
We also included two well-known members of
the MMP-family, MMP-2 and MMP-9, which
have also been reported to be increased in
malignant compared with normal breast tissue
[16–20]. Because most MMPs are localized to
the tumor stroma [17, 21], we suspected that
this might also be the case for the ADAMs. We
therefore compared mRNA levels measured
from human breast tissue sections containing
predominantly (>70%) epithelial tumor cells
with those measured in sections containing at
least 30% stromal cells.
In this report of our retrospective study which
includes 259 patients with estrogen receptor
(ER)–positive primary breast tumors treated
with tamoxifen for recurrent breast cancer, we
show that, especially in stroma-enriched pri-
mary tumors, ADAM-9 and ADAM-11 are able
to predict the efficacy of first-line tamoxifen
therapy.
PATIENTS AND METHODS
Patients
The Medical Ethical Committee of the Erasmus
Medical Center Rotterdam, the Netherlands,
approved our study design (MEC 02.953). This
retrospective study included 259 female breast
cancer patients for which the following inclu-
sion criteria were used: all patients should have
measurable disease that was treated with tamox-
ifen as first-line treatment for metastatic dis-
ease; all patients underwent primary surgery for
breast cancer; diagnosis took place between
1979 and 1996; the primary tumor should be
ER-positive and >100 mg tissue should be
available. Exclusion criteria were: neo-adjuvant
therapy or adjuvant hormonal treatment; if the
follow-up period during tamoxifen treatment
was only 6 months or less and patient was still
alive but showed no response or therapy was
stopped for other reasons than progression (e.g.,
subjective or objective toxicity) during these 6
months; if previous other cancers were experi-
enced (except basal cell skin cancer or early-
stage cervical cancer stage Ia/Ib). Following the
above criteria, 340 tumors were available for
analysis. Of the tissues, 15% were excluded
from this study because the sections contained
<30% tumor cell nuclei (see below). Another
9% were excluded because of poor RNA quality
(see below). The remaining 259 eligible patients
were treated either with breast-conserving sur-
gery (36%) or with modified mastectomy
(64%). An axillary dissection was done in 94%
of the patients (n=244). Twenty-five patients
received cyclophosphamide, methotrexate, 5-
fluorouracil, whereas 17 patients received
anthracyclin-containing adjuvant chemother-
apy. Relevant clinicopathologic characteristics
of the patients and their primary tumor are given
in Table 1. Follow-up scheduling of physical
and instrumental exams, which, depending on
the type of metastasis, included computerized
tomography scan, bone scan, magnetic reso-
nance imaging, X-rays as well as plasma tumor
marker levels, were done as described recently
in detail [22]. The date of diagnosis of metasta-
sis was defined as that at confirmation of metas-
tasis after symptoms reported by the patient,
detection of clinical signs, or at regular follow-
up. Twenty-four patients presented with distant
metastasis at diagnosis or developed distant
metastasis (including supraclavicular lymph
node metastasis) within 1 month after primary
surgery (M1 patients). These 24 patients and the
235 patients who developed a recurrence during
follow-up (24 patients with local-regional
relapse, 211 patients with distant metastasis)
were treated with first-line tamoxifen (40 mg
daily). Of the 235 M0 patients, the median time
between primary surgery and start of therapy
was 27 months (range, 4-164 months). At the
time of surgical removal of the primary tumor,
the median age of the patients was 58 years
(range, 26-89 years), and at the start of tamox-
ifen therapy for recurrent disease, the median
age of the patients was 61 years (range, 29-90
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years). Response to tamoxifen therapy was
defined by standard Unio Internationale Contra
Cancrum criteria [23]. Objective response was
observed in 53 patients (12 complete remission
and 41 partial remission), and 87 patients had an
increase in tumor size of 25% or more, or
showed new tumor lesions within 3 months
(progressive disease). The 119 patients with no
evident tumor reduction of 50% or more (com-
plete remission and partial remission) or a
tumor-progression (progressive disease), were
considered as patients with no change. These
patients with no change were divided into 103
patients who had no change at >6 months
(defined as stable disease) and 16 patients with
no change at ≤6 months. The median progres-
sion-free survival ratios were: complete remis-
sion, 37 months; partial remission, 16 months;
stable disease, 14 months; no change at ≤6
months, 5 months; and for progressive disease,
3 months. Because the patients with stable dis-
ease had a progression-free survival similar to
patients with partial remission, we classified
these patients as responders to tamoxifen as
advised by the European Organization for
Research and Treatment of Cancer [24]. There-
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Table 1. Associations of biological factors with clinicopathologic factors.
*   Due to different assay conditions and amplicon lengths, absolute values of the biological factors can only be compared within   
a gene assay.
†  Because of others and unknowns, numbers do not always add up to 259.
‡  At start of first-line therapy for recurrent disease.
§  P forMann-Whitney U test.
P for Kruskal-Wallis test, including a Wilcoxon-type test for trend when appropriate.
fore, as has been done before [25–27], disease
control was defined in our study as complete
remission + partial remission + stable disease.
For 156 patients (60%), disease was controlled
by tamoxifen therapy. The median follow-up of
patients alive after surgery was 90 months
(range, 10-190 months) and 37 months (range,
4-131 months) after start of tamoxifen therapy.
At the end of the follow-up period, 238 (92%)
patients had developed tumor progression and
202 (78%) patients had died.
Tissue processing
After primary surgery, a representative part of
the tumor was selected by the pathologist,
frozen in liquid nitrogen, and sent to our labora-
tory for routine determination of ER and
progesterone receptor (PgR) by ligand binding
assay or enzyme immunoassay [28]. Tumor
cytosols were prepared and processed as recom-
mended by the European Organization for
Research and Treatment of Cancer [29]. The
cut-point used to classify tumors as ER- or PgR-
positive was 10 fmol/mg cytosolic protein. The
remainder of the tumor tissue was stored in our
liquid nitrogen tumor bank at the Erasmus MC.
For RNA isolation, 20 to 60 cryostat sections of
30 µm, corresponding to 30 to 100 mg, were cut
from these tissues. Before, during, and after cut-
ting the sections for RNA isolation, 5 µm sec-
tions were cut for H&E staining to assess the
amount of tumor cells relative to the amount of
surrounding stromal cells. The amount of nuclei
evidently of epithelial tumor cell origin relative
to the amount of surrounding stromal cells was
estimated with a 100-fold magnification in 10
different areas covering the area of each of the
three H&E sections. The fraction of tumor cells
over stromal cells throughout the sections did
not change greatly between the first and last
section (mean coefficient of variation, 6%).
Only specimens with at least 30% of the nuclei
evidently of epithelial tumor cell origin and dis-
tributed uniformly over at least 70% of the sec-
tion area were included.
RNA isolation and cDNA synthesis
Total RNA was extracted with RNAzol B
(Campro, Veenendaal, the Netherlands) accord-
ing to the manufacturer and stored aliquoted in
RNase/DNase-free water at –80° C. Five micro-
grams of total RNA sample aliquots were
reverse-transcribed with oligo(dT)12-18 and
random hexamer primers in a final volume of
40 µl using the Superscript II RNase H- kit from
Invitrogen (Breda, the Netherlands) and used
according to the manufacturer’s instructions.
Prior to PCR, the resulting cDNA samples were
treated for 30 min at 37° C with four units of
RNase H- (Ambion, Huntington, United King-
dom). The quantity and quality of the isolated
RNA was established by UV spectroscopy, by
examination of ribosomal RNA bands after
agarose gel electrophoresis, and by the ability of
the sample to be linearly amplified in a serial
dilution with our housekeeping gene set (see
next section for further details). Samples of total
RNA not showing both the 18S and 28S bands
(6%) or at 15 ng reverse-transcribed total RNA
not amplifiable within 26 cycles at our fixed
threshold value of 0.02 (see below) with our
housekeeping set, which was the case for 3% of
our samples, were excluded from this study.
Quantification of specific mRNA species
Real-time quantitative PCR was done in an ABI
Prism 7700 Sequence Detection System
(Applied Biosystems, Nieuwerkerk a/d IJssel,
the Netherlands) using both the Assay-on-
Demand kits from Applied Biosystems and the
intron spanning forward and reverse primer
combinations shown in Table 2. PCR reactions
were done in a final volume of 25 µl containing
cDNA synthesized from 5 to 15 ng of total
RNA, 330 nmol/l forward and reverse primer
and 12.5 µl SYBR-green PCR master mixture
(Applied Biosystems) or Brilliant SYBR Green
Master Mix (Stratagene, Amsterdam, the
Netherlands). For the Assay-on-Demand kits,
the protocol with 40 rounds of amplification
recommended by the manufacturer was used.
For the SYBR-based assays, the following pro-
tocol was used. After 10 min of denaturation
and activation of the Taq-DNA polymerase,
PCR products were amplified in 35 cycles with
15 s of denaturing at 95° C, 30 s of annealing at
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62° C, 10 s of ramping to 72° C, 20 s of exten-
sion at 72° C, 10 s of ramping to 79° C, and 20
s at 79° C. To avoid possible detection of
primer-dimers, which usually melt at lower
temperatures, SYBR green fluorescent signals
of the products were acquired after each cycle at
79° C for PCR products with melting tempera-
tures >80° C and only at 72° C for those with
melting temperatures <80° C. A reference dye,
ROX, was included in all assays to normalize
data for non–PCR related signal variation. Ini-
tial PCRs followed by product-melting curve
analyses and gel electrophoresis experiments
were done to ensure that with the PCR condi-
tions and the different primer sets used, only
one product of the expected size was amplified,
and that for each gene an additional cycle
resulted in a doubling of PCR product, i.e., that
all genes were amplified with an efficiency of at
least 95%. In addition, the PCR efficiency of
each gene-specific real-time PCR session was
validated with a standard curve constructed
from a simultaneously run serially diluted
cDNA pool of human breast fibroblasts and
cell-lines. Negative controls included samples
without reverse transcriptase and samples
where total RNA and cDNA was replaced with
genomic DNA. Quantitative values were
obtained from the threshold cycle (Ct) at which
the increase in SYBR green or TaqMan probe
fluorescent signal associated with an exponen-
tial increase of PCR products reached the fixed
threshold value of 0.02, which was in all cases,
at least 10-fold the standard deviation of the
background signal. To enable comparison of the
levels of specific mRNAs in different samples,
they were evaluated relative to the average
expression levels of three housekeeping genes:
the low abundance housekeeping gene porpho-
bilinogen deaminase (PBGD), the medium
abundance housekeeping gene hypoxanthine-
guanine phosphoribosyltransferase (HPRT),
and the high abundance housekeeping gene β-2-
microglobulin (β2M). With this set of house-
keeping genes, the potential influence of
sample-specific fluctuations in one of the
housekeeping genes will be minimized. Levels
of the target genes expressed relative to this
72
Clin Cancer Res 2005Chapter 4
Table 2. Intron-skipping primers used for real-time PCR.
NOTE: Twenty-seven percent of the samples analyzed for ADAM-11 with the SYBR-based assay and 2% of the samples analyzed
for ADAM-12 with the probe-based assay did not show detectable levels after, respectively, 35 and 40 cycles of amplification. To
validate our personally designed SYBR-based ADAM-9 and ADAM-11 assays, we also analyzed samples with the commercially
available probe-based Assay-on-Demand kits forADAM-9 and ADAM-11. These assays correlated well with our personally-
designed SYBR-based assays (Spearman rs=0.75; n=245, P<0.001 for ADAM-9 and rs=0.45; n=243, P<0.001 for
ADAM-11).We chose to use our personally designed SYBR-based quantitative PCR assays for all factors, except for ADAM-10
and ADAM-12, for which we used the Assay-on-Demand kit.
Abbreviations: HPRT, hypoxanthine-guanine phosphoribosyltransferase; PBGD, porphobilinogen deaminase;
β2M, β-2-microglobulin.
*  Assay done with TaqMan probes in Universal PCR master mixture (Applied Biosystems).
† Assay done in Brilliant SYBR green PCR master mixture (Stratagene).
‡ Assay done in SYBR green PCR master mixture (Applied Biosystems).
housekeeping set were quantified as follows:
mRNA target = 2(mean Ct housekeeping genes - mean Ct target).
Immunohistochemistry
To assess the source of the relevant mRNA
species for this study, formalin-fixed, paraffin-
embedded breast tumor tissues were analyzed
by immunohistochemistry. Formalin-fixed,
paraffin-embedded tumors were sectioned at
5 µm, mounted on StarFrost slides, dried,
deparaffinized in xylene and rehydrated in
graded solutions of ethanol and distilled water.
Prior to immunostaining, specimens were pre-
treated with 1 mmol/l EDTA (pH 8.0) for 10
min at 121° C in an autoclave, cooled to room
temperature, rinsed in PBS followed by a 15
min peroxidase (0.3%) and a 30 min bovine
serum albumin (5%) block. The following pri-
mary antibodies were used: anti-ADAM-9 goat
polyclonal antibody (Santa Cruz Biotechnology,
Santa Cruz, CA; clone C-15; dilution 1:200);
anti- ADAM-11 goat polyclonal antibody
(Santa Cruz Biotechnology, clone H-19; dilu-
tion 1:200); anti-PR mouse monoclonal anti-
body (Dako Diagnostica GmbH, Hamburg,
Germany; clone 1A6; dilution 1:320); anti-ER-
α mouse monoclonal antibody (Dako Diagnos-
tica; clone 1D5; dilution 1:320). After the
primary antibody, ADAM-9 and ADAM-11
immunoreactions were visualized by a standard
streptavidin-biotinperoxidase complex (Strept
ABC) method (DAKO, Diagnostica GmbH,
Hamburg, Germany) followed by 3,3´-
diaminobenzidine enzymatic development. ER-
α and PgR were visualized using the DAKO
EnVision+System-HRP mouse kit (DAKO).
Sections were counterstained with hematoxylin.
The specificity of immunostaining was con-
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Table 3. Cox univariate and multivariate regression analysis for disease control with first-line tamoxifen
therapy.
* Biological factors were separately introduced as log-transformed continuous variable to the base multivariate  model that
included the factors menopausal status, DSR (dominant site of relapse), DFI (disease-free interval)  and ER-α and PGR mRNA
levels as log-transformed continuous variables.
† Because of missing values, numbers do not always add up to 259.
‡ At start of first-line therapy for recurrent disease.
trolled using normal goat and mouse IgG and by
omitting the primary antibodies.
To assess the correlation between ER-α and
PGR mRNA and protein levels, ER-α and PgR
immunoreactivity was also assessed in 108 ran-
domly selected frozen sections matching the
frozen sections used for RNA isolation. These
sections were cut, fixed in 4% paraformalde-
hyde, and analyzed for ER-α and PgR
immunoreactivity as described above for the
paraffin-embedded samples, except for the
deparaffinization and pretreatment steps and
with antibodies diluted 1:320. The percentage
of epithelial tumor cells with positive nuclei
was estimated with a 100-fold magnification in
10 different areas covering the section and
scored in five categories as follows: 0% (1),
<10% (2), 10% to 25% (3), 25% to 50% (4),
>50% (5).
Statistics
Differences in levels were assessed with the
Mann-Whitney U test or Kruskal-Wallis test,
including a Wilcoxon-type test for trend, when
appropriate. In these tests, patient and tumor
characteristics were used as grouping variables.
The strengths of the associations between con-
tinuous variables were tested with the Spearman
rank correlation (rs). For the analysis of treat-
ment benefit, transformations of the variables
were explored with fractional polynomials. The
gain in χ2 values was not substantial when using
transformations other than log-transformations.
Fractional polynomials did not result in statisti-
cally significantly better fit. The relation with
disease control-to-therapy was examined with
logistic regression analysis. Odds ratios (OR)
were calculated and are presented with their
95% confidence interval (CI). The likelihood
ratio test in logistic regression models was used
to test for differences. The Cox proportional
hazard model was used to calculate the hazard
ratio and 95% CI in the analysis of progression-
free survival. Progression- free survival was the
time that the patients were treated with tamox-
ifen as first-line systemic treatment for recurrent
disease. The start of tamoxifen therapy was set
at zero and the end point at the stop-date of
tamoxifen therapy or last date of follow-up. The
proportionality assumption was investigated
using a test based on the Schoenfeld residuals
[30]. Three equal thirds were used to categorize
the variable to low, intermediate, and high. Sur-
vival curves were generated using the method
of Kaplan and Meier (1958) and the logrank test
was used to test for differences. All P values are
two-sided and P<0.05 was considered statisti-
cally significant. Computations were done with
the use of STATA statistical package, release 8.2
(STATA Corp., College Station, TX).
RESULTS
Correlations between biological factors
To verify that the sections used for RNA isola-
tion were representative of the whole tumor
with respect to ER and PgR levels, all samples
were analyzed for ER and PGR mRNA expres-
sion. In agreement with the selection of ER pro-
tein–positive samples, none of the RNA
samples tested negative for ER mRNA. In addi-
tion, ER and PGR mRNA levels correlated sig-
nificantly with the amount of ER or PgR protein
as measured in the cytosols (Spearman rank
correlation, rs=0.62; P<0.001 for ER, n=259;
and rs=0.63; P<0.001 for PGR; n=255) and by
immunohistochemistry (Kruskal-Wallis test:
χ2=31.09; df=4; P<0.001 for ER, n=108; and
χ2=55.95; df=4; P<0.001 for PgR, n=108).
Spearman rank correlation further revealed
meaningful (defined as P<0.001 for n=250 to
259) correlations between ADAM-9 and ADAM-
10 (rs=0.28), ADAM-12 (rs=0.28), MMP-2
(rs=0.36), and MMP-9 (rs=0.27). In addition,
ADAM-10 correlated with ADAM-12 (rs=0.41),
MMP-2 (rs=0.34), and MMP-9 (rs=0.24),
ADAM-12 with MMP-2 (rs=0.69) and MMP-9
(rs=0.34), and MMP-2 with MMP-9 (rs=0.34).
ER-α mRNA only correlated with PGR mRNA
(rs=0.25), and ADAM-11 showed no correlation
(P<0.001) with any of the biological factors
studied.
Associations of the expression levels with clinico-
pathologic factors
The associations of clinicopathologic factors
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with the biological factors at the median mRNA
level are depicted in Table 1. None of the
mRNA levels correlated with the dominant site
of relapse or disease-free interval. ER-α mRNA
levels were inversely related with grade and
were higher in tumors from postmenopausal
patients compared with premenopausal patients.
MMP-2 and MMP-9 mRNA expression levels
were inversely related with tumor size, and
ADAM-10 expression levels varied between his-
tologic subtypes. The association with nodal
status is less straightforward. Although PGR
mRNA levels in these ER-positive tumors were
significantly lower in node-negative patients,
ER-α, ADAM-9, ADAM-11, and ADAM-12
mRNA levels were negatively related with the
number of positive lymph nodes.
Univariate and multivariate analysis for disease
control
In our analysis of the predictive value of the
ADAMs and the MMPs, the main clinical end
point was the measurable effect of tamoxifen
therapy on tumor size (disease control) from the
start of therapy. In univariate analysis using log-
transformed continuous variables, increasing
levels of ER-α, PGR, ADAM-9, and ADAM-11,
and decreasing levels of MMP-9 predicted a
favorable disease control (Table 3). In contrast,
no significant associations with treatment bene-
fit were observed for ADAM-10, ADAM-12, and
MMP-2 (Table 3). The predictive value of the
factors for disease control was studied with
multivariate logistic regression analysis (Table
3). For this multivariate analysis, we used the
same base multivariate model including the tra-
ditional predictive factors as described previ-
ously for a larger group of 691 patients treated
with first-line tamoxifen for recurrent disease
[10]. This base multivariate model includes the
traditional predictive factors menopausal status,
dominant site of relapse, disease-free interval,
and ER and PGR tumor levels. The contribu-
tions of the biological factors that were shown
to be significantly related with benefit of tamox-
ifen treatment in the univariate analysis were
separately included as log-transformed continu-
ous variables (Table 3). The analyses showed
that only ADAM-9 (OR, 1.41; P=0.015) and
MMP-9 (OR, 0.81; P=0.035) provided addi-
tional predictive information over the tradi-
tional predictive factors of the base model.
Effect of tumor cell percentage
Because most MMPs are localized to the tumor
stroma, we hypothesized that this might be the
case for the related ADAMs as well. Therefore,
we also checked for possible correlations
between the fraction of epithelial tumor cell
nuclei (range, 30-90%; median, 70%) and stro-
mal-derived cell nuclei in the primary tumor
and the predictive power of the various biologi-
cal factors with respect to tamoxifen benefit.
For this, we split our samples at the median
level of 70% tumor cell nuclei. The respective
groups consisted of n=106 patients with >70%
tumor cell nuclei (>70% TC) and a group of
n=153 patients containing ≤70% tumor cell
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Table 4. Cox univariate regression analysis for disease control with first-line tamoxifen.
NOTE: Biological factors separately evaluated for primary tumors with >70% and ≤70% tumor cell nuclei.
*  Log-transformed continuous variable.
† Includes 259 patients separately evaluated, based on the median level of 70% tumor nuclei in the whole population of 259
primary tumors, for106 patients with >70% tumor cell nuclei and 153 patients with ≤70% tumor cell nuclei in their primary
tumor. Because of missing values, numbers do not always add up to 259.
nuclei (≤70% TC) in their primary tumor. In the
group of patients with >70% TC tumors (Table
4), only mRNA levels of ER-α (OR, 2.10;
P=0.004) and PGR (OR, 1.24; P=0.025)
showed significant correlations with treatment
outcome. On the other hand, whereas the tradi-
tional predictive factors ER-α and PGR lost
their predictive power in the group of tumors
containing at least 30% stromal cells, ADAM-9,
ADAM-11, and MMP-9 mRNA levels gained
predictive power with respect to benefit of
tamoxifen treatment (OR, 1.59; P=0.007 for
ADAM-9; OR, 1.65; P=0.001 for ADAM-11;
and OR, 0.78; P=0.045, for MMP-9, respec-
tively; Table 4).
Having established that the predictive power of
some of the biological factors, as log-trans-
formed continuous variables, depended on the
cell type composition of the primary tumor, we
extended our analysis for these factors. For this,
we explored the significance of these factors
with respect to disease control and progression-
free survival after categorizing the mRNA
levels of the biological variables in the specific
tumor cell subpopulations in three equal thirds
(low, intermediate, high; Table 5). Figure 1
shows progression-free survival as a function of
the categorized ER-α tumor levels in all 259
patients (Figure 1A) against the 106 patients
with >70% TC tumors (Figure 1B) and likewise
for ADAM-9 in all patients (Figure 1C) against
the 153 patients with ≤70% TC tumors (Figure
1D). Because the proportional hazards assump-
tions for ER-α, ADAM-9, and ADAM-11 were
violated for the total follow-up time of 130
months (P<0.005), we analyzed the relation-
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NOTE: Due to different assay conditions and amplicon lengths, absolute values can only be compared within a gene
assay.
*  Three equal thirds were used to categorize the variable in the specific tumor cell subpopulation in low, intermediate,
and high.
† Based on the median level of 70% tumor cell nuclei in the whole population of 259 primary tumors, separately
evaluated for 106 patients with >70% tumor cell nuclei and 153 patients with ≤70% tumor cell nuclei in their primary
tumor.
‡ Number of patients entered into the study and corresponding disease control data are given for the low,
intermediate, and high mRNA expression levels in the specific tumor cell subpopulation.
Table 5. Cox univariate regression analysis of biological factors in primary tumors with >70% or ≤70% tumor
cell nuclei for disease control with first-line tamoxifen and progression-free survival (restricted to the first 9
months) after start of tamoxifen therapy.
ships of these factors with progression-free sur-
vival during the first 9 months of follow-up, the
time that half of the patients treated for
advanced disease showed disease progression
on tamoxifen [10, 31]. In this short-term analy-
sis (Figure 1), with 130 failures in all 259
patients, 53 in the group of 106 patients with
>70% TC tumors, and 77 failures in the 153
patients with ≤70% TC tumors, the proportional
hazards assumption was no longer violated
(P>0.1) for any of the factors further evaluated.
We therefore restricted our exploration of the
relationship of the factors with progression-free
survival to failures during the first 9 months of
follow-up (Table 5). The most notable findings
in these univariate analyses were: (a) that
MMP-9 mRNA levels analyzed as a categorized
variable lost its predictive value and (b) that ER-
α mRNA levels when measured in >70% TC
tumors and ADAM-9 and ADAM-11 mRNA
levels when measured in ≤70% TC tumors were
strong predictors for disease control by first-line
tamoxifen therapy and for the length of progres-
sion-free survival after the start of treatment.
Localization of ER-α, ADAM-9, and ADAM-11 protein
in human breast tissues
Finally, we employed immunohistochemistry to
determine the location of ADAM-9 and
ADAM-11 protein in our human breast tumor
tissues and compared this with the location of
ER-α protein. Representative results are shown
in Figure 2 for staining of pre-existent mam-
mary gland tissue (Figure 2A-D), carcinoma in
situ components (Figure 2E-H), and lobular
breast carcinomas (Figure 2I-L). Whereas ER-α
staining is mainly localized to the nuclei of
tumor cells, ADAM-9 and ADAM-11 are most
commonly found in the cytoplasm and less
commonly at the cell membrane. Immuno-
histochemical staining of ADAM-9 and
ADAM-11 protein in human breast carcinomas
yielded heterogeneous results with both pro-
teins found in tumor cells (Figure 2J and K),
adipocytes, smooth muscle cells of vessel walls,
and the myoepithelial and luminal layers of
nonneoplastic epithelium of the mammary
gland (Figure 2B and C).
DISCUSSION
Endocrine therapy is the most common treat-
ment in breast cancer patients with tumors that
express ER-α and/or PgR. Even though the ER-
α is the prime target for endocrine therapy, the
failure or success of this therapy is poorly
understood. Systemic endocrine therapy in
patients with recurrent disease at distant sites is
merely palliative and accomplishes a disease
control in about 50% to 60% of the patients.
However, progression is inevitable in these
patients because of the occurrence of acquired
therapy resistance. From a biological point of
view, first-line single-agent endocrine therapy
in patients with recurrent breast cancer is an
excellent setting to study response to therapy
because it is less subject to prognostic influ-
ences unavoidably present when a similar study
would be done in the adjuvant setting. In the
present study, the effect of endocrine therapy on
size of the metastatic or the occurrence of new
lesions were used as the main clinical end point.
We defined the type of response strictly before-
hand, and when there was any doubt, patients
were not included in this study. The size of the
metastases or the occurrence of new lesions is
an objective measure of treatment effect. How-
ever, because of the retrospective nature of our
study, the differentiation between partial remis-
sion and no change was difficult to assess, espe-
cially in patients with bone metastasis (60%). In
our study, the progression-free survival of
patients with stable disease (no change >6
months) was comparable with the progression-
free survival of patients with partial remission
and could therefore be considered as respon-
ders. This is in agreement with a previously
published prospective study which also reported
that objective benefit was not always easy to
assess and in which prolonged stable disease
was categorized as response [6].
In this study, ER and PgR were determined in
cytosols by biochemical methods and the cutoff
used to classify tumors as ER- or PgR-positive
was 10 fmol/mg cytosolic protein. These data
correlated significantly with ER and PGR
mRNA expression levels. However, although
these quantitative procedures are the most accu-
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rate methods, it is not currently the most widely
used method to evaluate hormonal receptor
status in breast cancer. In fact, immunohisto-
chemistry is nowadays more commonly used
for routine ER and PgR measurements. Because
this study shows a possible application for cur-
rent clinical practice, we compared the bio-
chemical and immunohistochemical methods in
a randomly selected subgroup of patients. In
agreement with a previously published study in
which ligand binding assay and immunohisto-
chemistry were compared in predicting
response to tamoxifen in 205 patients with ER-
positive metastatic breast cancer [32], ER and
PgR levels also showed comparable differences
in response rates in our study, whether defined
by mRNA, by biochemical methods, or by
immunohistochemistry.
The main findings of our study are that ADAM-
9 and ADAM-11 differentially from ER predict
the type of response to tamoxifen treatment in
patients with recurrent breast cancer and that the
fraction of tumor cells and stromal elements are
important in this respect. The actual ER level in
the ER-positive tumors (>10 fmol/mg cytosol
protein) containing >30% stromal elements did
not further contribute to the rate of response.
This finding supports the results of a previous
report that showed an association between ER
level and the volume fraction of actual cancer
cells present in the tumors [33]. Therefore, it
was advised that, when quantitative ER levels
are used to predict the response of tumors to
hormonal therapy, the cellularity of tumors
should be taken into consideration. We followed
this approach in our study by discriminating
between tumors with >70% epithelial tumor
cells and tumors with 30% to 70% epithelial
78
Clin Cancer Res 2005Chapter 4
Figure 1. Kaplan-Meier curves of progression-free survival with log-rank testing restricted to the first 9 months of follow-up for
patients with advanced disease treated with first-line tamoxifen.
The mRNA levels divided in three equal thirds given inTable 5 for ER-α (A + B) and ADAM-9 (C + D) were assessed in tumors before
(A + C) and after (B + C) dichotomization on the basis of the median level of 70% tumor cell nuclei in the total group of 259 patients.
Numbers below the x-axis show the patients at risk at the indicated time points.
tumor cells. Our results show that for tumors
with a relatively low percentage of epithelial
tumor cells, a marker set including ADAM-9
and ADAM-11 may have potential to assess the
efficacy of tamoxifen therapy.
Of the ADAMs and MMPs studied, all, except
ADAM-11, were readily detected by real-time
RT-PCR in all samples. The absence of
detectable ADAM-11 mRNA levels in 29% of
our primary breast tumors is most likely a
reflection of the loss of heterozygosity on chro-
mosome 17q21, where ADAM-11 is located
[13], as described to be the case for 30% of the
tumors [11]. Patterns of copy number gains and
losses define breast tumors with distinct clinico-
pathologic features and patient prognosis [34].
Several studies have already shown that ERBB2
amplification is associated with a shorter dis-
ease-free and overall survival in the subgroup of
patients receiving adjuvant tamoxifen therapy
when compared with the untreated group
[35–37]. However, whereas ERBB2 is located
on cytoband 17q12, a region of copy gain,
ADAM-11 is located on cytoband 17q21, a
region of copy loss. Our finding that low tumor
ADAM-11 mRNA levels are associated with
poor efficacy of tamoxifen treatment supports
the hypothesis that ADAM-11 is a candidate
tumor suppressor gene for human breast cancer
[13, 14], and extends its role as a candidate
tumor suppressor gene to a candidate gene asso-
ciated with tamoxifen responsiveness.
Our study shows that ADAM-9 and ADAM-11
mRNA levels are especially informative with
respect to tamoxifen treatment outcome in
tumors containing a relatively large proportion
of stromal cells. In agreement with a previously
published study describing the expression of
ADAM-9, ADAM-10, ADAM-12, ADAM-15,
and ADAM-17 in breast cancer specimens [38],
79
ADAMs and response to tamoxifen
Figure 2. Immunohistochemical
localization of ER-α, ADAM-9,
and ADAM-11 in breast cancer
tissue.
A-D, ×20 magnification. Pre-exis-
tent mammary gland tissue
expressing occasional positive
nuclear staining for ER-α (A),
abundant staining of the myoepi-
thelial layer and weak staining of
the luminal layer for ADAM-9 (B),
and weak staining of both layers
for ADAM-11 (C). E-H, ×40 mag-
nification. Carcinoma in situ com-
ponent expressing positive nuclear
staining for ER-α (E), intermediate
cytoplasmic staining for ADAM-9
(F) and abundant cytoplasmic and
membrane staining for ADAM-11
(G). I-L, ×40 magnification. Lobu-
lar carcinoma expressing positive
nuclear staining for ER-α (I), weak
cytoplasmic staining for ADAM-9
(J), and medium cytoplasmic stain-
ing for ADAM-11 (K).The speci-
ficity of immunostaining was
controlled using normal goat and
mouse IgG and by omitting the pri-
mary antibodies (negative controls,
D, H, and L).
immunohistochemical staining of ADAM-9 and
ADAM-11 protein in human breast carcinomas
yielded heterogeneous results with both pro-
teins found in tumor cells, adipocytes, nonneo-
plastic epithelium of the mammary gland, and
smooth muscle cells of vessel walls. The ques-
tion of how ADAM-11 and ADAM-9, either
stromal or tumor cell–derived, might prevent
the development of tamoxifen resistance
remains to be solved. Because proteases such as
urokinase-type plasminogen activator [9, 10]
and MMP-2 [39] have been shown to be related
to tamoxifen resistance, we hypothesized that
specific ADAMs might also be related to
tamoxifen resistance. We found that high levels
of ADAM-9 and ADAM-11 mRNA were related
to a better response rate. This is in contrast with
the findings for urokinase-type plasminogen
activator [10], showing high levels to be associ-
ated with poor benefit of tamoxifen treatment in
recurrent breast cancer, and for MMP-2 [39],
showing that high levels predicted failure to
adjuvant antiestrogen therapy. This suggests
that ADAM-9 and ADAM-11 function differ-
ently from urokinase-type plasminogen activa-
tor and MMP-2, and that it is therefore perhaps
not the protease function of the ADAMs that is
important in the prevention or delay of tamox-
ifen resistance. Increasing evidence indicates
that abnormalities occurring in growth factor
signaling pathways, as currently well-docu-
mented for epidermal growth factor receptor
(ERBB1) and ERBB2 (HER2/neu), could dra-
matically influence steroid hormone action and
may be critical for anti–hormonal-resistant
breast cancer cell growth [7, 8, 36, 40–43].
From this point of view, one might expect fac-
tors that target growth factor signaling pathways
are potentially able to prevent the development
of tamoxifen resistance. Many intercellular sig-
naling molecules are membrane-anchored pro-
teins, which are proteolytically processed after
becoming membrane-bound, to liberate their
extracellular domains (ectodomain shedding).
Genetic and biochemical studies have shown
that some ADAMs participate in these events
[3]. Therefore, it is perhaps the ectodomain
shedding function of the ADAMs that plays a
role in the prevention of tamoxifen resistance.
Furthermore, the disintegrin domain of ADAM-
9 can function as an adhesion molecule by inter-
acting with an α(v)β(5) integrin [44], thus
limiting the metastatic potential of the cell.
In summary, our study shows that patients with
primary tumors exhibiting a high percentage of
epithelial tumor cell nuclei over stromal cells
combined with high levels of ER-α have a good
chance to benefit from tamoxifen therapy. For
patients with tumors displaying ≥30% stromal
components intermingled with epithelial tumor
cells, the additional assessment of tumor mRNA
levels of ADAM-9 and ADAM-11 could be
helpful to refine treatment strategies for these
patients. However, taking into account that only
patients with ER-positive primary tumors
entered this study, this may only apply to
patients with ER-positive primary tumors. Fur-
ther studies are required to verify whether the
results of our study can be adapted to fit all
patients, irrespective of the ER status of the pri-
mary tumor. Based on recent advances in breast
cancer management, endocrine therapy with
aromatase inhibitors may become the treatment
of choice for postmenopausal women [45].
Because both aromatase inhibitors and tamox-
ifen aim to deprive the ER from estrogens, it
would be interesting to learn whether ADAM-9
and ADAM-11 could also be linked to disease
control of aromatase inhibitors. In addition, as
the majority of patients receive adjuvant treat-
ment today, it will be important to learn whether
ADAM-9 and ADAM-11 could also be inform-
ative for determining the outcome of breast
cancer patients treated with adjuvant endocrine
therapy.
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Which cyclin E prevails as prognostic marker
for breast cancer?
Results from a retrospective study involving 635
lymph node-negative breast cancer patients
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ABSTRACT
Purpose: To evaluate the prognostic value of
cyclin E with a quantitative method for lymph
node-negative primary breast cancer patients.
Patients and methods: mRNA transcripts of
full-length and splice variants of cyclin E1
(CCNE1) and cyclin E2 (CCNE2) were meas-
ured by real-time RT-PCR in frozen tumor sam-
ples from 635 lymph node-negative breast
cancer patients who had not received neoadju-
vant or adjuvant systemic therapy.
Results: None of the PCR assays designed for
the specific splice variants of the cyclins gave
additional prognosis-related information com-
pared with the common assays able to detect all
variants. In Cox multivariate analysis, corrected
for the traditional prognostic factors, high levels
of cyclin E were independently associated with
a short distant metastasis-free survival [hazard
ratio (HR), 3.40; P<0.001for CCNE1 and HR,
1.76; P<0.001 for CCNE2, respectively]. After
dichotomizing the tumors at the median level of
70% epithelial tumor cells, the multivariate
analysis showed particularly strong results for
CCNE1 in the group of 433 patients with
stroma-rich primary tumors (HR, 5.12;
P<0.001). In these tumors, the worst prognosis
was found for patients with estrogen receptor-
negative tumors expressing high CCNE1 (HR,
9.89; P<0.001) and for patients with small (T1)
tumors expressing high CCNE1 (HR, 8.47;
P<0.001).
Conclusion: Our study shows that both CCNE1
and CCNE2 qualify as independent prognostic
markers for lymph node - negative breast cancer
patients, and that CCNE1 may provide addi-
tional information for specific subgroups of
patients.
INTRODUCTION
Dysregulation of the cyclin-dependent kinase-2
(CDK2)–bound cyclins plays an important role
in the pathogenesis of cancer. High levels of
cyclin E expression are found in many types of
cancer, and elevated levels of the E1 cell cycle
protein have been associated with a poor prog-
nosis in primary breast cancer patients
(reviewed by Yasmeen et al.; ref. 1). Although
studies have mainly focused on cyclin E1, the
human genome encodes two E-type cyclins:
CCNE1 (formerly cyclin E) on chromosome
19q [2, 3] and CCNE2 on chromosome 8q
[4–6]. The encoded human cyclin E2 protein
shares 47% overall similarity to cyclin E1 and
contains a cyclin box motif that is characteristic
of all cyclins [5]. However, whereas a signifi-
cantly increased expression of cyclin E2 is
observed in breast cancers [7], its potential
association with tumor aggressiveness is still
unknown. Notwithstanding, CCNE2 and not
CCNE1 overlapped between the 76-gene pre-
diction signature from Wang et al. [8] and the
70-gene prediction signature from van’t Veer et
al. [9] for metastasis-free survival (MFS) of
lymph node–negative patients. This suggested
that at least for microarray techniques, and per-
haps for all gene expression levels measuring
methods, CCNE2 might be a better prognostic
marker when compared with CCNE1.
For both CCNE1 and CCNE2, alternatively
spliced transcript variants, which encode dis-
tinct protein isoforms, have been reported [5,
10–13]. Once translated in tumor cells, the pro-
tein products of such variants can give rise to
constitutively active forms of the cyclin E con-
taining complexes. To complicate matters, it has
been shown that in breast cancer compared with
normal cells and tissues, cyclin E1 protein is
overexpressed and post-translationally cleaved
by a protease into low molecular weight iso-
forms [14, 15]. These low molecular weight
forms of cyclin E1 show higher CDK2 kinase
activity, and the low molecular weight cyclin
E1/CDK2 complexes are more resistant to
inhibitors and antiestrogens [16]. Keyomarsi et
al. [17]  showed that levels of total cyclin E1
and low molecular weight cyclin E1 in tumor
Keywords: cyclin E1, cyclin E2, breast cancer, prognosis, real-time RT-PCR.
tissue measured by Western blot assay corre-
lated strongly with survival in patients with
breast cancer. A complicating factor was that
approximately two thirds of the patients
included in this study received either adjuvant
chemotherapy or hormonal therapy [18]. Trials
of adjuvant therapy in patients with breast
cancer no longer include an untreated control
group. Therefore, retrospective studies involv-
ing well-characterized tumor banks with tumors
from untreated patients will be necessary to
determine whether cyclin E is a pure prognostic
factor instead of a predictor for the benefits of
adjuvant systemic therapy. Our current study
involves such a cohort of 635 tumors from
lymph node–negative patients who did not
receive any adjuvant systemic therapy.
PATIENTS AND METHODS
Patients
The study was approved by the institutional
medical ethics committee (MEC 02.953).
Tumor samples were originally submitted to our
reference laboratory from 25 regional hospitals
for measurements of steroid hormone receptors.
Guidelines for primary treatment were similar
for all hospitals. To avoid bias, selection of
tumors from our tumor bank at the Erasmus
Medical Center (Rotterdam, the Netherlands)
was done by processing all available frozen
tumor samples from female patients with lymph
node–negative breast cancer who entered the
clinic during 1979 to 1996 and from whom
detailed clinical followup was available. Lymph
node negativity and tumor size was based on
pathologic examination by regional patholo-
gists. Information on grade was extracted from
the pathology records and reflects clinical prac-
tice during those years. Exclusion criteria were
residual disease or distant spread diagnosed at
or within 1 month after primary surgery, nonin-
vasive breast cancer, neoadjuvant or adjuvant
systemic therapy, a previous other cancer
(except basal cell skin cancer or early-stage cer-
vical cancer stage Ia/Ib), <100 mg frozen tissue
available, evaluation of tumor content not reli-
able (2%), <30% epithelial tumor cell nuclei in
the sample (15%), and poor RNA quality (8%).
The thus remaining 635 eligible patients were
treated either with breast-conserving surgery
(54%) or with modified mastectomy (46%).
Forty-one percent of the patients had T1 tumors.
The median age of the patients at surgery was
56 years (range, 25-88 years). Three hundred
eighty-seven patients (61%) received radio-
therapy. Routine post-surgical follow-up and
defining the date of MFS was as described [8].
Thirty-seven patients presented with a relapse
without signs of a distant metastasis. The
median follow-up time was 95 months (range,
11-202 months) with 256 failures in the analysis
of MFS and 226 failures in the analysis of over-
all survival. Other relevant clinicopathologic
characteristics are listed in Table 1.
Tissue processing
Tissue processing was done as described in
detail before [19]. In brief, 20 to 60 cryostat sec-
tions of 30 µm, corresponding to 30 to 100 mg,
were cut from frozen tissues. Before, in
between, and after cutting the sections for RNA
isolation, 5 µm sections were cut for H&E stain-
ing to assess the amount of tumor cells relative
to the amount of surrounding stromal cells. The
amount of nuclei evidently of epithelial tumor
cell origin relative to the amount of surrounding
stromal cells was estimated with a 100-fold
magnification in 10 different areas covering the
area of each of the three H&E sections. Only
specimen with at least 30% of the nuclei of
epithelial tumor cell origin and distributed uni-
formly over at least 70% of the section area
were included. Like done before [19], these esti-
mates were used to dichotomize our tumor
cohort at the median level of 70% tumor cell
nuclei in stroma-rich (primary tumors contain-
ing ≥30% stromal components) and stroma-
poor (primary tumors containing at least 70%
epithelial tumor cells).
RNA isolation, cDNA synthesis, and quantification
of specific mRNA species
RNA isolation, cDNA synthesis, quantification
of specific mRNA species, and quality control
checks were done as described in detail before
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[19]. Real-time quantitative PCR was done in
an ABI Prism 7700 Sequence Detection System
(Applied Biosystems, Nieuwerkerk a/d IJssel,
the Netherlands) and a Mx3000P Real-time
PCR System (Stratagene, Amsterdam, the
Netherlands) using both the Assay-on-Demand
assays from Applied Biosystems and the intron-
spanning forward and reverse primer combina-
tions at the conditions shown in Table 2A. In
our initial screening, we compared CCNE1 and
CCNE2 mRNA transcript levels of the various
variants in a set of 185 primary tumors from
breast cancer patients and various cultured cell
lines (Table 2B). Primer sequences for estrogen
receptor-α (ER-α), PGR, and the housekeepers,
as well as how PCR reactions and validations
were done to ensure PCR specificity, have all
been previously described [19]. Levels of the
88
Clin Cancer Res 2006Chapter 5
Abbreviations: DCIS, ductal carcinoma in situ; ILC, infiltrating lobular carcinoma; IDC, infiltrating ductal carcinoma.
* Due to different assay conditions, absolute values of the CCNEs can only be compared within a gene assay.
† P for Spearman rank correlation test.
‡ P for Mann-Whitney U test.
§ P for Kruskal-Wallis test. 
Due to 31missing values, numbers do not add up to 635.
Table 1. Associations of CCNE1 and CCNE2 mRNA levels with clinicopathologic factors.
target genes, expressed relative to our house-
keeping set, which included the low abundance
housekeeping gene porphobilinogen deami-
nase, the medium abundance housekeeping
gene hypoxanthine-guanine phosphoribosyl-
transferase, and the high-abundance house-
keeping gene β-2-microglobulin, were
quantified as follows:
mRNA target = 2(mean Ct housekeeping  - mean Ct target).
Statistics
Computations were done with the use of the
STATA statistical package, release 8.2 (STATA
Corp., College Station, TX). Differences in
levels were assessed with the Mann-Whitney U
test or Kruskal-Wallis test. In these tests, patient
and tumor characteristics were used as grouping
variables. The strengths of the associations
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NOTE: In our initial screening, we compared CCNE1 and CCNE2 mRNA transcript levels of the various variants (A) in a set of
185 primary tumors from breast cancer patients and various cultured cell lines (B). Note that due to different assay conditions,
absolute values of the CCNE’s can only be compared within a gene assay. The assay designed to detect specifically the CCNE1S
variant required >35 rounds of amplification for any product formation in our tumormaterial and was therefore considered too
insensitive for reliable SYBR-based real-time PCR measurement. For the CCNE2 assay aimed to specifically detect the variant
lacking part of the cyclin box (variant 2), correlation with the CCNE2 assay designed to detect both variants was highly significant
(rs=0.92, P<0.001, n=185), indicating that this splice variant did not play a role of significant importance.We, therefore,
continued with the CCNE2 assay able to detect both variants and the CCNE1 assay able to detect (a) all CCNE1 variants and
compared results with the CCNE1 assays able to detect; (b) all variants except variant E1L; (c) all variants except variant E1S and
E1T; and (d) the CCNE1T variant - specific assay.
* Assay done with Taqman probes in Universal PCR-master-mixture (Applied Biosystems).
† Assay done in Brilliant SYBR Green PCR-master-mixture (Stratagene).
‡ Assay done in SYBR-green PCR-master-mixture (Applied Biosystems).
§ Assay done in Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen).
Table 2A: Intron-skipping CCNE variant-specific primers used for real-time RT-PCR.
Table 2B: PCR traces of wild-type and CCNE variants in primary breast tumors and cell lines.
between continuous variables were tested with
the Spearman rank correlation (rs). Variables
were either log transformed or Box-Cox trans-
formed to reduce the skewness. The prognostic
values of the clinical and biological variables,
with MFS and overall survival as the end point
in the univariate, multivariate, and interaction
analyses, were investigated with the use of the
Cox proportional hazards model. The hazard
ratio (HR) and its 95% confidence interval were
derived from these results. The proportionality
assumption was investigated with a test based
on the Schoenfeld residuals. Kaplan-Meier sur-
vival plots and log-rank tests were used to
assess the differences in time to distant metasta-
sis of the predicted high-risk and low-risk
groups. All Ps are two sided, and P<0.05 was
considered statistically significant.
RESULTS
Correlation between real-time PCR and Affymetrix
GeneChip array
Comparing our real-time PCR data for all
CCNE1 and CCNE2 variants with expression
data obtained after hybridizing the same total
RNA samples on the Affymetrix oligonu-
cleotide Human U133a GeneChips [8] showed
significant correlations between our CCNE1
and CCNE2 real-time PCR assays and the
CCNE1 213523_at and CCNE2 205034_at
probe-based Affymetrix GeneChip array assays,
which also recognize all variants of CCNE1 and
CCNE2 (rs=0.70 for CCNE1 and rs=0.75 for
CCNE2, respectively; P<0.001, n=248). The
Spearman rank correlation between CCNE1 and
CCNE2 was 0.40 (P<0.001, n=635) for the real-
time PCR assays and 0.36 (P<0.001, n=248) for
the probe sets. Relating the CCNE expression
profiles to the subtypes of breast cancer as
defined by global profiling [20] showed for
both our real-time PCR and Affymetrix
GeneChip array data significant (P<0.05) dif-
ferences in median CCNE mRNA levels
between the subtypes. For both CCNE1 and
CCNE2, levels ranked according to the major
breast cancer subtype were luminal A (n=94) >
basal (n=42) > normal (n=48).
Associations with clinicopathologic factors
The associations of CCNE1 and CCNE2 mRNA
expression levels with patient and tumor char-
acteristics are shown in Table 1. Although based
on a relatively small number of patients, the
lowest median levels of the cyclins were found
in the histologic subgroup of medullary tumors.
CCNE1 and CCNE2 levels were both inversely
related with age and steroid hormone receptors
and higher in premenopausal patients and poor-
grade tumors. Furthermore, CCNE1 and
CCNE2 levels were higher in larger tumors,
although for CCNE2, this association was not
statistically significant. To further explore the
associations between the mRNA levels of the
cyclins and steroid hormone receptor status, we
correlated ER-α and PGR mRNA levels meas-
ured by quantitative real-time PCR with mRNA
levels of the cyclins measured in the same
preparations. Although at the mRNA level, a
strong negative correlation was present between
CCNE1 and ER-α and PGR (rs=-0.54 for ER-α
and -0.54 for PGR, respectively; P<0.001,
n=635), this was less striking for the correlation
between the CCNE2 and ER-α and PGR mRNA
levels (rs=-0.16 for ER-α and -0.23 for PGR,
respectively).
Univariate and multivariate analysis
We first did Cox univariate analyses for MFS
and overall survival as a function of continuous
CCNE1 and CCNE2 mRNA levels. In these
analyses, CCNE1 and CCNE2 were associated
with a poor MFS (HR, 1.29 for CCNE1 and HR,
1.59 for CCNE2; both P<0.001) and overall sur-
vival (HR, 1.24 for CCNE1 and HR, 1.45 for
CCNE2: both P<0.001). These significant rela-
tionships justified the search for a cut point to
analyze CCNE1 and CCNE2 as dichotomized
variables and to allow visualization of their
prognostic value in Kaplan-Meier analysis.
Because the proportional hazards assumption
was violated for grade and PGR for the total
follow-up time of 202 months (P<0.05), we
restricted our exploration of the relationships of
the cyclins with MFS to the first 5 years of
follow-up. In this analysis with 209 failures, the
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proportional hazards assumption was no longer
violated (P>0.1). The data of the Cox univariate
and multivariate analyses are summarized in
Table 3 for MFS during the first 5 years and in
Table 4 for overall survival during the total
follow-up period including all deaths. Both
cyclins, either when analyzed at their median
level (HR, 2.65 for CCNE1 and HR, 1.69 for
CCNE2, respectively) or at their optimized cut
point (HR, 3.40 for CCNE1 and HR, 1.76 for
CCNE2, respectively), contributed significantly
to the multivariate model for MFS (all P<0.001;
Table 3). Similar significant relationships were
observed in the analysis for overall survival
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Table 3. Cox univariate and multivariate analysis for 5 years MFS in 635 lymph node-negative patients.
* Cyclins were separately introduced to the base multivariate model that included the factors age,menopausal status, tumor size,
grade, and ER-a and PR mRNA levels as log-transformed continuous variables.
† Dichotomized in high and low levels by median level (0.04; range, 0.003-2.12 for CCNE1 0.70; range, 0.07-9.40 for CCNE2).
‡ Dichotomized in high and low levels by cut points (0.03 for CCNE1 and 1.16 for CCNE2).
(Table 4). No statistically significant interac-
tions were observed between the cyclins and the
prognostic factors included in the base multi-
variate model, between the cyclins and adjuvant
radiotherapy, and between the cyclins them-
selves. When CCNE1 and CCNE2 were added
simultaneously to the base model, they both
independently contributed to the MFS and over-
all survival models.
ER status and tumor size
To specifically investigate the differences
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Table 4. Cox univariate and multivariate analysis for overall survival in 635 lymph node-negative patients.
* Cyclins were separately introduced to the base multivariate model that included the factors age, menopausal status, tumor size, 
grade, and ER-α and PR mRNA levels as log-transformed continuous variables.
† Dichotomized in high and low levels by median level (0.04; range, 0.003-2.12 for CCNE1 and 0.70; range, 0.07-9.40 for
CCNE2).
‡ Dichotomized in high and low levels by cut points (0.03 for CCNE1 and 1.16 for CCNE2).
between the two cyclins with respect to the
strength of their associations with steroid hor-
mone receptor status and tumor size (see Table
1), we did Cox univariate analyses in the sub-
groups of ER-negative and ER-positive tumors,
and in small (≤2 cm) and larger (>2 cm) tumors
(Table 5). Although both cyclins were asso-
ciated with a poor prognosis in the ER-positive
subgroup (HR, 4.08 for CCNE1 and HR, 2.63
for CCNE2, respectively), only CCNE1 was
informative for the ER-negative subgroup
(HR, 5.04). With respect to tumor size, high
levels of both cyclins were significantly asso-
ciated with a poor MFS, both for patients with
small tumors (HR, 5.36 for CCNE1 and HR,
3.75 for CCNE2) and patients with larger
tumors (HR, 3.00 for CCNE1 and HR, 1.49 for
CCNE2).
Stroma-rich versus stroma-poor tumors
Interaction analysis showed that patients with
high levels of CCNE1 had an increased risk
(P=0.03) to develop a metastasis within 5 years
if their primary tumor was stroma enriched
compared with patients with a high level of
CCNE1 combined with a stroma-poor primary
tumor. Hence, a high CCNE1 level was a better
predictor of poor prognosis in the group of 433
patients with stroma-rich tumors (HR, 5.38)
compared with the group of 202 patients with
stroma-poor tumors (HR, 2.39; Table 5). A high
level of CCNE2 on the other hand was a better
predictor for the group of 202 patients with
stroma-poor tumors (HR, 2.77 compared with
HR, 1.86 for stroma-rich tumors). Note that,
whereas median CCNE2 mRNA levels did not
differ between stroma-poor tumors (median
level, 0.70; interquartile range, 0.89) and
stroma-rich tumors (median level, 0.71;
interquartile range, 0.80), median levels of
CCNE1 were higher in the group of stroma-rich
tumors (median level, 0.043; interquartile
range, 0.066 for stroma-rich tumors and median
level, 0.034; interquartile range, 0.059 for
stroma-poor tumors; P=0.01). In contrast to
CCNE2, for CCNE1, the importance of discrim-
inating between stromal content became even
more evident in the subgroups of ER-negative
tumors and small tumors. Especially for stroma-
rich ER-negative tumors (HR, 9.89) and
stroma-rich small tumors (HR, 8.47), a high
level of CCNE1 was a strong factor predicting a
poor prognosis (Table 5). The prognostic value
of the cyclins in all patients and in the sub-
groups of tumors with a low and high propor-
tion of tumor cells and separately analyzed for
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Table 5. Cox univariate analysis for 5 years MFS in 635 adjuvant untreated lymph node-negative patients.
* Dichotomized in high and low levels by cut points (0.03 for CCNE1 and 1.16 for CCNE2).
† Dichotomized in stroma-rich and stroma-poor at the median level of 70% tumor cells.
‡ Cut point used for ER is10 fmol/mg protein.
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Figure 1. MFS as a function of CCNE1 (A) and CCNE2 (B) in 635 lymph node-negative primary breast cancer patients before
(1) and after (2-4) dichotomizing patients according to the percentage of tumor cells present in the primary tumor and tumor size.
Patients at risk are indicated. Cut point used for CCNE1 is 0.03 and for CCNE2 is 1.16.
T1 tumors is visualized in Kaplan-Meier curves
(Figure 1).
CCNE1 and its mRNA splice variants
The contributions of the various mRNA variants
of CCNE (see also Table 2A and B) with respect
to prognosis was studied in a subgroup of 562
patients. Spearman rank correlation revealed
highly significant correlations among all
CCNE1 variants studied (rs>0.70, P<0.001,
n=562). Irrespective of which splice variant was
analyzed, increasing levels of CCNE1 predicted
a poor prognosis. The assay used in this study
aimed at detecting all variants of CCNE1 con-
tributed similarly to MFS and overall survival
compared with the various splice variants of
CCNE1 investigated (data not shown).
DISCUSSION
Many research groups have investigated the
link between immunohistochemically measured
cyclin E1 protein and prognosis in breast
cancer, although with conflicting results [1, 17,
21–28]. These heterogeneous results have been
attributed to differences in antibodies used to
detect cyclin E1 [17] and to differences in the
adjuvant treatment of patients [18, 29]. In our
present study, we aimed to overcome these pit-
falls by using quantitative real-time RT-PCR to
evaluate the prognostic value of cyclin E
mRNA levels in lymph node–negative breast
cancer patients who did not receive adjuvant
systemic therapy, which was common practice
in the Netherlands in the time period from
which we retrieved our primary tumor samples.
We evaluated, in addition to various mRNA
splice variants of CCNE1, the far less exten-
sively studied CCNE2 member of the cyclin E
family, and we are the first to present compre-
hensive data with respect to the prognostic
value of cyclin E2.
The mRNA splice variants of CCNE1 did not
add to the information we obtained from wild-
type CCNE1. Although our study shows that
both CCNE1 and CCNE2 are prognosticators
for lymph node–negative breast cancer, differ-
ences were observed between the two genomic
variants of cyclin E. In agreement with previous
studies [22], we found that ER-negative tumors
expressed significantly higher CCNE1 mRNA
levels. Based on this observation, a potential
role for cyclin E1 in mechanisms responsible
for estrogen-independent tumor growth has
already been suggested [22]. We showed that, in
contrast to CCNE1, median CCNE2 levels do
not largely differ between ER-negative and ER-
positive tumors. Furthermore, only CCNE1 was
a significant prognostic factor in patients with
ER-negative tumors.
Other dissimilarities between the two cyclin E
members were observed. Only recently, we
established that the predictive value of biologi-
cal factors, among which ER-α, may be further
refined by splitting tumor samples at the median
level of 70% epithelial tumor cell nuclei in a
cohort of stroma-poor tumors and a cohort of
stroma-rich tumors [19]. Interaction analyses
justified to perform a similar analysis for CCNE
and showed that high CCNE1 was a better pre-
dictor of poor prognosis in the group of patients
with stroma-rich tumors compared with the
group of patients with stroma-poor tumors. This
strongly suggests a paracrine interaction
between tumor cell derived cyclin E1 and a stro-
mal cell–derived factor, resulting in a more
aggressive tumor type with a very poor progno-
sis. High levels of CCNE2 were similarly asso-
ciated with poor prognosis in tumors with high
and tumors with a relatively low percentage of
tumor cell nuclei. For CCNE2, such an inter-
action mechanism between tumor cells and stro-
mal cells does, therefore, not seem to play a
role. Profiling studies usually focus on tumors
with a relatively high percentage of epithelial
tumor cell nuclei. This, together with the
already discussed differences associated with
ER status, most likely explains why it was the
more consistently informative CCNE2 variant
and not the more susceptible to tissue hetero-
geneity CCNE1 variant that overlapped
between the two gene expression profiles [8, 9].
Success in breast cancer treatment depends
greatly upon early detection. More sensitive and
specific indicators of prognosis are required to
identify those patients at risk for disease pro-
gression. Great advantage will be gained with
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markers that are able to anticipate disease
progress for patients with still small tumors, a
group of patients for whom prediction of prog-
nosis is especially difficult to assess. Trials of
adjuvant therapy in patients with breast cancer
no longer include an untreated control group.
Therefore, available tumor banks are very help-
ful to address specific questions. We did a retro-
spective study using tumors from patients who
had not received systemic adjuvant treatment to
determine whether cyclin E is a pure prognostic
factor. However, there are obvious limitations to
a retrospective study on frozen material that
must be acknowledged. The data in Table 1
describe clinicopathologic data that reflect
common practice in those days and are not
always as comprehensive as the data available
nowadays. Due to the frozen nature of our mate-
rial, (re)examination of histology, grade, prolif-
eration index or, for example, ERBB2
amplification by fluorescence in situ hybridiza-
tion will not provide the same results as the cur-
rent standardized methods used for
paraffin-embedded material. Furthermore,
because our tumor bank consists of frozen
tumor material that was left after the biochemi-
cal and pathologic examinations, small-sized
tumors of ≤1 cm are under represented in this
study. Despite this limitation, high levels of
CCNE1 and CCNE2 as measured by real-time
RT-PCR showed to be especially poor predic-
tors of MFS for the 260 of 635 patients with
small (T1) tumors.
Although gene expression profiling methods are
definitely more comprehensive, and immuno-
histochemical methods are more informative
with respect to localization of target molecules,
real-time PCR is a sensitive, fast, quantitative,
and cost-effective method suitable for high-
throughput screening. In summary, PCR-based
measurement of CCNE1 and CCNE2 fulfill the
criteria of a clinically attractive biomarker to
select early breast cancer patients at high risk
for distant metastases.
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HOXB13-to-IL17BR expression ratio is related
with tumor aggressiveness and response to tamoxifen
of recurrent breast cancer: a retrospective study
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ABSTRACT
Purpose: A HOXB13-to-IL17BR expression
ratio was previously identified to predict clini-
cal outcome of breast cancer patients treated
with adjuvant tamoxifen. However, this ratio
may predict a tumor’s response to tamoxifen, its
intrinsic aggressiveness, or both.
Patients and methods: We have measured the
HOXB13 and IL17BR expression levels by real-
time polymerase chain reaction in 1,252 pri-
mary breast tumor specimens. Expression levels
were normalized to housekeeper gene levels
and related to clinicopathologic factors for all
patients. The primary objective of this study
was to determine the relationship of a HOXB13-
to-IL17BR ratio with tumor aggressiveness
and/or with response to tamoxifen therapy in
estrogen receptor (ER) -positive disease. We
selected ER-positive tumors, and clinical end
points for the HOXB13-to-IL17BR ratio were
disease-free survival (DFS) in patients with pri-
mary breast cancer (n=619) and progression-
free survival (PFS) in patients with recurrent
breast cancer treated with first-line tamoxifen
monotherapy (n=193). The odds ratio (OR) and
hazard ratio (HR) and their 95% CI were calcu-
lated, and all P values were two-sided.
Results: The HOXB13-to-IL17BR ratio was
significantly associated with DFS and PFS. In
multivariate analysis, HOXB13-to-IL17BR ratio
expression levels were associated with a shorter
DFS for node-negative patients only. Corrected
for traditional predictive factors, the
dichotomized HOXB13-to-IL17BR ratio was the
strongest predictor in multivariate analysis for a
poor response to tamoxifen therapy (OR  0.16;
95% CI, 0.06 to 0.45; P<0.001) and a shorter
PFS (HR  2.97; 95% CI, 1.82 to 4.86; P<0.001).
Conclusion: High HOXB13-to-IL17BR ratio
expression levels associate with both tumor
aggressiveness and tamoxifen therapy failure.
INTRODUCTION
Approximately 70% to 75% of invasive breast
tumors express the estrogen receptor (ER), the
classical prognostic factor, which is an impor-
tant target for endocrine therapy. In the adjuvant
setting, tamoxifen therapy results in a 5.3% to
12.6% improvement in 10-year survival in
lymph node-negative (LNN) and lymph node-
positive (LNP) patients, respectively [1]. In
recurrent disease, approximately half of the
patients with ER-positive primary breast tumors
will not respond or will rapidly develop resist-
ance to tamoxifen.
Based on genome-wide screening, signatures
associated with response to tamoxifen therapy
of ER-positive breast cancer have been pub-
lished by Ma et al [2] for adjuvant treatment and
published by Jansen et al [3] for recurrent dis-
ease. Ma et al [2] identified a two-gene expres-
sion ratio, HOXB13-to-IL17BR, which
predicted clinical outcome in a retrospective
study of 60 patients and confirmed this in for-
malin-fixed paraffin-embedded (FFPE) samples
of 20 LNN patients. Reid et al [4], however,
failed to validate this two-gene ratio on frozen
samples from 58 patients, who were mainly
node-positive. A drawback in the adjuvant set-
ting is that the tumor’s response to tamoxifen
and its intrinsic aggressiveness are measured.
No accurate determination of response to
tamoxifen can be given because these studies
lacked randomization and a nontreated control
group.
Recent microarray data analyses showed that
the HOXB13-to-IL17BR ratio has no association
with relapse-free survival [5] but it does have a
weak association with response to first-line
tamoxifen therapy [6]. However, data from
microarray experiments need to be confirmed
with quantitative real-time reverse transcriptase
polymerase chain reaction (qRT-PCR), as these
data are considered to be more accurate [4].
Therefore, we measured mRNA expression
levels of HOXB13 and IL17BR with a qRT-PCR
100
J Clin Oncol 2007Chapter 6
Keywords: HOXB13-to-IL17BR ratio, breast cancer, tamoxifen, response prediction, real-time PCR.
101
HOXB13-to-IL17BR and response to tamoxifen
in RNA isolated from a set of 1,252 frozen
breast cancer specimens and related expression
levels with clinicopathologic factors. The main
clinical end points in ER-positive disease were
1) disease-free survival (DFS) of untreated
LNN patients to determine tumor aggressive-
ness and 2) response to first-line tamoxifen
monotherapy for recurrent disease. In addition,
we compared for IL17BR two primer sets (ps):
one at the 3' end region, comparable to the assay
of Ma et al (ps3) [2], and one at the 5' end
region, used by Reid et al (ps5) [4]. Finally, we
validated in our cohort predefined cutoff points
for untreated patients and tamoxifen-treated
patients [7,8].
PATIENTS AND METHODS
Patients
This retrospective study was approved by the
medical ethics committee of the Erasmus MC
(Rotterdam, the Netherlands; MEC 02.953),
and it included breast tumor tissue specimens of
1,683 female patients with primary operable
breast cancer. To avoid bias, frozen tumor sam-
ples were processed from patients with breast
cancer who entered the clinic between 1979 and
1996 and from whom detailed clinical follow-
up was available. Follow-up, tumor staging, and
response to therapy was defined by standard
International Union Against Cancer (Geneva,
Switzerland) classification criteria [9] and
applied previously by Foekens et al [10]. The
cutoff point to classify primary breast tumors as
ER and/or progesterone receptor (PgR) -posi-
tive was 10 fmol/mg cytosolic protein. The fol-
lowing tumors were excluded from analysis: 1)
with distant spread at or within the first month
of surgery; 2) with missing values for lymph
node status, ER protein status, and HOXB13
Table 1. Associations of HOXB13 and IL17BR mRNA levels with clinicopathologic factors.
NOTE. All P values are two-sided. The interquartile range is q25-q75.
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor.
* Spearman rank correlation.
† Mann-Whitney U test.
‡ Kruskal-Wallis test, followed by a nonparametric test for trend when appropriate.
§ In 378 samples (30%), grade was unknown. The median expression levels in this subset for HOXB13 was 0.0006 (∆ = 0.045),
for IL17BRps3 was 0.091 (∆ =0.172), and for IL17BRps5 was 0.015 (∆ =  0.0027).
Low and high steroid hormone receptor protein status as defined in the Patients and Methods section.
¶ In 71 tumors protein levels of PgR were not determined.
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and IL17BR expression; 3) with <30% epithelial
tumor cells in their tumor specimens; and 4)
with specimens of poor RNA quality [11].
After applying the exclusion criteria, tumor
specimens of 1,252 patients (74%) were ana-
lyzed for HOXB13 and IL17BR expression.
From these 1,252 patients (for clinicopathologic
details, see Table 1), 543 patients (43%) under-
went breast-conserving lumpectomy, and 709
patients (57%) underwent modified mastec-
tomy. The median follow-up time of all 1,252
patients was 72 months (2 to 248 months), of
the 692 patients alive was 91 months (3 to 248
months), and of the 560 deaths was 46 months
(2 to 205 months). Disease recurrence occurred
in 692 (55%) of 1,252 patients.
Four hundred six patients (32%) were treated
with adjuvant systemic therapy, of which 177
patients (44%) received hormonal therapy, 214
(53%) received chemotherapy, and 15 (3%)
received combination therapy. Of the 846
patients (68%) that had not received (neo)adju-
vant systemic therapy, 381 patients (45%) expe-
rienced a relapse treated with systemic therapy.
Two hundred eighty-five (75%) of these
patients were treated with hormonal
therapy, of which 193 patients (68%) received
first-line tamoxifen monotherapy. Therapy fail-
ure occurred in 73 patients (38%), of which 61
patients (84%) had progressive disease and 12
patients (16%) showed stable disease ≤6
months. One hundred twenty patients (62%) of
these 193 patients had experienced a clinical
benefit from first-line tamoxifen monotherapy,
of which 11 patients (66%) had a complete
response, 30 patients (25%) showed a partial
response, and 79 patients (66%) showed stable
disease > 6 months.
RNA isolation and qRT-PCR
Tissue processing, RNA isolation, cDNA syn-
thesis, and qRT-PCR were performed as
described previously by Sieuwerts et al [11].
qRT-PCR reactions were performed in 25 µl
reaction volume on an ABI Prism 7700
Sequence Detection System (Applied Biosys-
tems, Nieuwerkerk aan den IJssel, the Nether-
lands), in accordance with the recommended
protocol. Commercially available Assay-on-
Figure 1. Study design and patient subsets (framed boxes) analyzed.
Relationships with tumor aggressiveness were evaluated in estrogen receptor-positive tumors from patients who did not receive adju-
vant systemic therapy. Associations with response to first-line tamoxifen monotherapy were analyzed in 193 patients. PCR, poly-
merase chain reaction; ER, estrogen receptor.
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Demand kits (Applied Biosystems) were used
for HOXB13 (Hs00197189_m1) and IL17BR
(Hs00218889_m1; Hs00914532_m1). We used
a primer set (Hs00914532_m1; defined as
IL17BRps3), located in the 3' end region of
IL17BR (from exons 9 to 10), which is compa-
rable to the assay of Ma et al [2] and the primer
set (Hs00218889_m1; defined as IL17BRps5)
used by Reid et al [4], located in the 5' end
region (from exons 1 to 2). Both primer sets
amplify two published variants described in the
Entrez Gene database [4,6] of the National
Center for Biotechnology Information
(Bethesda, MD). Primer sequences for the three
reference genes (ie, porphobilinogen deami-
nase, hypoxanthine-guanine phosphoribosyl-
transferase, and β-2-microglobulin) and for the
ER and PGR have all been previously described
[11].
Forty rounds of amplification were performed
according to the supplier’s protocol, and at the
end of the amplification fluorescent signals of
the TaqMan probes (Applied Biosystems) were
used to generate cycle threshold (Ct) values
from which mRNA expression levels were cal-
culated. Expression levels of HOXB13 and
IL17BR were normalized against average
expression levels of three reference genes as
follows [11]:
mRNA target2(mean Ct Ref – mean Ct target). When
amplification rounds exceeded the manufac-
turer’s defined detection threshold of the ABI
Prism 7700 Sequence Detection System (Ct
values 35 to 40; Applied Biosystems,
http://docs.appliedbiosystems.com/pebiodocs/
04371095.pdf), quantities were considered to be
undetectable and were set to 50% of the expres-
sion level measurable at the detection threshold.
Data analysis and statistics
The relationship between HOXB13, IL17BR,
and a HOXB13-to-IL17BR ratio as continuous
variables with patient and tumor characteristics
were investigated with the use of nonparametric
methods (ie, Spearman rank correlations for
continuous variables and Wilcoxon rank sum
test or Kruskal-Wallis exact test for ordered
variables). Cox regression analysis was applied
to compute the hazard ratio (HR), which corre-
lates expression levels of the variables with
overall survival (OS), DFS, progression-free
survival (PFS), and postrelapse survival (PRS),
respectively. In multivariate analysis, Cox pro-
portional hazards regression models were
applied to compare the variables with tradi-
tional factors. The model for OS and DFS
included age, menopausal status, tumor size,
lymph node status, grade, and log ER and log
PGR mRNA levels. The model for PRS and
PFS included age, menopausal status, DFS, site
of relapse, and log ER and log PGR mRNA
levels [12]. The proportional hazards assump-
tion was not violated for HOXB13, IL17BRps3,
and IL17BRps5 in any of the analyses. Logistic
regression analysis was performed to calculate
the odds ratio (OR) that defines the relation
between expression ratio levels and response.
Both HR and OR were calculated on log-trans-
formed variables and were represented with
their 95% CI.
Only when the test for trend for a continuous
variable was statistically significant, a cutoff
point was considered justified. To define cutoff
points, isotonic regression was used to find the
points where the monotonic relationship
between the measured level and the hazard ratio
showed a distinct change. The cutoff with the
largest statistically significant change in hazard
ratio corrected for multiple testing was used
[12].
Ma et al [7] and Erlander et al [8] have
described cutoff points for untreated patients
(cutoff=1.00) and for adjuvant tamoxifen-
treated patients (cutoff=0.06) that separated
(tamoxifen-treated) nonrecurrence cases from
recurrent cases. These predefined cutoff points
were not directly applicable to our normalized
data set because of differences in assays, refer-
ence genes, qRT-PCR machines, and sample
specimens. As a result, our data were standard-
ized for each gene via a z-transformation step.
In concordance with Ma et al [7], a composite
index was generated by taking the difference
between the standardized HOXB13 and IL17BR
expression levels.
Based on the cutoff points, survival curves were
generated using the Kaplan-Meier method, and
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a log-rank test was used to test for differences.
Computations were performed with the STATA
statistical package, release 9.1 (STATA Corp,
College Station, TX). All P values were two-
sided, and P<0.05 was considered statistically
significant.
RESULTS
Associations of HOXB13 and IL17BR with clinico-
pathologic factors
The mRNA expression levels of HOXB13,
IL17BRps3, and IL17BRps5 were measured in
1,252 primary breast tumors by qRT-PCR and
normalized against our reference genes.
HOXB13 expression levels showed a weak but
significant inverse association with those of
IL17BR (Spearman’s rho=-0.16; P<0.0001),
whereas expression levels of IL17BRps3 and
IL17BRps5 correlated significantly (Spearman’s
rho=0.91; P<0.0001). In 448 tumors (36%),
HOXB13 expression levels were below detec-
tion level (see Patients and methods).
Table 1 shows median expression levels and the
interquartile range of all three transcripts and
their relation with patient and tumor character-
istics. The differences in IL17BR expression
levels measured with ps3 and ps5 only reflect
assay performance. HOXB13 levels associate
significantly with grade and inversely with
steroid hormone receptor status. The median
expression level of HOXB13 was 17 x higher in
poorly differentiated tumors compared with
good/moderately differentiated tumors. In con-
trast, the median HOXB13 expression level was
25 x lower in ER-positive tumors compared
with ER-negative tumors. Undetectable levels
of HOXB13 were significantly more prevalent
in ER-positive tumors, with 379 (41%) out of
917, compared with ER-negative tumors, with
Table 2. Cox univariate and multivariate analysis for disease-free survival in ER-positive primary breast
tumors from 468 lymph node-negative patients who did not receive adjuvant systemic therapy.
Abbreviations: ER, estrogen receptor; HR, hazard ratio; PgR, progesterone receptor.
* In 151 samples (32%), grade was unknown. For this subset, the HR was 1.04 (95% CI, 0.77 to 1.39; P=0.82) and 1.18 (95% CI,
0.87 to 1.61; P=0.29) in univariate analysis and multivariate analysis, respectively.
† Predefined cutoff point for the HOXB13-to-IL17BR index was determined by Ma et al [7] in a training set at 1.00 for untreated
patients.
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69 (21%) out of 335; P<0.001.
Except for tumor size, IL17BR levels were sig-
nificantly associated with all clinicopathologic
parameters studied (ie, positively with age and
menopausal status, and negatively with grade
and nodal status). ER-positive tumors showed a
two-fold higher median IL17BR expression
level than ER-negative tumors.
Next, expression levels of HOXB13 were
divided by IL17BR to generate a HOXB13-to-
IL17BR expression ratio. In all 1,252 tumors,
the HOXB13-to-IL17BR ratio measured as uni-
variate log-transformed continuous variable
was associated with a poor DFS (HRps3=1.04
[95% CI, 1.02 to 1.06; P<0.001] and
HRps5=1.05 [95% CI, 1.03 to 1.06; P<0.001],
respectively) and a poor OS (HRps3=1.06 [95%
CI, 1.04 to 1.08; P<0.001] and HRps5=1.06
[95% CI, 1.04 to 1.08; P<0.001], respectively).
HOXB13-to-IL17BR ratio and tumor aggressiveness
To test for a relation between expression ratio
and tumor aggressiveness, we included LNN
patients with ER-positive tumors who did not
receive adjuvant systemic therapy. Patients with
ER-positive tumors were selected because only
these patients are eligible for tamoxifen therapy.
Thus 468 ER-positive primary breast tumors
were analyzed (Figure 1). Of these patients, 217
(46%) had a relapse during the follow-up
period. The HOXB13-to-IL17BR ratio as a uni-
variate continuous variable was significantly
associated with a poor DFS (Table 2) and a poor
OS (HRps3=1.06 [95% CI, 1.02 to 1.10;
P=0.001] and HRps5=1.07 [95% CI, 1.03 to
1.10; P<0.001], respectively). When added to
the traditional factors of the base multivariate
model, the HOXB13-to-IL17BR ratios con-
tributed significantly to the model for DFS
(Table 2) and OS (P≤0.001; data not shown).
The prognostic value of HOXB13-to-IL17BR
ratios was also explored in ER-positive tumors
from 151 LNP untreated patients, who were
mainly enrolled in the early 1980s. In univariate
analysis, the HOXB13-to-IL17BR ratio in these
LNP patients associated with a poor DFS
(HRps3=1.05 [95% CI, 1.01 to 1.09; P=0.023],
and HRps5=1.05 [95% CI, 1.01 to 1.10;
P=0.016], respectively) and a poor OS
(HRps3=1.09 [95% CI, 1.04 to 1.14; P<0.001]
and HRps5=1.09 [95% CI, 1.04 to 1.14;
P<0.001], respectively). In the multivariate
model, theHOXB13-to-IL17BR ratio was signif-
icantly associated with OS (P<0.001), but not
with DFS (P=0.065).
Based on a predefined cutoff point (1.00) for
untreated patients [7,8] a HOXB13-to-IL17BR
index was dichotomized. In the LNN-untreated
468 patients cohort, this dichotomized index
had a significant relationship with a poor DFS
in univariate analysis (HRps3=1.69 and
HRps5=1.59) and multivariate analysis
(HRps3=1.74 and HRps5=1.61; Table 2). How-
ever, the dichotomized index was not related
with DFS in the LNP-untreated cohort of 151
patients (data not shown).
HOXB13-to-IL17BR expression ratio and response
to first-line tamoxifen monotherapy
Expression levels were evaluated in 193 ER-
positive primary breast tumors from patients
whose relapse was treated with first-line tamox-
ifen monotherapy (Figure 1). These patients had
not received any (neo)adjuvant systemic (ie,
endocrine or chemotherapy) treatment.
The HOXB13-to-IL17BR ratio, as a univariate
continuous variable, was significantly related
with a poor response (ORps3=0.93 [95% CI,
0.87 to 0.99]; P=0.027 and ORps5=0.92 [95%
CI, 0.86 to 0.98]; P=0.015, respectively), a
short PFS (Table 3), and a poor PRS (HRps3
1.07 [95% CI, 1.03 to 1.11; P<0.001], and
HRps5 1.07 [95%CI, 1.03 to 1.11; P<0.001],
respectively). In multivariate analysis, however,
the HOXB13-to-IL17BR ratio retained only its
significant association for PFS (Table 3) and
PRS (P<0.001; data not shown).
The significant findings in univariate analysis
justified the search for a predictive cutoff point.
Isotonic regression analysis defined optimal
cutoff points for PFS at 2.99 and 16.44 for
HOXB13-to-IL17BRps3 and IL17BRps5 ratio
with 26 (13%) and 28 (15%) tumors classified
as high, respectively. This resulted in an ORps3
for response of 0.18 and 0.16 ([95% CI, 0.06 to
0.45]; P<0.001) and an ORps5 of 0.12 and 0.12
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([95% CI, 0.04 to 0.33]; P<0.001) in univariate
and multivariate analyses, respectively. The uni-
variate HR for PFS of the dichotomized
HOXB13-to-IL17BRps3 and IL17BRps5 ratio
were 3.43 and 3.85 (both P<0.001; Table 3).
When added to the multivariate base model,
high levels of HOXB13-to-IL17BR ratios were
independently associated with a poor PFS
(Table 3; both P<0.001).
We also evaluated a previously defined cutoff
point of a HOXB13-to-IL17BR index for tamox-
ifen response in an adjuvant setting by Ma et al
[7]. This cutoff point (0.06) classified 65 (34%)
and 73 (38%) of the tumors as high for
HOXB13-to-IL17BRps3 and IL17BRps5
indexes, respectively. In univariate analysis, the
OR for response of the HOXB13-to-IL17BR
index based on this predefined cutoff point was
ORps3=0.59 (95% CI, 0.32 to 1.09; P=0.09)
and ORps5=0.42 (95% CI, 0.23 to 0.76;
P=0.004), and it resulted in a significant associ-
ation with PFS (ie, HRps3=2.15 and
HRps5=2.39; Table 3). In multivariate analysis,
the two-gene index remained only significantly
associated with a shorter PFS (Table 3).
The predictive value of HOXB13-to-IL17BRps3
is visualized with Kaplan-Meier curves in
Figure 2. Similar results were obtained for the
HOXB13-to-IL17BRps5 ratio. 
DISCUSSION
Ma et al [2] used microarrays to analyze ER-
positive tumors from patients treated with adju-
Table 3. Cox univariate analysis and multivariate analysis for progression-free survival in ER-positive tumors  
from 193 patients whose recurrence was treated with received first-line tamoxifen monotherapy.
Abbreviations: ER, estrogen receptor; HR, hazard ratio; PgR, progesterone receptor; PFS, progression-free survival.
* Predefined cutoff point for the HOXB13-to-IL17BR index was determined by Ma et al [7] and set at 0.06 for adjuvant
tamoxifen-treated patients.
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vant tamoxifen. They identified HOXB13 and
IL17BR as being differentially expressed
between relapsed patients and disease-free
patients. However, in the adjuvant setting, one
cannot discriminate between tumor aggressive-
ness and response to treatment [6]. The data
were confirmed with qRT-PCR on FFPE-
derived RNA in a small patient cohort that was
not similar to the original training set. It is gen-
erally accepted that RNA from FFPE samples is
significantly degraded and, therefore, of lower
quality compared to RNA from frozen samples.
This article describes expression levels of
HOXB13 and IL17BR measured with qRT-PCR
on frozen tissue–derived RNA in a large number
of tumors. Based on this technical approach and
the large sample size, a HOXB13-to-IL17BR
expression ratio can be more accurately quanti-
fied and related to outcome and clinicopatho-
logic data. Up to now, this is the only study that
allows for a relation of HOXB13-to-IL17BR
expression levels with both tumor aggressive-
ness and response to first-line tamoxifen
monotherapy.
Our study supports the finding that a HOXB13-
to-IL17BR ratio has prognostic value in LNN-
Figure 2. Relationship between dichotomized HOXB13-to-IL17BRv3 expression levels and progression-free survival curves ana-
lyzed in 193 patients with recurrent disease treated with first-line tamoxifen monotherapy.
A cutoff point for advanced tamoxifen (A: 2.99) and a predefined cutoff point for adjuvant tamoxifen (B: 0.06) [7] were used to
dichotomize the HOXB13-to-IL17BR ratio.
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untreated patients [7,8]. In contrast to others
[4,13], we found in a larger cohort of LNP-
untreated patients a statistically significant asso-
ciation with disease outcome in univariate
analysis. Interestingly, our findings demon-
strated for the first time the relationship of a
HOXB13-to-IL17BR ratio with response to first-
line tamoxifen monotherapy. We showed in
patients with recurrent disease that high
HOXB13-to-IL17BR ratio levels were associ-
ated with a poor response to therapy and a short
PFS, independent of traditional clinical and
pathologic predictive factors.
For their analysis of IL17BR expression levels,
Reid et al [4] used a primer set in the 5' end
region of IL17BR, whereas Ma et al [2] applied
a primer set in the 3' end region. Because of the
difference in primer design, we have evaluated
both primer sets. The 3' end primer set (ps3) of
IL17BR revealed 6 x higher expression levels
compared with levels determined with a 5' end
primer set (ps5). Despite this six-fold differ-
ence, levels of both correlated significantly. As
a consequence, corresponding HOXB13-to-
IL17BR ratios showed equivalent performances.
The HOXB13 gene is localized at the edge of a
HOXB-gene cluster at chromosome 17q21 and
belongs to the canonical family of homeobox
(HOX) genes [14]. HOX proteins often require
other homeodomain proteins to form DNA-
binding complexes [15,16]. Our data revealed
that in 36% of breast tumors, HOXB13 expres-
sion was below detection level. The observed
absence of HOXB13 expression in these tumors
may be caused by a chromosomal deletion of
the gene but also may be due to epigenetic
silencing, such as promotor methylation. In
renal cell carcinoma, complete methylation of 5'
CpG islands of HOXB13 and corresponding
loss of mRNA and protein expression were
reported to correlate with tumor progression
[17]. In contrast, HOXB13 was absent in normal
breast and prostate tissue, whereas elevated
levels were detected in breast and prostate
tumor tissue [2,18,19]. In prostate cancer cell
lines, it was shown that HOXB13 functions as
an androgen receptor (AR) repressor to modu-
late hormone-activated AR signaling and, in
contrast with observations in tumor tissue, to
suppress cell growth [15]. Likewise, we and
others found that the absence of HOXB13
expression was predominantly observed (85%)
in ER-positive breast tumors. This relation
between ER expression and transcriptional
repression of HOXB13 needs further investiga-
tion.
In conclusion, this retrospective qRT-PCR study
provides evidence that high HOXB13-to-
IL17BR expression levels are associated with
both tumor aggressiveness and tamoxifen
monotherapy failure.
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ABSTRACT
TIMP-1 is a promising new candidate as a prog-
nostic marker in colorectal and breast cancer.
We now describe the discovery of two alterna-
tively spliced variants of TIMP1 mRNA.
The two variants lacking exon 2 (del-2) and 5
(del-5), respectively, were identified in human
cancer cell lines by RT-PCR. The del-2 variant
was furthermore detected in extracts from 12
colorectal cancer tissue samples. By western
blotting additional bands of lower molecular
mass than full-length TIMP-1 were identified in
tumor tissue, but not in plasma samples
obtained from cancer patients. 
The two splice variants of TIMP-1 may hold
important clinical information, and either alone
or in combination with measurement of full-
length TIMP-1 they may improve the prognos-
tic and/or predictive value of TIMP-1 analyses. 
INTRODUCTION
Despite an increasing knowledge on the
molecular mechanisms underlying malignant
transformation and dissemination of disease, the
overall survival rates for the most common
malignancies in the Western world have only
improved slightly over the last decade. The
obvious challenge in future management of
cancer patients is therefore to improve existing
therapy and/or to develop new therapy strate-
gies. Another approach is to improve detection
of early cancer disease, as patients diagnosed at
the early stages of e.g. colorectal cancer often
will be cured by primary surgery alone [1]. Fur-
thermore, since stratification of cancer patients
for therapy is based on prognostic evaluations,
this calls for new and better prognostic markers.
Tissue inhibitor of metalloproteinases-1 (TIMP-
1) is a promising new marker for early detection
and prognostic stratification of patients suffer-
ing from colorectal cancer [2, 3]. In addition,
TIMP-1 also carries the potential as a predictive
marker for response to chemotherapy [4, 5].
TIMP-1 is a naturally occurring inhibitor of
matrix metalloproteinases (MMPs), a large
family of proteases involved in many physio-
logical and pathological processes like embry-
onic development, tissue morphogenesis,
wound healing, inflammation and cancer inva-
sion (for reviews see [6, 7] ). Four TIMPs
(TIMP-1 to -4) have been identified and they
differ in tissue distribution and ability to inhibit
different MMPs [8]. Mature TIMP-1 is a 28.5
kDa glycoprotein, consisting of 184 amino acid
residues. The unprocessed precursor contains a
signal peptide of 23 residues, which is cleaved
in the maturation of the protein [9]. TIMP-1
contains two sites of N-glycan linkage and six
disulfide bonds. The latter is folding the protein
into a two-domain structure. These disulfide
bonds renders TIMP-1 very robust to changes in
pH, temperature and denaturing conditions [10].
The MMP-inhibitory activity has been located
to the N-terminal domain of TIMP-1, which
forms non-covalent complexes with MMPs or
proforms of these, in particular proMMP-9 [11].
Although now named for its ability to inhibit
MMPs, TIMP-1 was first identified for its
growth stimulating activity of erythroid
progenitors [12], and its mitogenic ability has
since been demonstrated in many cell types [13,
14]. TIMP-1 has also been shown to inhibit
apoptosis [15, 16] and to participate in regula-
tion of angiogenesis [17]. It therefore seems that
TIMP-1 is a multifunctional protein demon-
strating a range of activities that in relation to
cancer can be both tumor promoting and sup-
pressing. Some functions of TIMP-1 can be
ascribed to its MMP inhibitory ability, while
others appear to be independent of binding to
MMPs.
TIMP-1 may exist in multiple molecular forms
in the cancer environment and subsequently in
the circulation, e.g. in complex with other pro-
teins like MMPs [18] or as different glycosyla-
tion variants [19]. The clinical value of TIMP-1
measurements  may be improved by detection
of specific forms of TIMP-1, as shown in breast
cancer, where measurement of unbound TIMP-
1 versus total TIMP-1 adds to the prognostic
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evaluation of the patients [2, 20]. We now
describe the expression of two newly dis-
covered splice variants of TIMP1 mRNA in
cancer cell lines and in colon cancer tissue.
They may hold important clinical information
and could either alone or in combination with
measurement of full-length TIMP-1 improve
the already established clinical value of TIMP-1
as a biological tumor marker.
MATERIALS AND METHODS
Cell culture 
The following human breast cancer cell lines
were used: MDA-MB-231-BAG [21], MDA-
MB-435-BAG [21], CAMA-1, EVSA-T,
ZR75.1, T47-D, SKBR-3 and MCF7-S1 (kindly
provided by Professor Marja Jäättela, Danish
Cancer Society, Copenhagen, Denmark). Fur-
thermore, three colon cancer cell lines DLD-1,
LoVo and LS 174T (all from ATCC, Manassas,
USA) as well as the prostate cancer cell line PC-
3, the human acute promyelocytic leukemia cell
line HL-60 (kindly provided by Professor Hau
C. Kwaan, Northwestern University, Chicago,
USA) and the endothelial cell line EAHY-926
were used. MCF7-S1 cells were propagated in
RPMI medium supplemented with 10% heat
inactivated fetal calf serum (FCS) and HL-60
cells were propagated in IMDM medium with
20% FCS. ZR75.1, T47-D, SKBR-3 and
EAHY-926 were propagated in HAMF/DME
medium with 10% FCS, 0.15% Na2HCO3 and
45 µg/ml Gentamycin. ZR75.1 cells were fur-
thermore supplemented with 10 nM estradiol
and to EAHY-926 cells 1x HAT medium was
added. DLD-1 cells were propagated in modi-
fied RPMI-1640 medium (ATCC) supple-
mented with 10% FCS. LoVo cells were
propagated in modified F-12K medium (ATCC)
supplemented with 10% FCS. LS 174T cell
were propagated in modified EMEM (ATCC)
supplemented with 10% FCS. All other cell
lines were propagated in DMEM medium.
MDA-MB-231-BAG and MDA-MB-435-BAG
cells were supplemented with 10% FCS and
CAMA-1, EVSA-T and PC-3 cells with 5%
FCS. All media (except for the colon cancer cell
lines) were purchased from Invitrogen, Taas-
trup, Denmark and were supplemented with
penicillin and streptomycin. The cells were
grown at 37º C in a humidified air atmosphere
with 5% CO2.
Patient material
Tumor tissue and blood samples from 12
patients who underwent surgery for colorectal
cancer (CRC) were obtained from Hvidovre
Hospital, Denmark, in accordance with an
approval by the Scientific Ethical Committee
for Copenhagen and Frederiksberg, Denmark
(Journal no. KF 01-078/93) and with informed
consent from the patients. The tissue samples
were taken from the peripheral area of the
tumor, snap frozen in liquid nitrogen and stored
at -80º C. At the time of surgical removal of the
tumor, blood samples were collected and EDTA
plasma samples prepared according to a previ-
ously described protocol [22]. A pool of control
EDTA plasma and platelets were obtained from
the blood bank at Rigshospitalet, Copenhagen,
Denmark.
Each tissue sample was divided into three parts.
One part was used for RNA extraction and RT-
PCR and one part was used for protein extrac-
tion and ELISA. The middle part of each tissue
was thawed and fixed in 4% neutral buffered
paraformaldehyde overnight at 4° C and
processed for paraffin embedding prior to histo-
logical analyses. The diagnosis of colon cancer
was confirmed in H&E stained sections of the
paraffin embedded material and the relative area
of neoplastic cells was estimated (0 -100%). 
For western blotting analysis we obtained an
additional 6 CRC tissue samples from the same
source as the 12 CRC samples described above.
RNA extraction and reverse transcription
RNA was extracted from tissue samples or cells
using a spin column kit (SV Total RNA isola-
tion system, Promega, Madison, USA) accord-
ing to the manufacturer's instructions. This
procedure includes an on-column DNase treat-
ment, minimizing the risk of DNA contamina-
tion. Prior to extraction approximately 30 mg of
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tissue sample was homogenized in 1 ml lysis
buffer. The cells were grown to a confluency of
approximately 60% in 900 ml flasks, washed
twice in PBS and lysed in 0.5 ml lysis buffer.
RNA was extracted from 175 µl lysate and the
concentration of total RNA was measured spec-
trophotometrically.
One microgram of total RNA was transcribed
into cDNA using the First Strand cDNA Synthe-
sis Kit (Fermentas, Helsingborg, Sweden). The
total volume of the reaction was 25 µl consist-
ing of 1x reaction buffer, 0.8 mM dNTPs, 20 U
RiboLock RNase inhibitor, 0.5 µg oligo(dT)
primer, 0.2 µg random hexamer primer and 40
U M-MuLV Reverse Transcriptase. Samples
were incubated at 25º C for 10 min, followed by
42º C for 1 h. The reaction was terminated by
incubating at 95º C for 5 min followed by cool-
ing on ice. 
PCR 
All primer sets used were intron-spanning to
avoid false positive results from contaminating
genomic DNA. Prior to PCR with TIMP1
primers all cDNA samples were subjected to
PCR with primers for GAPDH (Table 1) to
ensure that RNA extraction and reverse tran-
scription (RT) were carried out efficiently. PCR
was performed in 25 µl reactions containing 1x
HotStarTaq Mastermix (Qiagen Nordic, West
Sussex, UK), 1 µM of each gene-specific
primer and 1 µl cDNA. Reaction conditions
were 95º C for 15 min followed by 40 cycles of
94º C for 1 min, 60º C for 30 s and 72º C for 1
min. 
PCR products were separated on a 1.5 %
agarose gel (Fermentas, Sweden) stained with
ethidium bromide and visualized by UV light.
Quantitative real-time PCR (qPCR)
In order to estimate the expression level of the
del-2 TIMP1 variant compared with full-length
TIMP1, a qPCR assay determining relative
expression levels was developed. Relative
quantification was chosen in contrast to
absolute quantification, since tumor samples
contain various amounts of cells expressing
TIMP1. The absolute amount of transcript will
therefore depend on the composition of each
sample. Relative quantification using either
total TIMP1 or full-length TIMP1 as reference
gene will reflect only changes in transcription of
the cells expressing TIMP1.
qPCR was carried out using SYBR Green I
detection and the LightCycler System 2.0
(Roche Diagnostics, Hvidovre, Denmark)
essentially as previously described [23]. PCR
conditions for each primer set were optimized
by determining the MgCl2 concentration and
annealing temperature at which only the spe-
cific product was seen. Reactions were carried
out in 20 µl volumes consisting of 1x FastStart
Master SYBR Green Mix, 5 mM MgCl2 and 0.5
µM of the gene-specific primer. The amplifica-
tion program was as follows: Preincubation for
Fast Start Polymerase activation at 95º C for 10
min, followed by 45 amplification cycles (95º C
for 5 s (20º C/s), 65º C for 10 s (20º C/s), and
72º C for 6-10 s (20º C/s). SYBR Green fluores-
cence was acquired at 72º C in each amplifica-
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Table 1. Primers used for RT-PCR and qPCR analyses.
a  Except variants lacking exon 1 or 6.
b qPCR assay.
tion cycle. After the end of the last cycle the
melting curve was generated by starting the flu-
orescence acquisition at 65º C and taking meas-
urements every 0.1 s until 95º C was reached.
A standard curve for each primer set was gener-
ated using 10-fold dilutions of a pool of tumor
cDNA. The standard curve was used to correct
for differences in PCR efficiencies between
primer sets. Dilutions of tumor cDNA samples
were chosen for the generation of standard
curves to ensure the same PCR efficiency in
standards and samples. Relative quantification
was done using the Relative Quantification soft-
ware (LightCycler 2.0, Roche, Denmark).
Protein extraction for western blotting and ELISA
The frozen tissue samples used for ELISA were
fragmented on dry ice using a pestle and mortar
device (Arrow Fastener CO Inc., Saddle Brook,
N.J., USA). The powdered tissue was weighed
and dissolved in Camiolo buffer (75 mM
CH3COOK, 0.3 M NaCl, 0.1 M L-argenine, 10
mM EDTA, 0.25% Triton X-100, pH 4.2) in a
3:1 ratio of buffer to tissue. Samples were cen-
trifuged for 1 h at 20,000 g, and the supernatant
containing the proteins was used for further
analysis. For western blotting, the tissue powder
was dissolved in modified RIPA buffer (50 mM
Tris-HCl (pH 7.4), 1% NP-40, 0.25% Na-
deoxycholate, 150 mM NaCl, 1 mM EDTA)
supplemented with protease inhibitors (Pefa-
bloc, Aprotinin, Leupeptin, Pepstatin: 1 µg/ml
of each). 
The tumor cell lines were seeded in Petri dishes
(1x106/ dish). After 24 h, the cells were har-
vested in ice-cold PBS by scraping followed by
centrifugation for 5 min at 400 g. Platelets were
centrifuged for 5 min at 300 g. The tumor cells
and platelets were resuspended in lysis buffer
(25 mM Hepes, 5 mM MgCl2, 1 mM EDTA,
0.5% Triton; pH 7.5) supplemented with pro-
tease inhibitors (see above), incubated for 30
min on ice followed by centrifugation for 5 min
at 20,000 g. Protein concentration in plasma,
and tissue samples and in cell lysates was deter-
mined by the BCA Protein assay kit (Pierce,
Rockford, IL, USA). 
Western blotting
Protein samples were mixed with 0.25 x volume
of 4 x Laemmli sample buffer, boiled for 5 min
and equal amounts of protein (100 or 150 µg)
were separated on a 12% polyacrylamide gel
and blotted on nitrocellulose membrane. The
blot was blocked in PBS containing 0.1%
Tween 20 and 5% dry milk powder for 1 h, and
then incubated overnight with monoclonal anti-
human TIMP-1 (VT7; 1 µg/ml) [24]. Subse-
quently, the blot was washed 3 x 10 min in PBS
containing 0.1% Tween 20, incubated with
horseradish peroxidase (HRP)- conjugated goat
anti-mouse antibody diluted 1:1000 (DAKO,
Glostrup, Denmark) in PBS with 0.1% Tween
20 and 1% dry milk powder for 1 h followed by
3 x 10 min washing in PBS with 0.1% Tween
20. The blot was developed by the ECL+ detec-
tion system (Amersham, UK) according to the
manufacturer's instructions. Recombinant
human TIMP-1 (rhTIMP-1) and platelet lysate
were used as positive controls, and as a control
for the sensitivity of the assay we also included
a pool of control EDTA plasma (see Patient
material) with a known low level of TIMP-1
(Table 2).
ELISA
A well established sandwich ELISA was used to
measure total levels of human TIMP-1 in tissue
and plasma samples [22]. In brief, the
immunoassay employs an affinity-purified
polyclonal sheep anti-TIMP-1 antibody as cap-
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Table 2. TIMP-1 levels in plasma and tumor
extracts measured by ELISA.
a Relative area of neoplastic cells in tissue section.
ture antibody and a monoclonal anti-TIMP-1
antibody for detection. The complex was
detected with alkaline phosphatase-conjugated
rabbit anti-mouse antibodies (Dako, Denmark),
that enables a kinetic rate assay. The plate was
read at 405 nm, and the rate of the color devel-
opment was collected automatically over a 1 h
period in a Power Wavex Microplate Reader
(Biotek Instruments Inc., VT, USA) and the
results were evaluated using the KC4 software
(Biotek Instruments Inc., USA). A four-para-
meter fitted standard curve was generated from
which the TIMP-1 concentration of each sample
was calculated. TIMP-1 concentrations in tissue
samples were normalized for differences in pro-
tein concentrations.
Generation and sequencing of TIMP1 cDNA frag-
ments 
Full-length human TIMP1 cDNA (Genbank
accession no. NM_003254) was used as a tem-
plate to generate two non-overlapping cDNA
fragments of TIMP1 by PCR named TIMP1 01
(56-378 bp) and TIMP1 02 (398-680 bp). The
PCR reactions were carried out with upstream
primers flanked by a T3 RNA polymerase site
and downstream primers flanked by a T7 RNA
polymerase site (polymerase sites in bold). The
primers used for fragment 01 were: up 5'-CAT
TAA CCC TCA CTA AAG GGA GAA CCC
ACC ATG GCC CCC TTG-3' and down 5'-
TAA TAC GAC TCA CTA TAG GGA GAC
TCC TCG CTG CGG TTG TGG-3', and for
fragment 02: up 5'-CAT TAA CCC TCA CTA
AAG GGA GAG CAG GAT GGA CTC TTG
CAC A-3' and down 5'-TAA TAC GAC TCA
CTA TAG GGA GTA TCT GGG ACC GCA
GGG ACT-3'. The PCR was carried out in a 25
µl reaction containing 1xTaq buffer, 0.2 mM
dNTP mix, 2 mM MgCl2, 1 µM of each primer,
1 U Taq polymerase and 0.1-0.5 µg cDNA
template using standard reagents from Fermen-
tas (Sweden). The PCR products were analyzed
by gel electrophoresis and purified using Min-
Elute Gel Extraction kit from Qiagen Nordic
(UK) according to the manufacturer's instruc-
tions. 
For the two splice variants of TIMP1 lacking
exon 2 (del-2) or exon 5 (del-5), RT-PCR
products from cell lines and colon cancer tissue
samples were gel purified as described above
and used as a template for a PCR reaction with
the following T3 and T7 flanked primers: up 5'-
CAT TAA CCC TCA CTA AAG GGA GAA
GTG GGT GGA TGA GTAATG C-3' and down
5'-TAA TAC GAC TCA CTA TAG GGA GTC
TGG TTG ACT TCT GGT GTC C-3'.
All TIMP1 fragments generated with T3 and T7
flanked primers were sequenced (AGOWA,
Berlin, Germany) with both T3 and T7 primers
and the sequences were confirmed by BLAST
search.
Preparation of digoxigenin-labeled RNA probes
Antisense and sense RNA probes were synthe-
sized by in vitro transcription from TIMP1 frag-
ment 01, 02 and del-2 variant using T3 and T7
polymerases and Dig RNA labeling mix
(Roche, Basel, Schwitzerland) according to the
manufacturer's instructions. The labeled probes
were purified using RNeasy MinElute Cleanup
Kit (Qiagen, UK) and the yield of labeled probe
was estimated by spot blot analysis. Antisense
and corresponding sense probes were adjusted
to the same concentration and diluted with de-
ionized formamide to a final concentration of
50%. 
In situ hybridization
Paraffin sections were cut at 3 µm, dried
overnight, dewaxed and treated with 10-15
µg/ml of proteinase K for 5 min, dehydrated and
air-dried before 25 µl of hybridization solution
containing 5 µl probe (50 ng) was added to each
section. Hybridization was carried out overnight
at 42° C. After hybridization, the sections were
washed with 2x SSC/0.1% SDS for 1 h and with
0.5x SSC/0.1% SDS for 30 min at 55° C. The
sections were then treated with RNase A for 10
min at 37°C to remove non-hybridized probe
followed by a final stringency wash with 0.1x
SSC/0.1% SDS for 30 min at 37° C. Prior to
immunological detection of hybridized probe,
the sections were blocked with 5% BSA in 0.1
M Tris, 0.15 M NaCl pH 7.5 containing 0.1%
Triton X-100 for 30 min. Alkaline phosphatase-
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labeled anti-digoxigenin antibody diluted 1:500
was then applied to the sections for 2 h, and the
reaction was visualized by incubating the sec-
tions with NBT/BCIP (Roche, Schwitzerland)
overnight in the dark. The sections were
counter-stained with Mayer's hematoxylin and
mounted with Glycergel (Dako, Denmark).
Sense probes were applied to each case as
negative controls. For each in situ hybridization
experiment, a positive control case (human
colon carcinoma known to contain TIMP1
mRNA) was included.
Immunohistochemistry
Paraffin sections (3 µm) were dewaxed in
xylene and rehydrated through a graded series
of ethanol.  Antigen retrieval was carried out by
boiling the sections for 10 minutes in a conven-
tional microwave oven in 10 mM citrate buffer
pH 6.00 followed by 30 min in the hot buffer at
room temperature. To block endogenous
peroxidase activity, the sections were treated
with 0.5% hydrogen peroxide in 99% ethanol
for 10 min. Sections were incubated at 4° C
overnight with primary antibodies diluted to the
following IgG concentrations: 0.25 µg/ml
monoclonal anti-TIMP-1 antibody, clone VT7
[24] and 3.75 µg/ml monoclonal anti-α-smooth
muscle actin (α-SMA; Dako, Denmark). Anti-
TIMP-1 antibody was detected with HRP-
labeled PowerVision Kit, (ImmunoVision
Technologies, Brisbane, CA, USA) and anti-α-
SMA antibody was detected with HRP-labeled
rabbit Envision (Dako, Denmark). The reac-
tions were in all cases visualized by incubating
the sections with 0.1% diaminobenzidine con-
taining 0.02% H2O2 for 5 min. The sections
were counterstained with Mayer's hematoxylin.
For each tissue sample a negative control was
performed on a serial section, where the pri-
mary antibody was substituted by an irrelevant
monoclonal antibody against trinitrophenyl
hapten (TNP) (IgG1 subtype) diluted to the
same IgG concentration as the respective pri-
mary antibodies. For each immunohistochemi-
cal experiment, a positive control case (human
colon carcinoma known to contain TIMP-1)
was included. 
RESULTS
RT-PCR
The TIMP1 gene consists of 6 exons and the ini-
tial RT-PCR screening of the cultured cell lines
was carried out using a forward primer in exon
1 and a reverse primer in exon 6 (Table 1 and
Figure 1A). After detection of more than one
PCR product, indicating various splice variants,
RT-PCR was performed using combinations of
primers located 2 exons apart to identify any
exon-skipping variants. All cell lines except
EVSA-T and CAMA-1 expressed more than
one TIMP1 transcript (Figure 1A). These were
identified as a variant lacking exon 2 (del-2)
(Figure 1B), and in MDA-MB-231-BAG,
MDA-MB-435-BAG, PC-3 and EAHY-926
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Figure 1. RT-PCR on cultured cell lines (A–C) and colon
cancer tissue samples (D).
The following primer combinations were used. Panel A: for-
ward exon 1 and reverse exon 6; panel B and D: forward exon
1 and reverse exon 3; panel C: forward exon 4 and reverse
exon 6. Full-length TIMP1 mRNA was detected in all cell
lines (A, upper band at 648 bp), and all cell lines except
EVSA-T and CAMA express more than one transcript, most
abundantly a second transcript of 515/519 bp (lower band in
A). RT-PCR with primers located in exon 1 and 3 shows that
all cell lines except EVSA-T and CAMA express del-2 variant
(B, lower band at 134 bp), and RT-PCR with primers located
in exon 4 and 6 shows that MDA-MB-231-BAG, MDA-MD-
435-BAG, EAHY-926 and PC-3 cell lines express del-5
variant (C, lower band at 127 bp). Both full-length TIMP1
and del-2 variant mRNA were detected in 11 of the 12 colon
cancer tissue samples (D). L: 100 bp DNA ladder.
cells also a variant lacking exon 5 (del-5)
(Figure 1C). The identification of full-length,
del-2 and del-5 transcripts was confirmed by
sequencing. No variants lacking exon 3 or 4
could be detected. MDA-MB-231-BAG, MDA-
MB-435-BAG and PC-3 cells also expressed
additional variants, which could not be identi-
fied by the single exon-skipping analysis and
were therefore not analysed further.
Screening of the 12 colon cancer tissue samples
revealed both full-length and del-2 variant in 11
samples (Figure 1D). In one of the samples no
transcript could be detected when the primer
located in exon 1 was used. However amplifica-
tion with both GAPDH primers and TIMP1
primers other than the one located in exon 1
revealed that there was TIMP1 expression in
this sample (data not shown). qPCR in which
the primer partly located in exon 1 (see below)
was used, showed that in this sample the del-2
variant was also expressed. The results indicate
that in this sample exon 1 is either partially
missing or the sequence located at the 5' end is
altered compared to the other samples. No del-5
variant could be detected in any of the 12 tissue
samples. 
qPCR
To detect full-length TIMP1 transcript, the for-
ward primer located in exon 2 was combined
with the reverse primer located in exon 3 (Table
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Figure 2. Detection of TIMP-1 and alternative TIMP-1 products in cancer cell lines (A), lysates of tumor samples from CRC
patients (B) and in plasma from CRC patients (C). 
Equal amounts of protein were separated by SDS-PAGE, and TIMP-1 was subsequently detected with a monoclonal anti-TIMP-1
antibody (VT7). Low control, platelet lysate (contains high TIMP-1 protein levels) and recombinant human (rh) TIMP-1 serve as con-
trols. The plasma samples are representative of a total of 12 samples analysed. The experiment was repeated once with similar
results.
1). To detect only the del-2 transcript a forward
primer designed to anneal to the last 18 bases of
exon 1 and the first 3 bases of exon 3 (Table 1)
was combined with a reverse primer in exon 4.
In the 12 CRC samples, the mean relative
expression level of the del-2 variant compared
to the full-length transcript was 0.00802 (±
0.00206 SD). This means that the variant is
transcribed at a level approximately 1/1000 of
the full-length transcript. The cancer cell lines
generally displayed a higher level of del-2 vari-
ant expression ranging from 0.0021 to 0.05. 
Western blot analysis
Next, it was investigated if the splice variants
detected by RT-PCR and qPCR also generated a
protein product detectable by western blotting
analysis. To analyse if the presence of different
transcripts results in different protein expression
we chose to analyse one cell line that only
expresses full-length TIMP1 mRNA (EVSA-T),
2 cell lines that express both full-length TIMP1
mRNA and the del-2 variant (MCF-7S1 and
HL-60) and 2 cell lines that express both full-
length TIMP1 mRNA, the del-2 variant and the
del-5 variant. We also included all three colon
cancer cell lines to compare with the tumor
tissue. As shown in Figure 2A, all the tumor cell
lines, except for EVSA-T, expressed full-length
TIMP-1 protein, although at different levels of
expression. The anti-TIMP-1 antibody recog-
nized two bands around 24 kDa in the positive
controls and in the tumor cell lines, probably
representing glycosylation variants of full-
length TIMP-1. Below full-length TIMP-1 addi-
tional bands were detected, in particular in
PC-3, DLD-1, LoVo and LS 174T cell lines.
When tumor tissue extracts from CRC patients
were analysed for presence of TIMP-1 protein,
additional bands were detected below full
length TIMP-1 in tissue sample 1, 3 and 6
(Figure 2B). Both cells and tumor extracts were
lysed in a buffer containing a cocktail of pro-
tease inhibitors minimizing the risk of break-
down products, and therefore the alternative
products may represent splice variants. When
plasma samples from CRC patients were ana-
lyzed by western blotting no alternative TIMP-
1 products were detected (Figure 2C). 
ELISA
ELISA detecting the amount of total TIMP-1
protein was performed on both plasma samples
and tumor tissue extracts. The results are dis-
played in Table 2. Compared with a control
plasma pool, it is evident that all the plasma
samples from CRC patients displayed an ele-
vated level of TIMP-1 protein (mean 326.4 ±
163.4 ng/ml), supporting our previous reports
[2, 25]. In the tumor tissue samples, the mean
concentration of TIMP-1 was 18.6 ± 9.3 ng/mg
of protein. In order to evaluate if the tumor
extract levels were elevated we would need to
compare with a matched sample of normal
colon tissue, which unfortunately was not avail-
able for this study. There was no obvious corre-
lation between TIMP-1 levels in plasma
samples and tumor extracts. As TIMP-1 levels
in the tumor tissue samples are likely to reflect
the amount of tumor tissue/invasive front pres-
ent in the sample, we evaluated histopathologi-
cally a section taken from the middle part of
each biopsy. However, there was no apparent
correlation between TIMP-1 levels in the tumor
extracts and the relative area of neoplastic cells
in the corresponding tissue sections (Table 2). 
Localization of TIMP1 mRNA and TIMP-1 protein
TIMP1 full-length mRNA expression was
detected in 9 of the 12 colon cancer samples by
in situ hybridization. The positive signal was
seen in single cells located adjacent to tumor
cells. The cells were elongated and resembled in
all cases fibroblasts (Figure 3A and C). No
signal was observed in tumor cells in any of the
samples. The specificity of the in situ hybridiza-
tion signal was evaluated by using probes tran-
scribed from two non-overlapping fragments of
TIMP1 cDNA. In all 9 positive samples, the two
non-overlapping antisense probes gave identical
hybridization patterns (Figure 3A and C), while
no specific signal was seen with the two corre-
sponding sense probes (Figure 3D). The inten-
sity of the hybridization signal was generally
weaker than the signal observed in the positive
control tissue, possibly due to differences in fix-
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ation procedure. The 12 colon cancer samples
were also hybridized with a specific antisense
probe against the TIMP1 del-2 splice variant,
and a very weak signal was observed in 2 of the
samples. However a stronger signal was seen in
the control tissue, were the positive cells co-
localized with a proportion of cells expressing
full-length TIMP1 mRNA (Figure 3B). 
TIMP-1 protein was detected in all 12 colon
cancer samples by immunohistochemistry using
a monoclonal antibody against human TIMP-1.
This antibody recognizes a linear epitope
located in the C terminal end of TIMP-1 trans-
lated from part of exon 6 [24].  Intense positive
immunostaining was seen in fibroblast-like
cells in all samples (Figure 4B), and in addition
tumor cells also showed weak staining in 9 of
the 12 samples investigated. No staining was
observed in any of the samples when the pri-
mary antibody was replaced by an irrelevant
control antibody against TNP (Figure 4D). 
There was a good correlation between TIMP-1
immunohistochemistry and in situ hybridization
for full-length TIMP1 mRNA performed on
serial sections (Figure 4A and B). The positive
cells were further characterized by immuno-
staining with a monoclonal antibody against α-
SMA. On serial sections, TIMP1 mRNA and
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Figure 3. TIMP1 expressions in colon cancer. 
Serial sections from a colon adenocarcinoma were hybridized with antisense or sense probes for full-length TIMP1(A, C, D) or exon
2 splice variant of TIMP1(B). Full-length TIMP1 mRNA is seen in fibroblast-like cells localized in the stroma (St) adjacent to the
cancer cells (Ca) with similar hybridization patterns seen with two non-overlapping antisense probes (transcribed from pTIMP1 01
and 02) (arrows in A and C). The exon 2 variant of TIMP1 mRNA is detected in some of the same fibroblast-like cells seen in a par-
allel section (arrows in B). No signal is detected with a sense probe corresponding to the antisense probe shown in panel A (D). Scale
bar: A–D=50 µm.
TIMP-1 protein positive cells co-localized with
a sub-population of α-SMA positive cells
(Figure 4A-C), indicating that the TIMP-1
expressing cells are smooth muscle cells or
myofibroblasts.
DISCUSSION
By screening tumor tissue from 12 patients suf-
fering from colorectal cancer and a panel of
human cancer cell lines, we have in addition to
full-length TIMP1 mRNA, identified two exon-
skipping splice variants. In most cell lines and
in all the cancerous tissue samples we detected
a variant of TIMP1 lacking exon 2 (del-2), and
in a few of the cell lines a variant lacking exon
5 (del-5). The observed splice variants were all
sequenced, confirming that they represented
TIMP1 transcripts.
In full-length TIMP1 mRNA the translation
is initiated from the first ATG site in
exon 2. Sequence analysis of information on
the del-2 variant (Ensembl gene report
OTTHUMG00000021447), revealed that the
most likely initiation site containing part of the
Kozak consensus sequence [26] is located at the
end of exon 3 (Figure 5). This does not change
the reading frame, but results in a shorter pro-
tein (143 amino acids) lacking the signal pep-
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Figure 4. Identification of TIMP-1 positive cells in colon cancer.
Serial sections from a colon adenocarcinoma were processed for in situ hybridization with TIMP1 antisense probe 01 (A), or
immunostained with monoclonal antibodies against TIMP-1 (B) or a-SMA (C). TIMP1 mRNA expressing cells (arrows in A) are seen
in the stroma (St) with no signal observed in the cancer cells (Ca), and immunoreactivity for TIMP-1 is detected in the same cells
(arrows in B). TIMP1 mRNA and protein co-localize with a sub-population of a-SMA positive cells, as seen on an adjacent section
(arrows in C). No immunoreactivity is seen when the primary antibody is substituted with an irrelevant antibody against TNP (D).
Scale bar: A–D=50  µm.
tide sequence, which directs full-length TIMP-1
to the secretory pathway. Thus, this variant, if
translated, is probably a soluble, intracellular
protein. In the del-5 variant, any translation ini-
tiation is likely to start at the same ATG site in
exon 2 as full-length TIMP1. However, a theo-
retical translation (ExPASy translation tool)
gives a shift in the reading frame of the exon 6
sequence with an introduction of a new stop
codon, which would result in a protein consist-
ing of 136 amino acids (Figure 5). Full-length
TIMP-1 is N-glycosylated at position 53 and
101 [27], and although the second site is
retained in the shorter del-2 variant, it is
unlikely to be exposed to the N-glycosylation
machinery because of the lack of signal peptide,
and thus may not be glycosylated in vivo.
Although residues throughout the TIMP-1 mol-
ecule are involved in inhibition of MMPs, the
main inhibitory activity has been assigned to the
N-terminal end of the molecule [11], more
specifically to a region surrounding the second
disulfide knot [28]. Part of this region is missing
in a putative del-2 variant of TIMP-1, which
may therefore have compromised MMP
inhibitory activity. The del-5 variant of TIMP-1
is more likely to retain its inhibitory activity.
By performing western blotting analyses on the
tumor tissue samples, we could in addition to
full-length TIMP-1 demonstrate additional
TIMP-1 bands of lower molecular mass. How-
ever, these extra products are absent in the
plasma samples suggesting that they could rep-
resent the exon-2 variant, which if translated
would not be secreted into the circulation
because of the lacking signal peptide. Even
though the del-2 mRNA transcript was
expressed in all the analysed cell lines (except
EVSA-T) we were only able to detect additional
TIMP-1 bands of lower molecular mass in the
PC-3, DLD-1, LoVo and LS 174T cell lines.
The western blot analyses show different levels
of TIMP-1 in the cell lines and we could only
detect the additional TIMP-1 band in cells with
high expression of the full-length TIMP-1 pro-
tein. The additional TIMP-1 bands could there-
fore be present in the other cell lines as well,
however, below detection level. This is further
supported by the finding that the del-2 variant
mRNA is expressed at a much lower level than
full-length TIMP1 mRNA. 
When we quantified the total level of TIMP-1
protein by using a thoroughly validated ELISA
assay, there was no correlation between tumor
extracts and plasma either. This however, could
be explained by the fact that a tumor extract
only represents a small part of the whole tumor,
not necessarily from the invasive front, where
we have previously demonstrated that the
TIMP1 expressing fibroblast-like cells are
localized [29]. These fibroblast-like cells are in
this study further characterized as myofibro-
blasts or smooth muscle cells, and are now
shown to also express the del-2 variant,
although at a much lower level than full-length
TIMP1, which is in agreement with our qPCR
data.
The paradox of raised levels of inhibitors of
tissue-degrading enzymes in advanced disease
is well-described, but little is known about the
biology of this phenomenon. High levels of
TIMP-1 in the circulation and in tumor extracts
may simply reflect the raised levels of MMPs,
but there is increasing data describing tumor-
122
Mol Oncol 2007Chapter 7
Figure 5. Schematic representation of full-length and alter-
natively spliced TIMP-1.
Exons are numbered from 1 to 6 and translated regions are
shown in grey. White boxes indicate untranslated regions.
Translation initiation sites are marked by black arrow and
ATG. The corresponding translated proteins are shown
underneath the mRNAs and the theoretical size is marked
with number of amino acids (aa). The signal peptide
sequences are shown as black boxes at the N-terminal end of
full-length TIMP-1 and the del-5 variant. The translation ini-
tiation site in del-2 TIMP1 is shifted from exon 2 to exon 3,
which results in a shorter protein lacking the signal peptide.
A theoretical translation of the del-5 variant results in a pro-
tein consisting of 136 aa due to a shift in reading frame of the
exon 6 sequence.
promoting activities of TIMP-1 independent of
MMP inhibition, including inhibition of apopto-
sis. It is possible that different variant forms of
TIMP-1 are responsible for the diverse and con-
trasting functions of the protein, similarly to
what has been found for other cancer-related
proteins [30]. A further investigation of this
requires expression and characterization of the
variant forms of the protein.
The prognostic value of TIMP-1 has been
described at both mRNA and protein level. In
breast cancer however, the mRNA data are
somewhat conflicting. One semi-quantitative
study has shown an inverse correlation between
high level of TIMP1 expression and lymph node
metastasis [31], whereas other investigators
have found high TIMP1 mRNA levels to be cor-
related with poor prognosis [32, 33]. However,
Span et al. found no association between levels
of full-length TIMP1 mRNA and disease pro-
gression, when measured by a quantitative RT-
PCR assay [34]. At the protein level, high
TIMP-1 has repeatedly proved to be a marker of
poor prognosis in both colorectal and breast
cancer [2, 3, 20, 35, 36], making measurements
of TIMP-1 protein more attractive in the clinical
setting. The development of quantitative assays
specific for full-length and del-2 variant of
TIMP-1 may improve the prognostic and pre-
dictive value and be useful in the management
of cancer patients. 
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Concentrations of TIMP1 mRNA splice variants
and TIMP-1 protein are differentially associated
with prognosis in primary breast cancer
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ABSTRACT
Background: TIMP-1 protein is a prognostic
factor for recurrence-free and overall survival
(OS) time in breast cancer. We evaluated the
prognostic value of TIMP1 mRNA and a novel
TIMP1 mRNA splice variant in 1,301 primary
breast cancer patients.
Methods: We measured mRNA transcripts of
full-length TIMP1 (TIMP1-v1) and the novel
splice variant lacking exon 2 (TIMP1-v2) by use
of real-time RT-PCR in frozen primary tumor
samples. Transcript concentrations are corre-
lated with histomorphological and biological
factors, TIMP-1 protein, and distant metastasis-
free survival (MFS) and OS time.
Results: TIMP1-v1 and TIMP1-v2 alone were
not informative with respect to predicting prog-
nosis. However, the PCR assay designed to
measure the combination of v1+v2 showed that
high concentrations of this combination were
associated with good prognosis. In Cox multi-
variate regression analysis, which also included
the traditional prognostic factors, increasing
concentrations were independently associated
with prolonged MFS (P=0.004) and OS
(P=0.048). Including TIMP-1 protein and
TIMP1-v1+v2 mRNA together in the multivari-
ate model revealed that protein and mRNA were
both independently associated with prognosis,
with hazard ratios pointing in opposite direc-
tions.
Conclusion: High concentrations of TIMP1-
v1+v2 mRNA are associated with good progno-
sis in patients with primary breast cancer. Since
high concentrations of TIMP-1 protein are asso-
ciated with poor prognosis, the presence of pos-
sible posttranscriptional mechanisms requires
further investigation.
INTRODUCTION
Tissue inhibitor of metalloproteinases-1 (TIMP-
1) is one of the naturally occurring inhibitors of
matrix metalloproteinases (MMPs). A number
of studies have demonstrated an association
between high tumor-tissue concentrations of
TIMP1 mRNA and TIMP-1 protein and a poor
prognosis for breast cancer patients [1–7]. How-
ever, TIMP-1 overexpression in malignant cells
has also been associated with decreased prolif-
eration [8] and with favorable clinical outcome,
particularly in lymph node–negative (LNN)
patients [8, 9], or was not associated with breast
cancer prognosis at all [10]. One of the reasons
for these contradictory reports might be the
multifunctional roles ascribed to this protein.
TIMP-1 not only inhibits MMPs [11, 12] but
also affects cellular proliferation [13, 14], apop-
tosis [15–17], and angiogenesis [18], both
dependent on and independent of its MMP-
inhibiting function. Furthermore, TIMP-1 may
exist in multiple molecular forms in the cancer
environment and in circulation, e.g., in complex
with other proteins or as differentially glycosy-
lated variants. Cox regression analysis of recur-
rence-free survival in breast cancer patients
suggested that a score  based on both uncom-
plexed and total TIMP-1, reflecting the tumor
level of TIMP-1/MMP complexes, would be a
more precise estimate of prognosis than total
TIMP-1 alone [19].
In analogy with free and complexed TIMP-1
protein, the prognostic value of TIMP-1 may be
improved by detection of specific splice vari-
ants of TIMP1 mRNA. Furthermore, biological
understanding of TIMP-1 protein and its gene
might help in understanding the controversial
findings about TIMP-1 with respect to tumor
development and prognosis. To address this, we
analyzed mRNA concentrations of the common
full-length variant of TIMP1 (v1) and a newly
discovered splice variant (v2) lacking exon 2
(see also chapter 7 of this thesis) in a large
cohort of 1,301 primary breast tumors. We
related TIMP1-v1 and v2 expression with histo-
morphological and clinical factors, mRNA
expression of the proliferation marker Ki-67,
and total TIMP-1 protein concentrations.
Finally, we investigated whether mRNA expres-
sion of the TIMP1 splice variants adds to the
prognostic value of total TIMP-1 protein.
Keywords: TIMP-1, splice variants, breast cancer, prognosis, real-time PCR.
PATIENTS AND METHODS
Patients
A protocol for studying biological markers
associated with disease outcome was approved
by the medical ethics committee of the Erasmus
Medical Center Rotterdam, The Netherlands
(MEC 02.953). The present study, in which
coded tumor tissues were used, was performed
in accordance with the Code of Conduct of the
Federation of Medical Scientific Societies in the
Netherlands (http://www.fmwv.nl/). Tumor
samples were originally submitted to our refer-
ence laboratory from 25 regional hospitals for
measurements of steroid hormone receptors.
Guidelines for primary treatment were similar
for all hospitals. To avoid bias, tumors were
selected from our tumor bank at the Erasmus
Medical Center (Rotterdam, The Netherlands)
by processing all available frozen tumor sam-
ples from female patients with breast cancer
who entered the clinic during 1979–2001 from
whom detailed clinical follow-up was available.
Further inclusion criteria were as follows: >100
mg frozen tissue available, invasive breast
cancer, no previous other cancer (except basal
cell skin cancer or early-stage cervical cancer
stage Ia/Ib), no second primary breast tumor at
first relapse, no adjuvant systemic treatment for
the LNN patients, and >30% epithelial tumor
cell nuclei. Of the remaining samples, 8% were
excluded because of poor RNA quality.
The remaining 1,301 patients were treated
either with breast-conserving surgery (44%) or
with modified mastectomy (56%); 931 patients
(72%) received adjuvant radiotherapy. During
this period, 195 of the 620 lymph node–positive
(LNP) patients did not receive adjuvant sys-
temic therapy; 425 of the LNP patients were
treated with adjuvant systemic therapy, of these
patients 197 received hormonal therapy, 210
chemotherapy, and 18 received combination
therapy. Routine postsurgical follow-up and
definition of time to metastasis were as
described [20]. Median follow-up was 92
months (range 3–248 months). Six hundred
sixty-nine (51%) patients developed a  distant
metastasis and count as events in the analysis
for metastasis-free survival (MFS). Seventy-
two patients (6%) died without evidence of dis-
ease and were censored at last follow-up in the
analysis of MFS. Five hundred twenty-six
patients (40%) died after a previous relapse.
Thus, 598 patients (46%) were counted as
events in the analysis of overall survival (OS).
Tumor staging was according to the Union
Internationale Contre le Cancer tumor node
metastasis classification. Other relevant patient
and tumor characteristics are listed in Table 1
(see also Table 1 in the Data Supplement that
accompanies the online version of this article at
http://www.clinchem.org/content/vol53/issue7).
Tissue processing and estimation of the amount of
epithelial tumor cells
We processed tissue and estimated amount of
invasive tumor cells as described [21, 22]. Only
specimens with at least 30% of the nuclei of
epithelial tumor cell origin and distributed uni-
formly over at least 70% of the hematoxylin-
eosin–stained tissue section area were included.
Furthermore, we dichotomized our tumor
cohort at the median of 70% tumor cell nuclei in
stroma-rich tumors (primary tumors containing
≥30% stromal components) and stroma-poor
tumors (primary tumors containing at least 70%
tumor cells).
RNA isolation, cDNA synthesis, and quantification
of specific mRNA species
RNA isolation, cDNA synthesis, quantification
of specific mRNA species, and quality control
checks were done as described in detail [21].
We performed real-time RT-PCR in an ABI
Prism 7700 Sequence Detection System
(Applied Biosystems) and a Mx3000P Real-
Time PCR System (Stratagene) using both
Assay-on-Demand from Applied Biosystems
and the intron-spanning forward and reverse
primer combinations at the conditions shown in
Table 2A. RT-PCR products generated with
these primers by cell lines and cancer tissue
samples were gel-purified and sequenced
(AGOWA, Berlin, Germany), and sequences
were confirmed by BLAST search as described
[23]. Primer sequences for ESR1, PGR, and the
129
TIMP1 mRNA, protein and breast cancer prognosis
130
Clin Chem 2007Chapter 8
Table 1. Associations of TIMP1 mRNA variant concentrations with histomorphological and clinical factors.
See Supplemental Data Table 1 in the online Data Supplement (http://www.clinchem.org/content/vol53/issue7) for the 25% to 75%
interquartile mRNA range. IDC, infiltrating ductal carcinoma; DCIS, ductal carcinoma in situ; ILC, infiltrating lobular
carcinoma.
aCutpoint used for ER mRNA positive ≥ 0.2, for PGR mRNA positive ≥ 0.1.
bDichotomized at the median level of 70% tumor cells with tumors with over 70% epithelial tumor cells grouped in the stroma-poor
subgroup.
cBecause only the major histological types are shown, numbers do not add up to 1301.
dSpearman rank correlation test.
eMann-Whitney U test.
fKruskal-Wallis test, including a Wilcoxon-type test for trend when appropriate.
housekeeping genes have all been described, as
have the PCR reactions and validations per-
formed to ensure PCR specificity [21]. To
measure concentrations of the proliferation
marker Ki-67, we used the Hs00606991_m1
Assay-on-Demand from Applied Biosystems.
Concentrations of the target genes, expressed
relative to our housekeeping set [low-abun-
dance housekeeping gene hydroxymethylbilane
synthase (HMBS, formerly porphobilinogen
deaminase, PBGD), medium-abundance
hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT), and high-abundance β−2-
microglobulin (B2M)], were quantified as
follows, as described [21]:
mRNA target = 2(mean Ct housekeeping -  mean Ct target).
ESR1 and PGR mRNA receptor status
We established mRNA cutpoints to define
tumors as steroid hormone positive at 0.2 for
estrogen receptor (ER) and 0.1 for progesterone
receptor (PGR). We compared these mRNA cut-
offs with the established protein cutpoints of 10
fmol/mg protein in the 1,203 samples with
known protein concentrations as established by
ELISA. For ER, sensitivity and specificity were
93% and 72%, respectively, and positive and
negative predictive accuracy were 90% and
81%. For PGR, sensitivity and specificity were
84% and 83%, respectively, and positive and
negative predictive accuracy rates were 90%
and 75%.
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Table 2B. mRNA concentrations of TIMP1 variants.
In our initial screening, we measured TIMP1 mRNA transcript concentrations of the two variants (see Table 2A for assay specifics)
in a representative selection of 180 primary breast cancer tumors and various cultured cell lines.
Table 2A. Intron-skipping TIMP1 variant-specific primers and probes used for sequencing and real-time
RT-PCR.
a Assay performed in SYBR-green PCR-master-mixture (Applied Biosystems).
b Assay performed in Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen).
c Assay performed with Taqman probes in Universal PCR-master-mixture (Applied Biosystems).
ELISA
To compare TIMP1 mRNA concentrations with
TIMP-1 protein, we used protein concentrations
that were previously measured in cytosol prepa-
rations of the same tumors [6].
Statistics
Computations were done with the use of the
STATA statistical package, release 9 (STATA).
We assessed differences in concentrations with
the Mann–Whitney U-test or Kruskal–Wallis
test. In these tests, patient and tumor character-
istics were used as grouping variables. We
tested the strengths of the associations between
continuous variables with the Spearman rank
correlation (rs). Variables were either log-trans-
formed or Box-Cox–transformed to reduce the
skewness. We investigated the prognostic
values of the clinical and biological variables,
with MFS and OS as the endpoints in the uni-
variate, multivariate, and interaction analyses,
with the use of the Cox proportional hazards
model. The hazard ratio (HR) and its 95% CI
were derived from these results. The propor-
tionality assumption was investigated with a
test based on the Schoenfeld residuals. We used
Kaplan-Meier survival plots and log-rank tests
for trend to assess the differences in time of the
predicted high-risk, intermediate-risk, and low-
risk groups of patients. All tests were 2-sided,
and P<0.05 was considered statistically signifi-
cant.
RESULTS
Correlations between real-time TIMP1 PCR assays
In our initial screening using combinations of
primers located 2 exons apart to cover the 6
exons of TIMP1, we measured mRNA tran-
scripts of 2 variants of TIMP1 in a set of cul-
tured cell lines and primary breast tumors:
full-length TIMP1 (v1) and a novel variant lack-
ing exon 2 (v2). The identification of these
mRNA variants was confirmed by gel elec-
trophoresis and sequence analysis and was fur-
ther evaluated by real-time RT-PCR with the
assays shown in Table 2A in a representative
selection of 180 primary breast tumors and var-
ious cell lines (Table 2B). In these analyses,
only EVSA-T and CAMA-1 cells lacked
expression of TIMP1-v2 (Table 2B). Although
with our TaqMan probe–based TIMP1-v2 assay
we were unable to detect v2 transcripts above
baseline in ZR75.1 and T47-D cells within 45
amplification rounds, gel analysis showed that a
faint 134 bp product representative for TIMP1-
v2 was produced by these cells when amplified
in 45 cycles with our SYBR-based TIMP1-
v1+2 assay. The highest expression of TIMP1
mRNA was measured in a primary breast
tumor–derived fibroblast strain [24] (Table 2B,
19T).
All tumors readily expressed TIMP1-v1 mRNA;
for only 16 of 1,301 tumors were we unable to
detect v2 transcripts within 45 amplification
rounds. Because TIMP-1 protein overexpres-
sion has been inversely associated with cell pro-
liferation [8], we matched our TIMP1 PCR data
with those of the proliferation marker Ki-67
measured in the same preparations. The strength
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Table 3. Spearman rank correlations between mRNA concentrations measured by real-time RT-PCR.
of the associations between TIMP1-v1, TIMP1-
v2, TIMP1-v1+2, and Ki-67 mRNA are summa-
rized in Table 3. Whereas TIMP1-v1+2 showed
a statistically significant association with
TIMP1-v1, no correlation was observed with
TIMP1-v2 (Spearman rs=0.51 and 0.04, respec-
tively). TIMP1-v1+2, compared with TIMP1-v1
and TIMP1-v2 separately, showed the strongest
(inverse) correlation with Ki-67 (rs=-0.31,
-0.09, and 0.01, respectively).
133
TIMP1 mRNA, protein and breast cancer prognosis
Table 4. Cox univariate and multivariate analysis for 5-year MFS as a function of TIMP1 variants
in primary breast tumors from 1,301 breast cancer patients.
a TIMP1 variants were separately introduced to the base multivariate model that included the following factors: age, menopausal
status, nodal status, pathologic tumor size, grade, and ER and PGR status.
b Categorized by 3 equal parts in high, intermediate, and low concentrations.
Associations with histomorphological and clinical
factors
Associations of mRNA expression of TIMP1-
v1, TIMP1-v2, and TIMP1-v1+2 with patient
and tumor characteristics are shown in Table 1.
Most notable are the opposing results of the
TIMP1-v2 assay with the TIMP1-v1 and
TIMP1-v1+2 assays. Whereas concentrations
assessed with the TIMP1-v2 assay were nega-
tively associated with age, and were lower in
postmenopausal patients, results were the oppo-
site for the other 2 TIMP1 assays. Furthermore,
only for the TIMP1-v2 assay were concentra-
tions significantly lower in the group of LNN
patients compared with the group of LNP
patients, and higher in the stroma-rich tumors
compared with the group of stroma-poor
tumors. On the other hand, concentrations
measured with the TIMP1-v1 and TIMP1-v1+2
assays were significantly higher in ER-positive
tumors compared with ER-negative tumors. No
such difference was observed for concentrations
measured with the TIMP1-v2 assay. Also with
respect to grade and tumor size, only the
TIMP1-v1 and TIMP1-v1+2 assays showed a
relation i.e. higher concentrations in the prog-
nostically more favorable tumors. Finally, for
all TIMP1 variants, concentrations were higher
in infiltrating lobular carcinoma compared with
infiltrating ductal carcinoma.
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Figure 1. Relationship between TIMP1-v1+2, divided in 3 equal parts in high, intermediate, and low concentrations, and MFS
(A) and OS (B) in 1,301 primary breast cancer patients.
Patients at risk are indicated.
Univariate and multivariate analysis for MFS and OS
To assess a possible relationship of TIMP1
mRNA with prognosis, we first performed Cox
univariate analyses for MFS and OS as a func-
tion of continuous TIMP1 mRNA concentra-
tions. Because the proportional hazards
assumption was violated for the total follow-up
time, we restricted our exploration of the rela-
tionships of TIMP1 with MFS to the first 5
years of follow-up, with 571 failures in the
1,301 patients. In these analyses, only concen-
trations measured with the TIMP1-v1+2 assay
were significantly associated with MFS (HR
0.80, P<0.001) and OS (HR 0.85, P<0.001).
Next, the TIMP1 variants were separately intro-
duced to the base multivariate model that
included the factors of age, menopausal status,
nodal status, tumor size, grade, ER, and PGR
(Table 4). Of the three TIMP1 assays, only the
assay measuring both variant 1 and variant 2
(TIMP1-v1+2) contributed significantly to the
multivariate model for MFS (HR 0.89,
P=0.004) (Table 4) and OS (HR 0.92, P=0.048)
(data not shown in a table). Adding Ki-67 and
adjuvant systemic therapy or radiotherapy to the
multivariate model that included TIMP1-v1+2
did not alter the coefficients of TIMP1-v1+2. To
visualize the prognostic value of TIMP1-v1+2
in Kaplan-Meier curves, we divided mRNA
concentration curves into 3 equal parts (low,
intermediate, and high). These curves are shown
in Figure 1A for MFS and Figure 1B for OS.
Nodal and ER status
We next performed exploratory Cox univariate
analyses for MFS and OS as a function of
mRNA expression in the clinically relevant sub-
groups of LNN, LNP, ER-positive and ER-neg-
ative patients. Only those analyses that gave
significant results after concentrations were
entered as transformed continuous variables are
shown in Table 5. TIMP1-v1 mRNA concentra-
tions alone were not significantly associated
with nodal status and steroid hormone receptor
status. But the following two divergent observa-
tions between the various assays are notable.
First, whereas concentrations measured with the
TIMP1-v2 assay were associated with good
prognosis only in the subgroup of LNP patients,
the association of increasing concentrations
measured with the TIMP1-v1+2 assay and good
prognosis were independent of nodal status.
Second, whereas increasing concentrations of
TIMP1-v1+2 were associated with good prog-
nosis exclusively in the group of ER-positive
tumors, concentrations measured with the
TIMP1-v2 assay were associated with good
prognosis only in the group of ER-negative
tumors.
Correlations between TIMP1 mRNA and protein
To compare TIMP1 mRNA with total TIMP-1
protein, we made use of protein concentrations
that were previously measured with ELISA in
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Table 5. Cox univariate analysis for distant metastasis-free and overall survival
before and after categorizing tumors according to histomorphological and clinical criteria.
a Restricted to the first 5 years of follow-up.
b ER cutpoint of mRNA ≥ 0.2.
cytosol preparations of the same tumors [6]. In
the 839 tumors with both measures, the highest
correlation between total protein and mRNA
was observed for the real-time RT-PCR assay
able to measure TIMP1-v1 (rs=0.34, P<0.001).
The strength of the association was lower for
the PCR assay able to measure both variant 1
and 2 (TIMP1-v1+2) (rs=0.28, P<0.001) and
inverse for the TIMP1-v2 assay (rs=0.11,
P=0.01).
To ensure that our cohort of 1,301 patients did
not differ from the cohort of 2,984 patients with
protein data, we repeated all analyses for the
overlapping cohort of 839 patients. We divided
the protein concentrations in 3 equal parts to
classify the tumors at the protein level as TIMP-
1 low, intermediate, or high. High and interme-
diate vs low concentrations of TIMP-1 protein
were significantly associated with shorter MFS
in univariate analysis (HR intermediate vs low
1.56, HR high vs low 1.37, P=0.002) and multi-
variate analysis (HR intermediate vs low 1.42,
HR high vs low 1.42, P=0.010), which is in
agreement with the original study, in which high
tumor tissue concentrations of TIMP-1 protein
were identified as an independent marker of
poor prognosis in 2,984 primary breast cancers
[6].
Next, we similarly compared the prognostic
value of mRNA concentrations measured with
our TIMP1-v1, v1+2, and v2 PCR assays in
these 839 patients. Only increasing concentra-
tions of TIMP1-v1+2 mRNA were significantly
associated with a prolonged MFS in univariate
analysis (HR intermediate vs low 0.81, HR high
vs low 0.59, P<0.001) and multivariate analysis
(HR intermediate vs low 0.89, HR high vs low
0.66, P=0.020).
Finally, we explored a potential interaction
between TIMP-1 protein and TIMP1 mRNA
with respect to MFS. No such interaction was
observed (P=0.56). Including log-transformed
continuous concentrations of both TIMP-1 pro-
tein and TIMP1-v1+2 mRNA to the base multi-
variate model for MFS revealed that TIMP-1
protein and TIMP1-v1+2 mRNA were both
independently associated with prognosis, with
HRs pointing in opposite directions (HR 1.36,
95% CI 1.16 –1.61, P=0.001, n=839 for protein
and HR 0.78, 95% CI 0.69–0.87, P=0.001,
n=839 for mRNA).
DISCUSSION
Many research groups have investigated the
link between prognosis in breast cancer and
TIMP-1 protein or mRNA measured in primary
tumors and TIMP-1 protein in serum/plasma,
with conflicting results [1–10]. In agreement
with earlier studies on TIMP1 mRNA [9, 10],
but in contrast to other studies [1, 3, 4], we were
unable to confirm that high concentrations of
TIMP1 mRNA were associated with poor prog-
nosis similar to results for TIMP-1 protein.
However, mRNA transcript concentrations
cannot always be compared with protein con-
centrations. This was confirmed in this study, in
which we found a rather poor correlation
between full-length TIMP1 mRNA and TIMP-1
protein. In our view, the apparently contrasting
findings between the prognostic value of
TIMP1 mRNA expression and TIMP-1 protein
suggests that key regulators of TIMP-1 protein
involved in an adverse outcome act posttran-
scriptionally. Such regulatory mechanisms
affecting protein concentrations, activity, and
stability can act at the level of mRNA transla-
tion, protein folding, glycosylation, and (proteo-
somal) protein degradation. This possibility
needs further investigation.
Our main purpose was to investigate the poten-
tial prognostic value of TIMP1 mRNA and a
newly discovered splice variant to gain more
knowledge on the biology of TIMP-1 in breast
cancer. To address this, our retrospective study
that included RNA preparations from tumor
tissue obtained from 1,301 patients suffering
from primary breast cancer is, to the best of our
knowledge, the largest study performed on the
mRNA concentrations of TIMP1 to date.
Because of different assay conditions, absolute
values of real-time RT-PCR assays can be com-
pared only within an assay, and values from dif-
ferent assays, such as our 2 assays measuring
individual transcripts of TIMP-v1 and TIMP-v2,
cannot simply be added. With our multiplex
TIMP1-v1+2 assay that measures both tran-
scripts in the same reaction with the same
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primer pairs, we corrected as much as possible
for such differences in assay conditions. How-
ever, by measuring both transcripts in the same
reaction, we cannot exclude that the shorter (v2)
variant was favored relative to the larger (v1)
variant.
All tumors expressed full-length TIMP1-v1
mRNA; we were unable to detect v2 transcripts
for only 16 of 1301 tumors. Sequence analysis
of TIMP1-v2 has already revealed that this vari-
ant lacking exon 2, if translated, is probably a
soluble, intracellular protein lacking part of the
region that directs the main inhibitory MMP
activity (see also chapter 7 of this thesis). It is
therefore unlikely that a putative protein of
TIMP1-v2 forms complexes with MMPs, and
thus it probably exhibits a biological function
different from full-length TIMP-1—indeed, our
data suggest that. We found that TIMP1-v1
mRNA concentrations increase with age, are
higher in ER/PGR-positive tumors, and are
higher in smaller-sized and moderately to well
differentiated tumors. In contrast to some
reports [3, 4, 9], but in agreement with another
report [10], TIMP1-v1 mRNA concentrations
were not different in our cohort of 620 LNP
patients compared with the group of 681 LNN
patients. These discrepancies might be due to
the relatively small sample sizes in the earlier
studies (n=30 LNN and 24 LNP [3]; n=49 LNN
and 66 LNP [4]).
Separate evaluation of TIMP1-v2 in our patient
cohort revealed a strong inverse correlation
with age and no correlation with ER, PGR,
grade, and tumor size. In addition, only for
TIMP1-v2, concentrations were higher in
stroma-rich compared with stroma-poor pri-
mary breast tumors. The lack of a correlation
between ER and TIMP1-v2 concentrations sug-
gests that TIMP1-v2, unlike TIMP1-v1, is regu-
lated by an ER-independent mechanism.
Moreover, the lower TIMP1-v2 and higher
TIMP1-v1 mRNA concentrations in the older
age group support our hypothesis that v2 is reg-
ulated by a different mechanism. Another obser-
vation we made is the relatively strong negative
correlation between the proliferation marker Ki-
67 and TIMP1-v1+2. No such correlation was
observed for the TIMP1 assays able to measure
the variants separately. This finding suggests
that only the combined action of full-length
TIMP-1 and its del-2 variant are effectively able
to downregulate proliferation or to monitor
reduced proliferation.
We recently raised the hypothesis that high con-
centrations of total TIMP-1 protein are not nec-
essarily associated with poor prognosis but that
the association depends on the ratio of uncom-
plexed/total TIMP-1 [19]. In analogy with this,
our present study shows that TIMP1-v1 mRNA
and TIMP1-v2 mRNA alone were not associ-
ated with prognosis. However, our real-time RT-
PCR assay developed to measure both
transcripts at the same time revealed that high
mRNA concentrations of the combination of
both variants were associated with low tumor
aggressiveness. Whether changing the balance
between full-length TIMP-1 and its variant
lacking exon 2 has potential as a possible thera-
peutic approach to reduce tumor aggressiveness
remains to be investigated. To establish this, and
since it is only the actual protein that is biologi-
cally active, variant-specific immunohisto-
chemistry and a quantitative assay (ELISA)
able to measure the putative del-2 protein in
relation to full-length TIMP-1 protein are
required.
In conclusion, this retrospective study on a large
cohort of primary breast cancers provides evi-
dence that the combined expression of full-
length TIMP1-v1 mRNA and its v2 variant
lacking exon 2 are associated with low tumor
aggressiveness. This splice variant-dependent
association might help our understanding of the
role of TIMP-1 with respect to breast cancer.
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ABSTRACT
Background: Published prognostic gene signatures in breast cancer have few genes in common. Here
we provide a rationale for this observation by studying the prognostic power and the underlying
biological pathways of different gene signatures. 
Methods: Gene signatures to predict the development of metastases in estrogen receptor-positive and
estrogen receptor-negative tumors were identified using 500 re-sampled training sets and mapping to
Gene Ontology Biological Process to identify over-represented pathways. The Global Test program
confirmed that gene expression profilings in the common pathways were associated with the
metastasis of the patients.
Results: The apoptotic pathway and cell division, or cell growth regulation and G-protein coupled
receptor signal transduction, were most significantly associated with the metastatic capability of
estrogen receptor-positive or estrogen-negative tumors, respectively. A gene signature derived of the
common pathways predicted metastasis in an independent cohort. Mapping of the pathways represented
by different published prognostic signatures showed that they share 53% of the identified pathways. 
Conclusions: We show that divergent gene sets classifying patients for the same clinical endpoint
represent similar biological processes and that pathway-derived signatures can be used to predict
prognosis. Furthermore, our study reveals that the underlying biology related to aggressiveness of
estrogen receptor subgroups of breast cancer is quite different.
INTRODUCTION
Microarray technology has become a popular tool to classify breast cancer patients into histological
subtypes, subgroups with a different prognosis, different site of relapse, and different types of response
to treatment [1-9]. A major challenge for application of gene expression profiling is stability of the gene
list as a signature [10]. Considering that many genes have correlated expression on a gene expression
array, especially for genes involved in the same biological process, it is quite possible that different
genes may be present in different signatures when different training sets of patients and different
statistical tools are used. Furthermore, genes are usually included in a classifier applying stringent
statistical criteria. At these strict significance levels, there is only a small chance for any specific gene
to be included. Reproducibility in gene signatures identified in different datasets is thus unlikely [11].
To our knowledge, so far prognostic gene signatures were identified based on the performance of
individual genes, regardless of their biological functions. We and others have previously suggested that
it might be more appropriate to interrogate the gene lists for biological themes, rather than individual
genes [8, 12-19]. Moreover, identification of the distinct biological processes between subtypes of
cancer patients is more relevant to understand the mechanism of the disease development and for
targeted drug development. 
In this study we associated biological processes with the tumor's metastatic capability. We re-sampled
our data set numerous times to get multiple gene lists whose expression correlated with patients'
survival. Based on these gene lists, over-represented pathways defined in Gene Ontology Biological
Process (GOBP) were identified for estrogen receptor (ER)-positive or ER-negative breast cancer
patients, separately. One step further, we compared the pathways represented by different published
prognostic gene signatures with the over-represented pathways associated with metastatic capability.
This study also demonstrated it is feasible to construct a gene signature from the key pathways to
predict clinical outcomes.
Keywords: pathway, biology, breast cancer, prognosis, gene signatures.
MATERIALS AND METHODS
Patient population 
The study was approved by the Medical Ethics Committee of the Erasmus MC Rotterdam, The
Netherlands (MEC 02.953), and was performed in accordance to the Code of Conduct of the Federation
of Medical Scientific Societies in the Netherlands [20]. A cohort of 344 breast tumor samples from our
tumor bank at the Erasmus Medical Center (Rotterdam, Netherlands) was used in this study. All these
samples were from patients with lymph node-negative breast cancer who had not received any adjuvant
systemic therapy, and had more than 70% tumor content. Among them, 286 samples had been used to
derive a 76-gene signature to predict distant metastasis [8]. Fifty-eight additional ER-negative cases
were included to increase the numbers in this subgroup. According to our previous study [21], array-
measured ESR1 status and clinical ER status have the best correlation when the cutoff is set at 1000,
after scaling the average intensity of probe sets on an Affymetrix HG-U133A chip to 600. Using array-
based ESR1 status allows us to avoid the variations of the measures of ER by either immunohisto-
chemistry or biochemical assays, as well as including tumors whose ER status is undetermined.
Therefore, ER status for a patient was determined based on the expression level of the ESR1 gene on
the chip in this study. A sample is considered ER-positive if its ESR1 expression level is higher than
1000. Otherwise, the sample is ER-negative [21]. As a result, there are 221 ER-positive and 123 ER-
negative patients in the 344-patient population. The mean age of the patients was 53 years (median 52,
range 26-83 years), 197 (57%) were premenopausal and 147 (43%) postmenopausal. T1 tumors ( ≤2
cm) were present in 168 patients (49%), T2 tumors (>2-5 cm) in 163 patients (47%), T3/4 tumors (>5
cm) in 12 patients (3%), and 1 patient had unknown tumor stage. Pathological examination was carried
out by regional pathologists as described previously [22] and the histological grade was coded as poor
in 184 patients (54%), moderate in 45 patients (13%), good in 7 patients (2%), and unknown for 108
patients (31%). During follow-up 103 patients showed a relapse within 5 years and were counted as
failures in the analysis for DMFS. Eighty-two patients died after a previous relapse. The median follow-
up time of patients still alive was 101 months (range 61-171 months).
RNA isolation and hybridization 
Total RNA was extracted from 20-40 cryostat sections of 30 µm thickness with RNAzol B (Campro
Scientific, Veenendaal, Netherlands). After being biotinylated, targets were hybridized to Affymetrix
HG-U133A chips as described [8]. Gene expression signals were calculated using Affymetrix
GeneChip analysis software MAS 5.0. Chips with an average intensity less than 40 or a background
higher than 100 were removed. Global scaling was performed to bring the average signal intensity of a
chip to a target of 600 before data analysis. For the validation dataset [23], quantile normalization was
performed and ANOVA was used to eliminate batch effects from different sample preparation methods,
RNA extraction methods, different hybridization protocols and scanners.
Multiple gene signatures 
For ER-positive and ER-negative patients, 80 samples were randomly selected as a training set and
univariate Cox proportional-hazards regression was performed to identify genes whose expression
patterns were most correlated to patients' DMFS time. Our previous analysis suggested that 80 patients
represent a minimum size of the training set for producing a prognostic gene signature with stable
performance [8]. Because the majority of the published gene expression signatures had less than 100
genes, the top 100 genes from the Cox regression were used as a signature to predict tumor recurrence
for the remaining patients. A relapse score for a patient was used to calculate a patient's risk of distant
metastasis and was defined as the linear combination of logarithmically transformed gene expression
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levels weighted by the standardized Cox regression coefficient as described [8]. ROC analysis with
distant metastasis within 5 years as a defining point was conducted. Patients who did not have 5-year
follow-up were excluded from ROC analysis. The AUC of the ROC plots was used as a measure of the
performance of a signature in the test set. The above procedure was repeated 500 times (Figure 1). Thus,
500 signatures of 100 genes each were obtained for both the ER-positive and ER-negative subgroups.
The frequency of the selected genes in the 500 signatures was calculated and the genes were ranked
based on the frequency.
As a control, the patient survival data for the ER-positive patients or ER-negative patients was
permuted randomly and re-assigned to the chip data. As described above, 80 chips were then randomly
selected as a training set and the top 100 genes were selected using the Cox modeling based on the
permuted clinical information. The clinical information was permuted 10 times. For each permutation
of the survival data, 50 training sets of 80 patients were created. For each training set, the top 100 genes
were obtained as a control gene list based on the Cox modeling. Thus, a total of 500 control signatures
were obtained. The predictive performance of the 100 genes was examined in the remaining patients.
A ROC analysis was conducted and AUC was calculated in the test set.
Mapping signatures to GOBP and identification of over-represented pathways 
To identify over-representation of biological pathways in the signatures, genes on the Affymetrix
HG-U133A chip were mapped to the categories of GOBP based on the annotation table downloaded
from [24]. Categories that contained at least 10 probe sets from the HG-U133A chip were retained for
subsequent pathway analysis. As a result, 304 categories were used for following pathway analysis. The
100 genes of each signature were mapped to GOBP. Hypergeometric distribution probabilities for all
included GOBP categories were calculated for each signature to evaluate its statistical significance. A
pathway that had a hypergeometric distribution probability < 0.05 and was hit by two or more genes
from the 100 genes was considered an over-represented pathway in a signature. The total number of
times a pathway occurred in the 500 signatures was considered as the frequency of over-representation. 
To evaluate the relationship between a pathway as a whole and the clinical outcome, each of the top 20
over-represented pathways that have the highest frequencies in the 500 signatures were subjected to
Global Test program [12, 14]. The Global Test examines the association of a group of genes as a whole
to a specific clinical parameter such as DMFS. The contribution of individual genes in the top over-
represented pathways to the association was also evaluated.
Building pathway-based signatures 
To explore the possibility of using the genes from over-represented pathways as a signature to predict
distant metastasis, the top two pathways for ER-positive and ER-negative tumors that were in the top
20 list based on frequency of over-representation and had the smallest P values with the Global Test
program were chosen to build a gene signature. First, genes in the pathway were selected if their z-score
was greater than 1.96 from the Global Test program. A z-score greater than 1.96 indicates that the
association of the gene expression with DMFS time is significant (P<0.05) [12, 14]. To determine the
optimal number of genes in a given pathway used for building the signature, combinations of gene
markers were tested by adding one gene at a time according to their z-scores. The number of significant
genes that gave the highest AUC value of the ROC analysis with distant metastasis within 5 years as the
defining point was considered optimal and used to build a pathway-based signature.
The relapse score for a given patient was calculated as the difference between the linear combination of
the logarithmically transformed expression signals weighted by their z-scores for negatively correlated
genes and that for positively correlated genes. The predicting performance of the gene signature was
evaluated by ROC and Kaplan-Meier survival analysis in an independent patient group [23] for
ER-positive patients and ER-negative patients both separately and combined.
144
BMC Cancer 2007Chapter 9
Comparing multiple gene signatures 
To compare the genes from various prognostic signatures for breast cancer, five gene signatures were
selected [3, 8, 23, 25, 26]. Identity of the genes between the signatures was determined by BLAST
program. To examine the representation of the top 20 pathways in the signatures, genes in each of the
signatures were mapped to GOBP.
Data availability 
The microarray data analyzed in this paper have been submitted to the NCBI/Genbank GEO database
(series entry GSE2034 for the first 286 patients, and GSE5327 for the additional 58 patients). The
microarray and clinical data used for the independent validation testing set analysis were obtained from
the GEO database with accession number GSE2990.
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Figure 1. Work flow of data analysis for deriving core genes and over-represented pathways. 
RESULTS
Multiple gene signatures 
Using re-sampling, we constructed a total of 1,000 prognostic gene signatures derived from different
patient groups aiming to improve understanding of the underlying biological processes of breast
cancer metastasis. Since gene expression patterns of ER-subgroups of breast tumors are quite
different [1-4, 8, 27] data analysis to derive gene signatures and subsequent pathway analysis were
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Figure 2. Evaluation of the 500 gene signatures.
Each of the 100-gene signatures for 80 randomly selected tumors in the training set was used to predict relapsed patients in the
corresponding test set. Its performance was measured by the AUC of the ROC analysis. (A) Performance of the gene signatures for
ER-positive patients in test sets. (B) Performance of the gene signatures for ER-negative patients in test sets. (Left) Frequency of
AUC in 500 prognostic signatures panels as derived following the flow chart presented in Figure 1. (Right) Frequency of AUC in 500
random gene lists. To generate a gene list as a control, the survival data for the ER-positive patients or ER-negative patients was per-
mutated randomly and reassigned to the chip data. 
conducted separately [8]. For both ER-positive and ER-negative patients, 80 samples were randomly
selected as a training set and the 100 genes most significantly associated with distant metastasis-free
survival (DMFS) were used as a signature to predict tumor recurrence for the remaining ER-positive
and ER-negative patients, respectively (Figure 1). The area under the curve (AUC) of receiver
operating characteristic (ROC) analysis with distant metastasis within 5 years as a defining point was
used as a measure of the performance of a signature in a corresponding test set. The above procedure
was repeated 500 times. The average of AUCs for the 500 signatures in the ER-positive test sets was
0.70 (95% confidence interval (CI): 0.61-0.77) whereas the average of AUCs for 500 random gene lists
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Table 1. Genes with highest frequencies in 500 signatures.
The top 20 genes are ranked by their frequency in the 500 signatures of 100 genes for ER-positive and ER-negative tumors (for
details see Figure 1). 
was 0.50 (95% CI: 0.33-0.66), indicating a non-random prediction for the true test sets (Figure 2A). For
ER-negative datasets, these values of average AUCs were 0.67 (95% CI: 0.53-0.80) and 0.51 (95% CI:
0.31-0.76), respectively (Figure 2B). The results demonstrate that depending on the training set
different gene signatures can be identified with comparable performance. This could explain the results
obtained by earlier studies, which reported different gene signatures with similar power to predict risk
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Table 2. Top 20 pathways in the 500 signatures of ER-positive and ER-negative tumors evaluated by Global Test.
Each of the top 20 over-represented pathways that have the highest frequencies in the 500 signatures of ER-positive and
ER-negative tumors were subjected to Global Test program [12, 14]. The Global Test examines the association of a group of
genes as a whole to a specific clinical parameter, in this case DMFS, and generates an asymptotic theory P value for the
pathway. The pathways are ranked by their P value in the respective ER-subgroup of tumors. 
groups. The 20 most frequently found genes in the 500 signatures for ER-positive and ER-negative
tumors are listed in Table 1. The most frequent genes were KIAA0241 protein (KIAA0241) for
ER-positive tumors, and zinc finger protein multitype 2 (ZFPM2) for ER-negative tumors. There was
no overlap between genes of the ER-positive and  -negative core gene lists suggesting that different
molecular mechanisms are associated with the subtypes of breast cancer disease.
Over-represented pathways in gene signatures and Global Test 
The 100 genes in each of the 500 signatures for ER-positive and ER-negative tumors were mapped to
the categories of GOBP. For a given gene signature, a pathway (or category) that had a hypergeometric
distribution probability smaller than 0.05 and included two or more genes was considered an
over-represented pathway. The "inclusion of 2 or more genes" as a selection criterion in addition to the
statistical significance was to avoid selecting statistically significant pathways containing only one gene
in the signature. The frequency of over-representation of GOBP in the 500 signatures for ER-positive
and ER-negative dataset was calculated. Like the observation of most frequently found genes, the
biological pathways over-represented in the gene signatures are distinct for ER-positive and
ER-negative tumors (Table 2). 
For ER-positive tumors, cell division-related processes and immune-response-related pathways are
frequently found in the top 20 over-represented pathways. All of the 20 pathways had a significant
association with DMFS as analyzed by the Global Test program [12, 14], with the 2 most significant
being "apoptosis" (mainly containing genes of the extrinsic apoptotic pathway) and "regulation of cell
cycle" (Table 2). For ER-negative tumors, many of the top 20 pathways are related with RNA
processing, transportation and signal transduction. Eighteen of the top 20 pathways demonstrated a
significant association with DMFS in the Global Test, the 2 most significant being "regulation of cell
growth" and "regulation of G-protein coupled receptor signaling" (Table 2). 
The contribution and significance of individual genes in the top over-represented pathways to the
association with DMFS were determined for ER-positive (see Additional Data Files 1 and 2 available
on line) and ER-negative tumors (see Additional Data Files 3 and 4 available on line). Genes can either
show a positive association with DMFS, indicating a higher expression in tumors without metastatic
capability, or a negative association, indicative of a higher expression in metastatic tumors. In ER-
positive tumors, pathways with a mixed association include the 2 most significant pathways
"apoptosis" and "regulation of cell cycle" (Figure 3A). There were also a number of pathways that had
a predominant positive or negative correlation with DMFS. For example, the pathway "immune
response" is associated with 379 probe sets, of which the majority showed positive correlation to DMFS
(Figure 3A). Similarly in the biological processes "cellular defense response" and "chemotaxis", most
genes displayed a strong positive correlation with DMFS (see Additional Data File 1). On the other
hand, genes in "mitosis" (Figure 3A), "mitotic chromosome segregation" and "cell cycle" showed a
predominant negative correlation with DMFS (see Additional Data File 1). 
In ER-negative tumors (Figure 3B), examples of pathways with genes that had both positive and
negative correlation to DMFS include "regulation of cell growth", the most significant pathway, and
"cell adhesion". Of the top 20 pathways in ER-negative tumors, none showed a dominant positive
association with DMFS. Although for some pathways most genes correlated negatively with DMFS
(see Additional Data File 3), including "regulation of G-protein coupled receptor signaling" and
"skeletal development" (Figure 3B), ranked among the top 3 pathways in significance (Table 2). Of the
top 20 core pathways 4 overlapped between ER-positive and -negative tumors, i.e., "regulation of cell
cycle", "protein amino acid phosphorylation", "protein biosynthesis", and "cell cycle" (Table 2). 
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Figure 3. Association of the expression of individual genes with DMFS time for selected over-represented pathways. 
The Geneplot function in the Global Test program [12, 14] was applied and the contribution of the individual genes in each selected
pathway is plotted. The numbers at the X-axis represent the number of genes in the respective pathway in ER-positive (Left) or
ER-negative tumors (Right). The values at the Y-axis, represent the contribution (influence) of each individual gene in the selected
pathway with DMFS. Negative values indicate there is no association between the gene expression and DMFS. Horizontal markers
in a bar indicates one standard deviation away from the reference point, two or more horizontal markers in a bar indicate that the
association of the corresponding gene with DMFS is statistically significant. The grey bars reflect genes that are positively
associated with DMFS, indicating a higher expression in tumors without metastatic capability. The black bars reflect genes that are
negatively associated with DMFS, indicative of higher expression in tumors with metastatic capability. (A) ER-positive tumors: from
top to bottom: "apoptosis" pathway consisting of 282 genes, "regulation of cell cycle" pathway consisting of 228 genes, "immune
response" pathway consisting of 379 genes, and "mitosis" pathway consisting of 100 genes. (B) ER-negative tumors: from top to
bottom: "regulation of cell growth" pathway consisting of 58 genes, "cell adhesion" pathway consisting of 327 genes, "regulation of
G-coupled receptor signaling" pathway consisting of 20 genes, and "skeletal development" pathway consisting of 105 genes.   
151
Identification of prognostic pathway-based signatures
Pathway-derived gene expression profiles as a predictor 
In an attempt to use gene expression profiles in the most significant biological processes to predict
distant metastases we used the genes of the top 2 significant pathways in both ER-positive and 
-negative tumors (Table 3) to construct a gene signature for the prediction of distant recurrence.
A 50-gene signature was constructed by combining the 38 genes(represented by 38 unique probe sets)
from the top 2 ER-positive pathways ("apoptosis", "regulation of cell cycle") and 12 genes for the top
2 ER-negative pathways ("regulation of cell growth", "regulation of G-coupled receptor signaling").
Figure 4. Validation of pathway-based breast cancer classifiers constructed from the optimal significant genes. 
The 152-patient test set [23] consisted of 125 ER-positive tumors and 27 ER-negative tumors based on the expression level of ER
gene on the chip. (A) ROC (Left) and Kaplan-Meier (Right) analysis of the 38-gene probe set signature (see also Table 3A and 3B)
for ER-positive tumors. Thirteen patients with less than 5-year follow-up were excluded from ROC analysis. (B) ROC (Left) and
Kaplan-Meier (Right) analysis of the 12-gene probe set signature (see also Table 3C and 3D) for ER-negative tumors. One patient
with less than 5-year follow-up was excluded from ROC analysis. (C) ROC (Left) and Kaplan-Meier (Right) analysis of a combined
50-gene probe set signature for ER-positive and ER-negative tumors. Fourteen patients with less than 5-year follow-up were
excluded from ROC analysis. 
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Table 3. Genes used for prediction in top pathways.
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This signature was further validated using an independent 152-patient cohort [5], which consisted of
125 ER-positive tumors and 27 ER-negative tumors (after removing 36 lymph node-positive patients
and a patient who died 15 days after surgery). When the 38-gene probe set was applied to the 125 ER-
positive patients, a ROC analysis gave an AUC of 0.782 (95% CI: 0.681-0.883) (Figure 4A, left), and
Kaplan-Meier analysis for DMFS showed a clear separation in risk groups (P<0.001, HR: 3.36 and
95% CI: 1.68-6.70) (Figure 4A, right). For the 12-gene probe set for the 27 ER-negative patients, an
AUC of 0.872 (95% CI: 0.719-1) (Figure 4B, left) and  separation between risk groups with a P<0.001
and a HR of 19.8 (95% CI: 2.41-163) (Figure 4B, right) was obtained. The combined 50-gene probe set
signature for ER-positive and ER-negative patients gave an AUC of 0.795 (95% CI: 0.705-0.878)
(Figure 4C, left) and a P<0.001 and a HR of 4.44 (95% CI: 2.31-8.54) for separation between risk
groups (Figure 4C, right).
Pathway analysis of published prognostic gene signatures 
To compare genes from various prognostic signatures for breast cancer, five published gene signatures
were selected [3, 8, 23, 25, 26]. We first compared the gene sequence identity between each pair of the
gene signatures and found, consistent with previous reports, very few overlapping genes (Table 4). The
grade index gene expression signature comprising 97 genes, of which most are associated with cell
cycle regulation and proliferation [23], showed the highest number of overlapping genes between the
various signatures ranging from 5 of the 16 genes of Genomic Health [25] to 10 with Yu's 62 genes [26].
The other 4 gene signatures showed only 1 gene overlap in a pair-wise comparison, and there was no
common gene for all signatures. In spite of the low number of overlapping genes across signatures, we
hypothesized that the representation of common pathways in the various signatures may underlie their
Table 3. continued. Genes used for prediction in top pathways.
Genes in the top 2 significant prognostic pathways in both ER-positive and ER-negative tumors were sorted based on their "z-
score" (significance), reflecting their association with distant metastasis-free survival time (DMFS) time. To find the optimal
number of genes as a signature, ROC analyses, with 5-year DMFS as defining point, with an increasing number of genes were
conducted in the training set of ER-positive tumors or ER-negative tumors. For ER-positive tumors, in the "apoptosis" pathway,
24 probe sets (reaching an AUC of 0.784) were considered optimal. For the "regulation of cell cycle" pathway in ER-positive
tumors, 17 probe sets (AUC of 0.777) were considered optimal. For ER-negative tumors, the optimal number of probe sets was 7
(AUC of 0.790) for the "regulation for cell growth" pathway, and 5 (AUC of 0.788) for the "regulation of G-protein coupled
receptor signaling" pathway, respectively. The selected unique probe sets for the top 2 pathways for ER-positive and ER-negative
tumors were subsequently used to construct prognostic gene signatures separately for the 2 ER-subgroups of tumors (see Figure
4).
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individual prognostic value [8]. Therefore, we examined the representation of the core prognostic
pathways (Table 2) in the 5 signatures. The Genomic Health 16-gene signature mapped to 10 of the 36
distinct core pathways (20 for both ER-positive and -negative tumors but 10 counting the 4 overlapping
pathways once) whereas it mapped to a total of 25 out of 304 GOBPs. The statistical significance for
the enrichment of GOBP, as computed by hypergeometric distribution probability was 2x10-5. Each of
the other 4 signatures have 62 or more genes and were mapped to 19 (53%) distinct prognostic
pathways and their statistical significance of enrichment was 1x10-7 for Wang and van 't Veer, 1x10-6 for
Sotiriou and 6x10-11 for Yu's signature (Table 5). Of these 19 pathways, 9 were identical for all 4
signatures, i.e., "mitosis", "apoptosis", "regulation of cell cycle", "DNA repair", "cell cycle", "protein
amino acid phosphorylation", "DNA replication", "intracellular signaling cascade", and "cell adhesion". 
Table 4. Number of common genes between different gene signatures for breast cancer prognosis.
aAffymetrix HG-U133A Genechip
bAgilent Hu25K microarray
cNo genome-wide assessment; RT-PCR.
To compare genes from various prognostic signatures for breast cancer, five gene signatures were selected, the 76-gene signature
[8], the 70-gene signature [3], the 16-gene signature [25], the 62-gene signature [26], and the 97-gene signature [23]. Identity
of genes was determined by BLAST program when gene signatures were derived from different platforms. Except for the 97-gene
expression grade index [23], which showed an overlap with 5 to 10 genes with the other gene signatures, a maximum overlap of
only 1 identical gene was found between the other gene signatures. The initially reported 3-gene overlap between the 76-gene
and the 70-gene prognostic signatures [8] included genes with high similarity in sequences. In this study, only genes with an
identical sequence in two signatures are considered overlapped based on results from BLAST program. Therefore, CCNE2 gene
is the only common gene between the two signatures.
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Table 5. Mapping various gene signatures to core pathways.
aPublished gene signatures that were studied include the 76-gene signature [8], the 70-gene signature [3], the 16-gene signature
[25], the 62-gene signature [26], and the 97-gene signature [23]. Individual genes in each signature were mapped to the top 20
core pathways for ER-positive and ER-negative tumors, a cross indicates a match.
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DISCUSSION
Gene-expression profiling for separating patients into different subtypes and risk groups have been
focused on the identification of differential expression of individual genes rather than obtaining
biological insight. In the present study we have used an alternative approach to identify in ER-positive
and ER-negative populations of breast cancer patients the underlying biological processes associated
with metastasis. Using a stringent re-sampling and permutation methodology we were able to show that
indeed multiple signatures can be identified showing similar prognostic power while the genes from
these different samplings have similar functions. Similar observations were made when we mapped the
core prognostic pathways to 5 published prognostic signatures [3, 8, 23, 25, 26]. Thus, we showed that
in spite of the low number of overlapping genes between the various published gene signatures, the
signatures had many pathways in common, implying that different prognostic gene signatures represent
common biology. In a recent study, comparing the prognostic performance of different gene-signatures,
agreement in outcome predictions were found as well [28]. However, in contrast to our present
approach, the underlying pathways were not investigated. Instead, the performance of various gene
signatures on a single patient cohort, heterogeneous with respect to nodal status and adjuvant systemic
therapy [29], was compared [28]. It is important to note, however, that although similar pathways are
represented in various signatures, it does not necessarily mean the individual genes in a pathway are
equally significant or are all similarly associated with tumor aggressiveness (see Additional Data Files
1 and 3). 
The fact that none of the 20 genes most frequently present in the 500 signatures for the ER-positive
tumors were among the top 20 core gene list of the ER-negative tumors, was not surprising and is in line
with the fact that ER-subgroups of tumors are biologically very different entities [1-4, 8, 27].
Furthermore, although among the top 20 over-represented pathways, 4 were common for ER-positive
tumors and ER-negative tumors, there were in total only 2 shared genes pointing into the same
direction with respect to metastatic capability of the tumors. Both genes, KIAA0256 in the "protein
biosynthesis" pathway and CCNT2 in the "cell cycle pathway", were associated with an aggressive
tumor behavior. These results imply that the underlying biological processes between ER-subgroups of
tumors with respect to their metastatic behavior have little if any in common. Of the top 20 core
prognostic pathways for the ER-positive tumors many biological processes are related to cell division
activities, immunity, signal transduction, and extrinsic apoptosis-related biological processes. The cell
division-related pathways have predominantly negative correlation with survival time, while
immune-related pathways have predominantly positive correlation. This indicates that ER-positive
tumors with metastatic capability tend to have higher cell division rates, are more resistant to external
apoptotic stimuli, and induce a poor immune reaction in the host body. In ER-positive tumors, one or
more of these pathways, or genes in these pathways, have also been described to be associated with the
efficacy of tamoxifen therapy in recurrent breast cancer [7], in the various prognostic signatures
described in the present paper [8, 23, 25, 26], as well as in other published signatures not specifically
designed for ER-positive tumors, such as the 70-gene prognostic signature [3], the stromal signatures
[30], and the hypoxia signature [31]. The differences in metastatic behavior between ER-subgroups of
tumors is further substantiated by the finding that in ER-negative tumors other pathways showed the
strongest involvement, including those related with cell growth regulation, possibly through JAK/STAT
signaling, and modulation of G-protein receptor signal transduction, RNA splicing or processing, and
ion transport. No comparison can be made with the literature since no other studies so far have
described prognostic of predictive pathways specifically in ER-negative breast cancer.
We were able to construct a 50-gene signature by combining the genes from the 2 most significant
ER-positive and ER-negative pathways. This signature was validated and performed well on an
independent published patient cohort [23], herewith showing the feasibility to derive a gene signature
from biological pathways. Although further methodology and analysis would be required to optimize
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the selection of such a pathway-based prognostic signature, our example provides not only a new way
to derive gene signatures for cancer prognosis, but also gives insight into the distinct biological
processes between subgroups of tumors.
CONCLUSIONS
Our study for the first time applied a method that systematically evaluated the biological pathways
related to patient outcomes of breast cancer and showed that various published prognostic gene
signatures providing similar outcome predictions are based on the representation of largely overlapping
biological processes. Identification of the key biological processes, rather than the assessment of
signatures based on individual genes, allows not only to build a biological meaningful gene signature
from functionally related genes, but also provides insight into the mechanism of the disease
development and, as spin off, potential targets for future drug development. In this respect, as
pharmacologic inhibitors for specific pathways become available for the clinic, the signatures that
define tumors according to their vital pathways may provide crucial guidance for designing
appropriate drug combinations [32].
ADDITIONAL DATA FILES
The following Additional Data Files are available with the online version of this paper:
- Additional Data File 1: Top 20 prognostic pathways in ER-positive tumors 
- Additional Data File 2: Significant genes in the top 20 prognostic pathways for ER-positive 
tumors
- Additional Data File 3: Top 20 prognostic pathways in ER-negative tumors 
- Additional Data File 4: Significant genes in the top 20 prognostic pathways for ER-negative
tumors
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10. GENERAL DISCUSSION AND FUTURE PERSPECTIVES
The aims of this thesis were firstly to gain insight into the interaction between breast tumor cells and
the surrounding stromal fibroblasts. Secondly, to integrate the concept of a multi-cellular program in
which the epithelial tumor cells, the tumor-associated fibroblasts, and diverse other cells in the tumor
micro-environment are active participants, in our search for novel prognostic and predictive
biomarkers. Finally, to place the concept of biomarkers in a larger context by looking at pathways rather
than individual biomarkers.
In this general discussion I would like to take the opportunity to discuss in more depth three concepts
that emerged from the studies described in this thesis in relation to future perspectives: 
1) if and how assessment of stromal content may aid to put a putative tumor marker in a
biological context;
2) if and how genes localized on the long arm of chromosome 17q may play a dominant role in
tamoxifen responsiveness;
3) if and how there is a future for testing biomarkers with real-time RT-PCR. 
10.1 Stromal content in breast cancer subtypes
Three studies presented in this thesis (described in chapter 4, 5 and 8) show that additional prognostic
and/or predictive information can be obtained if tumors are subdivided at the median level of 70%
epithelial tumor cell nuclei in stroma-rich (tumors with 30% or more nuclei from stromal origin) and
stroma-poor (tumors with over 70% tumor cell nuclei from epithelial origin), with the relatively large
group of tumors with 70% epithelial tumor cell nuclei grouped with the stroma-rich tumors [1]. The
rationale for this was that certain genes, like specific matrix metalloproteases and their inhibitors, are
known to be mainly expressed in the stroma, while others, such as ESR1 (ER-alpha), are predominantly
expressed by the epithelial cancer cells. 
Such cell-type specific localizations were confirmed in this thesis using real-time RT-PCR, in situ
hybridization, western blotting and immunostaining. In chapter 2 and 3 for example we compared
mRNA levels of various genes in breast fibroblasts derived from breast tumor tissue and adjacent
'normal' breast tissue and showed that gene and protein expression levels of tumor-derived fibroblasts
in response to either external stimuli [2] or during aging [3] can differ significantly from those of
fibroblasts derived from a location adjacent to normal breast tissue. For the tissue inhibitor of
metalloproteinases-1 (TIMP-1), highest expression was measured in fibroblasts located adjacent to
tumor cells [4, 5]. Further investigation revealed that concentrations of full-length TIMP1 mRNA did
not differ between stroma-rich and stroma-poor tumors. However, mRNA levels of the novel by us
identified TIMP1 splice variant lacking exon 2 (TIMP1-v2), were higher in stroma-rich compared with
stroma-poor primary breast tumors [5]. These and other observations supported our hypothesis that
TIMP1-v2, with clinical features distinct from full-length TIMP1, is regulated by a different,
ER-independent, mechanism. In chapter 4 we showed that ER-alpha staining was mainly localized to
the nuclei of epithelial tumor cells. Immunohistochemical staining of ADAM-9 and ADAM-11 protein
in human breast carcinomas yielded heterogeneous results with both proteins found in epithelial tumor
cells, adipocytes, smooth muscle cells of vessel walls, and the myoepithelial and luminal layers of non-
neoplastic epithelium of the mammary gland [1].
In chapter 4 we were able to demonstrate that especially for primary tumors containing a large
proportion of stromal cells, the assessment of mRNA expression levels of the disintegrin and
metalloproteinase ADAM9 and ADAM11 can be useful to identify patients with recurrent breast cancer
who are likely to benefit or fail from tamoxifen therapy [1]. In addition, we showed in chapter 5 that
patients with high levels of CCNE1 had an increased risk (P=0.03) to develop a metastasis within 5
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years if their primary tumor was stroma-rich compared with patients with a high level of CCNE1
combined with a stroma-poor primary tumor [6]. Thus, it has been established in this thesis that the
prognostic and predictive value of biological factors, among which CCNE-1, ER-alpha, ADAM-9,
ADAM-11 and TIMP-1, may be further refined by dividing tumor samples at the median level of 70%
epithelial tumor cell nuclei in a cohort of stroma-poor tumors and a cohort of stroma-rich tumors. 
Although we have shown that this pragmatic subdivision in stroma-poor and stroma-rich enabled us to
discriminate between breast cancer subtypes with specific clinical implications, thus far no rationale
other than that some biomarkers are known to be expressed more frequently in either the epithelial
tumor cells or the stromal cells was given. However, another obvious explanation for the differences in
gene expression levels we measured in the stroma-poor and stroma-rich cohorts might be the influence
of the housekeeper set used in our studies to normalize the real-time RT-PCR gene expression data. To
accurately quantify gene expression, the measured amount of mRNA from the gene of interest was
divided by the amount of mRNA from a reference housekeeping gene set measured in the same sample
to normalize for possible variation in the amount and quality of mRNA between different samples. Such
a normalization is only valid provided that the expression of the reference gene is very similar across
all the samples. Choosing a reference gene fulfilling this criterion is therefore of high importance, and
often challenging, because only very few genes show equal levels of expression across a range of
different conditions or tissues [7-10]. To smoothen the possible differential influence of one specific
housekeeping gene for a specific condition, i.e. stromal content, we choose to use a set of 3
different housekeeping genes: the low abundance hydroxymethylbilane synthase (HMBS, formerly
porphobilinogen deaminase, PBGD), the medium abundance hypoxanthine-guanine phosphoribosyl-
transferase 1 (HPRT1), and the high abundance beta-2-microglobulin (B2M). Comparing the levels of
our housekeeping set after splitting tumor samples at the median level of 70% tumor cell nuclei, with
the group of 70% tumor cell nuclei grouped with the stroma-rich, in stroma-poor (n=390) and stroma-
rich (n=1290), showed no significant differences between the two groups (Mann-Whitney U test
P=0.999). Hence, the differences in gene expression levels we measured in the stroma-poor and stroma-
rich cohorts are not the result of our normalization method. 
But before considering applying this relatively simple method for high throughput screening, an
understanding of what this subdivision in stroma-rich and stroma-poor implies in terms of histology is
essential. Please refer to table 10.1.1 for a summary of the significant differences we observed and that
are discussed in more detail below.
For the purpose of this general discussion we investigated if the various histological types described in
table 1.1.1 of this thesis display a preference for stroma-rich or for stroma-poor tumors. In the 1137
primary breast tumors with known histology we noticed that stroma-poor tumors were significantly
associated with infiltrating lobular carcinoma (ILC; chi-squared=3.88, P=0.049, n=110) and mucinous
tumors (chi-squared=5.19, P<0.0001, n=36). Infiltrating ductal carcinoma (IDC) on the other hand
were mainly of the stroma-rich phenotype (chi-squared=5.19, P=0.023, n=921). No such differences in
stromal distribution were seen for the remaining tumor types (LCIS, DCIS, medullary, papillary, and
tubular). These data imply that the stroma-poor phenotype is in general associated with the less
common ILC subtype and the clinically more favorable mucinous type. The stroma-rich phenotype is
more likely to resemble an IDC, the most common histologic breast cancer type. 
But these observations, with IDC comprising about 80% of the invasive breast cancers, still do not
sufficiently explain our findings described in chapter 4, 5 and 8 that stroma-rich and stroma-poor
primary breast tumors might behave quite different with respect to prognosis. Another way to approach
the clinical implications of our pragmatic division in stroma-rich and stroma-poor is to look at possible
differences in grading in these 2 phenotypes. For the 978 primary tumors with known grade and tumor
cell content no significant differences were observed in this respect: stroma-rich and stroma-poor
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tumors were equally distributed over the n=198 low to moderate grade tumors with an overall favorable
prognosis and the n=780 more aggressive high-grade tumors.
Fortunately, in this genomics era sophisticated microarray based methods are available to supplement
the histological grading data provided by the pathologist. So how do microarray based grading
signatures compare with our empirical distribution in stroma-rich and stroma-poor? To further explore
this, we used our distribution in stroma-poor (n=102) and stroma-rich (n=203) after splitting samples at
the median level of 70% tumor cell nuclei to classify 305 lymph-node negative primary breast tumors
with known tumor cell content essentially like described by Smid et al., [11]. Modulated genes were
identified in the two groups using Significance Analysis of Microarrays (SAM) with a 10% false
discovery rate (FDR) cut-off. These analyses showed that of the almost 450,000 probe sets
representing more than 39,000 transcripts, 1,268 probe sets were significantly higher expressed in the
stroma-rich subgroup and only one probe set (220942_x_at; representing the E2-induced E2IG5 gene)
was higher expressed in the stroma-poor group. When including only the 191 ER-positive breast tumors
present in this cohort, the distribution did not change much with 197 probe sets representing 153 known
genes and 11 yet unidentified transcripts higher expressed in the stroma-rich group of 122 tumors and
only 2 genes (ESR1 and FAM134B, a gene coding for the hypothetical protein FLJ20152 or
LOC54463), higher expressed in the stroma-poor group of 69 tumors. In the 114 ER-negative breast
tumors 58 probe sets, representing 48 known genes and 4 yet unidentified transcripts, were higher
expressed in the stroma-rich group of 81 tumors and not one single gene was higher expressed in the
stroma-poor group of 33 tumors. Of note, for the highly expressed genes in these stroma-rich
ER-positive (153 known genes) and ER-negative (48 known genes) cohorts only 8 genes overlapped
(CCL19, CCND2, DCN, FBLN1, HLA-DOB, ITM2C, KLRB1, and PTGDS).
Next, we similarly tried matching our stroma-rich and stroma-poor phenotypes with three microarray
based signatures aimed at classifying breast carcinomas based on gene expression patterns: two
grading signatures that specifically focus on the stromal micro-environment of the epithelial tumor cells
[13, 15], and the intrinsic breast cancer subtypes described by Perou and Sorlie [16-19].
In the stromal-related wound healing signature that, based on gene expression profiles of fibroblasts
from ten anatomic sites, reflects the multifaceted role of fibroblasts in wound healing [12-14],
stroma-rich and stroma-poor tumors were evenly distributed over the tumors exhibiting this wound
healing signature and those that did not. Differences between the two phenotypes were however
observed based on the stromal signature introduced by West et al [15]. This signature is based on
differences between two types of fibroblastic tumors: the locally aggressive desmoid-type fibromatosis
(DTF) and the generally benign solitary fibrous tumors (SFT). DTF expresses numerous collagens that
are present in a fibrotic response. Numerous myofibroblastic genes are also expressed by DTF. In
contrast, SFT express collagens and other extracellular matrix proteins that are typically found in the
basement membrane. DTF tumors express several genes of the ADAM and MMP families involved in
extracellular matrix remodeling, which might be relevant to the more infiltrative behavior of these
tumors [15]. SFT express few of these genes and the ADAMs that are expressed in SFT (ADAM22 and
ADAM23) are probably more involved in cell adhesion than in extracellular matrix remodeling. In
addition, DTF tumors express growth factors involved in the profibrotic response, such as transforming
growth factor beta and connective tissue growth factor [15]. Clustering our tumors according to these
signatures revealed that the SFT subtype could be subdivided in 3 different groups (SFT-a, SFT-b and
SFT-c). Stroma-rich tumors were most abundant in the 125 tumors defined by the expression of DTF
genes and stroma-poor tumors were most abundant in the 83 tumors defined by expression of genes of
for the SFT-c subtype (chi-squared=11.6, P=0.0006). Thus, according to these observations, our
stroma-rich primary breast tumors are representative for the more aggressive DTF genotype.
Finally, the intrinsic breast cancer subtypes (n=67 luminal A, n=74 luminal B, n=64 ERBB2, n=17
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normal-like and n=83 basal tumors) were identified in our cohort like described [11]. These intrinsic
subtypes showed a significant (P<0.0001) relationship with the stromal subgroups. Stroma-rich tumors
were most abundant in the ERBB2+ subtype (P=0.002) but were found less than would be expected in
the luminal A subtype (P<0.0001). Survival analyses in a prospective study on a subcohort of
uniformly treated patients with locally advanced breast cancer showed significantly different
outcomes for the patients belonging to the various intrinsic breast cancer subtypes. These correlations
with clinical outcome included a significant difference in outcome for the two estrogen receptor-
positive (luminal A versus B+C) groups, with the best prognosis associated with the luminal A subtype.
Furthermore, the basal-like and ERBB2+ subtypes were associated with the shortest relapse-free
survival [17]. According these data, stroma-rich tumors are characterized by a higher proportion of the
more aggressive ERBB2+ subtype and stroma-poor tumors by a higher proportion of the aggressive
luminal A subtype. 
To summarize the above, when compared to stroma-poor tumors, stroma-rich tumors are more likely to
express higher gene levels, especially genes associated with DTF tumors, are more likely to be an IDC,
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*     Dichotomized at the median level of 70% epithelial tumor cells with tumors with at least 70% epithelial tumor cells grouped
in the stroma-poor, i.e. predominantly epithelial, subgroup.
**   Significantly higher expressed genes were identified in the two groups using SAM with a 10% FDR cut-off.
↑ Histological or genotypic feature more frequently expressed by the specified stromal  phenotype.
Table 10.1.1. Associations of stromal content with histological and genotypic features.
and are more likely to be of the ERBB2+ breast cancer subtype. All features associated with poor
prognosis. Stroma-poor tumors on the other hand are more likely to express genes associated with the
generally benign SFT tumors, are more likely to be mucinous or an ILC, and are more likely to be of
the luminal A subtype. All features associated with a better prognosis. 
Thus, solely based on tumor cellularity we have been able to roughly discriminate between histological
phenotypes and microarray based genotypes with different prognostic features. However, we do
definitely not advocate that such a rough assessment of tumor cellularity can replace these methods. But
when the more laborious and expensive molecular profiling approach is not feasible, our relatively easy
to perform pragmatic approach should be taken into consideration to add information to the traditional
prognostic and predictive parameters. In addition, the observations described underline the notion that
cancer should be seen as a multi-type cellular program in which the epithelial tumor cells themselves,
the tumor-associated fibroblasts, and diverse other cell types in the tumor micro-environment are active
participants [13, 20-22].
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10.2 Overrepresentation of genes associated with tamoxifen responsiveness on
chromosome 17q12-25?
Using microsatellite length polymorphisms, comparative genomic hybridization (CGH) and molecular
cytogenetics (FISH), frequent allelic losses and gains on chromosome 17q have been detected in cell
lines and sporadic breast carcinoma [23-30]. These and other studies suggest that chromosome 17q
accomodates potential tumor suppressor genes as well as oncogenes.
In a recent study we discovered a set of markers predictive for the type of response to endocrine
therapy with the antiestrogen tamoxifen using gene expression profiling [31]. In total, 81 genes were
differentially expressed in the responsive and non-responsive groups. When assigning these genes to
chromosomes, we observed that a relatively high number of 8 genes (nearly 10% in stead of the 3.2%
expected on this chromosomal arm that contains 997 out of 31,210 Ensembl genes) was localized to
chromosome 17q12-q25: EZH1, FMNL, KIAA0563, APPBP2 and CDC42EP4, for which high levels
were associated with favorable response to tamoxifen, and LOC117584, COL1A1 and NAT9 for which
high levels were associated with adverse response to tamoxifen. Interestingly, two additional studies
included in this thesis describe markers located on 17q that correlate with tamoxifen response: HOXB13
[32] and ADAM11 [1]. In addition, unpublished data of our group indicate that high levels of the
eukaryotic translation initiation factor EIF1 (SUI1) on 17q21.2 are associated with favorable response
to tamoxifen while high levels of TIMP2 on 17q25 are associated with adverse response to tamoxifen. 
Besides the above mentioned genes located on 17q and linked by work of our group to tamoxifen
responsiveness, 17q harbors two additional interesting genes that have drawn much attention in the past
years: the familial susceptibility tumor suppressor gene BRCA1 [33] and the in breast cancer often
amplified ERBB2 oncogene. These two genes might, in addition to the widely demonstrated association
with prognosis, be related to tamoxifen response. Although it is not yet clear whether tamoxifen can
reduce breast cancer incidence in women with BRCA mutations in general, use of tamoxifen does
reduce the risk of contralateral breast cancer [34]. Patients with ERBB2 amplification have lower ER
levels and have been shown to be, albeit modestly, less responsive to tamoxifen [35-38]. This was
confirmed in our own studies where we found amplified levels of ERBB2 and the co-amplified GRB7
as measured by real-time RT-PCR significantly associated with reduced tamoxifen responsiveness
(unpublished data).
As demonstrated for the ERBB2-blocking antibody trastuzumab (Herceptin) [39-41], especially agents
blocking expression of genes or gene products for which high levels are associated with unfavorable
response to tamoxifen are therapeutically interesting. Therefore genes with increased expression levels
in tamoxifen unresponsive cases, such as the genes depicted with a downward arrow in figure 10.2.1,
are expected to be the most promising candidates for targeted therapy. Another interesting approach
might however be to induce genes, such as ADAM11 and others depicted with an upward arrow in
figure 10.2.1, for which high expression has been associated with treatment benefit. 
In view of another publication included in this thesis, where we showed that aging accompanied by
telomere loss could contribute to breast cancer progression [3], it is noteworthy that telomeric length on
17q shortens more than global telomere length in the development of breast cancer [42, 43]. This
increased level of telomere shortening on 17q may be involved in the chromosomal instability of 17q
and the progression of DCIS to IDC [43]. By using telomerase RNA (TERC) and dyskerin, the reverse
transcriptase enzyme telomerase (TERT) is able to maintain telomere length [44]. With respect to
tamoxifen sensitivity, an increase of telomerase activity has been implicated in the transition from a
tamoxifen sensitive to tamoxifen resistant phenotype [45-47]. It will therefore be interesting to see if
artificially decreasing telomere length, for example by blocking TERT activity with antibodies or
through mRNA silencing, is able to reverse tamoxifen resistance and how this correlates with
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Figure 10.2.1. Genes associated with tamoxifen responsiveness on chromosome 17q12-25.
* → Gene expression levels are not associated with response to tamoxifen treatment for metastatic disease. 
↑ Gene expression levels are higher in tamoxifen responsive cases and/or lower in unresponsive cases.
↓ Gene expression levels are lower in tamoxifen responsive cases and/or higher in unresponsive cases.
expression of genes located on 17q.
In figure 10.2.1 our findings with respect to genes located at 17q in relation to tamoxifen
responsiveness are summarized. Here it is also shown that we observed no correlation between
tamoxifen response and vitronectin (VTN) located on 17q11 and NR1D1 on 17q11.2. This indicates that
a possible association of genes located on 17q and tamoxifen responsiveness could be confined to genes
located upstream 17q11. Taken together, our data suggest that a condensation of genes localized on the
long arm of chromosome 17q12-25 are, in addition to their association with breast cancer
biology in general, associated with tamoxifen responsiveness. 
10.3 Is there a future for the discovery or validation of biomarkers by real-time PCR?
Surprisingly in this high-throughput era, the only established breast biomarkers are currently the
serum-based cancer antigens CA 15-3, CA 125, CA 27-29 and CEA, the tissue-based ER and PgR,
markers measuring DNA-ploidy/content and/or cellular proliferation, the oncogene ERBB2, the tumor
suppressor gene p53, and the protease uPA and its inhibitor PAI-1 [40, 41, 48]. 
In aid of the urgently needed establishment of new biomarkers, our department decided to process the
Rotterdam fresh frozen human breast tumor tissue bank, containing over 5,000 tissues with clinical
follow-up available, into a RNA, DNA and protein bank. These three banks now enable us to
characterize the breast tumors by means of genomics and proteomics. In chapter 6 of this thesis a
detailed overview of the RNA collection stored in this bank with sufficient clinical follow-up for
reliable statistical analyses is presented [32]. These RNA samples were the very important source of
clinical samples discussed in this thesis [1, 5, 6, 32, 49]. In addition to the data presented in these
published studies, we have so far tested an impressive set of over 300 other genes by real-time RT-PCR.
In most cases over 600 lymph node-negative patients who did not receive any adjuvant systemic
therapy were analyzed to evaluate the prognostic value of genes, very similarly as described in chapter
5 of this thesis [6]. To evaluate the predictive value, in most cases at least 190 hormone naïve patients
with ER-positive primary breast tumors treated with tamoxifen for recurrent breast cancer, were
evaluated as described in chapter 4 [1] and 6 [32]. Perhaps disappointing, relatively few of these
markers fulfil the criteria of a clinically attractive biomarker in this stage. Furthermore, with a rapidly
expanding field of tumor associated biomarkers and a concomitant increase in published reports, it has
become increasingly apparent that a strong need exists to establish consensus guidelines for the
development and use of established as well as novel tumor associated markers [40, 50, 51]. For this
purpose, the tumor marker utility grading system (TMUGS) has been introduced as a framework tool
to define the quality of data that exist and to place the available data into one or several levels of
evidence (LOE-5 to LOE-1) (table 1.4.1) [52]. 
Despite the large number of samples we have analyzed in the different studies included in this thesis,
the putative biomarkers that emerged (ADAM-9, ADAM-11, CCNE1, CCNE2, HOXB13-to-IL17BR
ratio, and TIMP1-v1+v2) do not exceed evidence-based level 3 (LOE-3; evidence from large but
retrospective studies from which variable numbers of samples are available or selected). To reach 
LOE-2 (evidence from a study in which marker data are determined in relationship to a prospective
therapeutic trial that is performed to test a therapeutic hypothesis but not specifically designed to test
the marker utility), we need access to new tumor material from such a prospective trial and preferably
also optimize our qRT-PCR assays for formalin-fixed paraffin-embedded (FFPE) tissues. Literature and
data base searches might tell whether other groups have taken up on the putative new biomarker, in
which case those data might help to reach LOE-2. Only then can the markers that are discussed in this
thesis even be considered for entering LOE-1 (evidence from a single, high-powered, prospective,
controlled study that is specifically designed to test marker or evidence from meta-analysis and/or
overview of level II or III studies.). Taking this into consideration, there is still a long way to go for the
biomarkers discussed in this thesis. Does this mean that in our search for new biomarkers the future for
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real-time PCR looks bleak? No, I do not think so. Firstly, we have already shown that contributions of
our group can result in biomarkers entering LOE-1 [53]. Secondly, even when no antibodies are
available, real-time RT-PCR at least allows assessment of mRNA levels of candidate markers,
nowadays also in FFPE tissue. Although gene expression profiling methods are definitely more
comprehensive, especially low expressed tags might be adversely biased and validation at the single
gene level by real-time RT-PCR will remain essential. In addition, the amount of valuable patient
material, elaborate equipment and costs required to perform these genome-wide screenings must be
taken into consideration. Thirdly, for example a 21 multigene real-time RT-PCR based assay (Oncotype
DX™) to predict recurrence of tamoxifen-treated, node-negative breast cancer [54], and a FDA
approved 2-gene (mammaglobin (MGB1) and cytokeratin 19 (KRT19)) RT-PCR assay (GeneSearch™)
to detect the spread of breast cancer into the lymph nodes have already entered the clinic. 
Taken together, real-time PCR is a sensitive, fast, quantitative, and cost-effective method suitable for
high-throughput screening. In this thesis it has been shown that real-time RT-PCR is indeed a powerful
method to quantify mRNA levels of genes that are differentially expressed in primary tumors of breast
cancer patients with different prognostic and predictive features. Therefore, the single gene or
multiplex real-time PCR approach will remain an important quantification method for fast screening of
diagnostic markers and therapeutic targets that are already established or that emerge from the literature
and microarray based techniques.
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11.1 SUMMARY
The aims of this thesis and outlined in more detail below were firstly to gain insight into the interaction
between breast tumor cells and the surrounding stromal fibroblasts. Secondly, to integrate this concept
of a multi-type cellular program in which the epithelial tumor cells, the tumor-associated fibroblasts,
and diverse other cells in the tumor micro-environment are active participants, in our search for novel
prognostic and predictive biomarkers. Finally, to place the concept of biomarkers in a larger context by
looking at pathways rather then individual biomarkers. The more specific subjects discussed in this
thesis were: 1) studies on the interaction between different biological systems, 2) studies on prognosis,
and 3) studies on prediction to tamoxifen therapy response.
General introduction
To familiarize the reader with basic aspects of breast cancer and histological and molecular techniques
used to study breast cancer relevant for this thesis, a general introduction was provided in chapter 1. To
summarize this chapter, breast cancer is the most common type of cancer and accounts for about 30%
of all cancers in women. In the well developed countries for women between 35-55 years of age it is
overall even the main cause of death. Early detection and new treatment modalities, in part based on
new insights, have improved clinical outcome and survival rates. The difficulty with breast cancer is
that it is a heterogeneous disease which encompasses several entities with distinct prognosis.
Furthermore, now there is an increasing insight that signals provided by the tissue supporting the
epithelial cancer cells, i.e., the stroma, can be responsible for genetic alterations that underlie tumor
formation, can stimulate tumor growth and progression, and can dictate both therapeutic response and
ultimate clinical outcome. So, cancer should be seen as a multicellular process in which the epithelial
tumor cells themselves, the tumor-associated fibroblasts, and diverse other cells in the tumor
micro-environment are active participants. To aid the clinician in the management of this heterogeneous
and multi-type cellular disease, breast cancer is characterized by histology, stage, grade, and expression
of biomarkers. Biomarkers are biological substances normally present in small amounts in tumor
tissues or body fluids and encompass a wide variety of molecules, including transcription factors, cell
surface receptors, and secreted proteins. These biomarkers are measured in the management of breast
cancer patients for the following purposes: 1) early detection, 2) monitoring of advanced breast cancer
patients, 3) prediction of prognosis, 4) prediction of site of relapse, and 5) prediction of therapeutic
response. For this thesis it is important to understand the difference between a prognostic and a
predictive biomarker: a prognostic marker predicts disease recurrence or tumor progression,
independently of future treatment effects. A predictive biomarker predicts response or resistance to a
specific therapy. Any change in disease status must be reflected by a change in the biomarker status.
Surprisingly in this high-throughput era, the only established breast biomarkers are currently the
serum-based cancer antigens CA 15-3, CA 125, CA 27-29 and CEA, the tissue-based estrogen and
progesterone receptors, markers measuring DNA-content and/or cellular proliferation, the oncogene
ERBB2, the tumor suppressor gene p53, the protease uPA and its inhibitor PAI-1, and two markers for
hereditary breast cancer susceptibility (BRCA1 and BRCA2). In brief there is still an urgent need for
new biomarkers. 
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Methods
The techniques to search for new biomarkers, to validate their usefulness, and assign biological
functions has made great progress in this computerized era of proteomics to study proteins and
genomics to study genes. Quantitative real-time reverse transcriptase polymerase chain reaction
(real-time RT-PCR or qRT-PCR) is one of the methods that enables quantification of gene products as
they accumulate in "real-time" during the PCR amplification process. With scientists pinning their
hopes for new diagnostics and cures on molecular biomarkers, they need access to human tissue
samples from large numbers of patients. For this, biobanks with stored tissues, body fluids and related
products such as DNA, RNA and protein lysates are essential. One such well characterized fresh frozen
breast tumor tissue bank has been established by the department of Medical Oncology, Erasmus
Medical Center, Rotterdam, The Netherlands. This fresh frozen breast tumor tissue bank currently
contains over 14,000 samples that are collected since 1978 and stored in liquid nitrogen immediately
after surgery. Of 5,500 patients a computerized database with updated clinical follow-up is available. In
addition, information on high quality extracts of DNA from 3,000 tissues, RNA from 2,000 tissues, and
protein from over 10,000 tissues are stored in computerized databases. These RNA samples have been
the very important source of clinical samples for the marker discovery studies discussed in this thesis.
Results and conclusions
To achieve the aims set for this thesis, the role of peri-tumoral fibroblasts in relation to the expression
of components of the plasminogen activator (PA) system and the insulin-like growth factor (IGF)
system in normal- and tumor-tissue-derived human breast fibroblasts exposed to various fibroblast
growth factors (FGFs) was investigated in chapter 2. The in vitro data presented proposed that of the
FGFs studied (FGF-1, -2, -4, -5, and -7), FGF-2 is the most attractive target for therapeutical strategies
aimed at diminishing the contribution of stromal fibroblasts in the PA-directed proteolysis. 
With our aging population, especially the age-related increase in breast cancer incidence is worrying.
In chapter 3 the role of peri-tumoral fibroblasts was investigated in relation to this important aspect.
For this, we have investigated whether breast fibroblasts aged in vitro through passage in culture
displayed altered levels of components of the PA system and growth factors that are known to modulate
that system. Our results showed that aging accompanied by telomere loss induces PAI-1 and FGF-1
mRNA expression in all breast fibroblast strains, increases uPA and decreases IGF-1 mRNA expression
in a subset, and increases matrix metalloproteinases-2 (MMP-2) protein expression only in
tumor-derived breast fibroblasts. Thus, the aging-dependent levels of these biomarkers in stromal breast
fibroblasts could contribute to breast cancer progression. 
In chapter 4 the importance of the multi-cellular notion was experienced in the clinical setting. Here
we evaluated the predictive value of the disintegrin and metalloproteinases, ADAM-9, ADAM-10,
ADAM-11, and ADAM-12, and of the matrix metalloproteinases, MMP-2 and MMP-9, in patients with
recurrent breast cancer treated with tamoxifen. The data showed that especially for primary tumors
containing a high proportion of stromal elements, the assessment of mRNA expression levels of
ADAM-9 and ADAM-11 could be useful to identify patients with recurrent breast cancer who are likely
to benefit or fail from tamoxifen therapy. 
One of the applications of qRT-PCR is validation of putative biomarkers that emerge from microarray
experiments in a larger patient cohort. One such biomarker is cyclin E2 (CCNE2), a gene that
overlapped between two independently established prognostic gene signatures. In chapter 5 we
described the prognostic evaluation of cyclin E with this quantitative method in a large cohort of 635
lymph node-negative (LNN) breast cancer patients that did not receive systemic adjuvant therapy. The
study showed that both CCNE1 and CCNE2 qualified as independent prognostic markers for LNN
breast cancer patients, and that CCNE1 may provide additional information for specific subgroups of
patients with stroma-enriched primary tumors. 
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Another validation study, discussed in chapter 6, concerned the HOXB13-to-IL17BR expression ratio
that was previously identified to predict clinical outcome of breast cancer patients treated with adjuvant
tamoxifen. Here we demonstrated that, in addition to tamoxifen therapy failure for advanced disease,
high HOXB13-to-IL17BR ratio expression levels are also associated with intrinsic tumor
aggressiveness. 
Having discovered and identified two alternatively spliced variants of tissue inhibitor of
metalloproteinases-1 (TIMP1) mRNA in cancer cell lines and colon cancer tissue (chapter 7), the
prognostic value of these variants were tested in 1301 primary breast cancer specimens (chapter 8).
While high concentrations of TIMP-1 protein are associated with poor prognosis, high concentrations
of TIMP1-v1+2 mRNA measured in the primary tumors of breast cancer patients were associated with
good prognosis. Such a differential association, implicating the presence of possible posttranscriptional
mechanisms, might help our understanding of the role of TIMP-1 with respect to breast cancer
progression.  
As discussed in chapter 5, published prognostic gene signatures in breast cancer have few genes in
common. In chapter 9 we demonstrated that these divergent gene sets classifying patients for the same
clinical endpoint represented similar biological processes and that pathway-derived signatures can be
used to predict prognosis. Such signatures that define tumors according to their vital pathways may
provide crucial guidance for designing appropriate drug combinations 
General discussion and future perspectives
Finally, in chapter 10, three concepts that have emerged from the studies described in this thesis in
relation to future perspectives were discussed in more depth, leading to the following conclusions and
recommendations: 
Firstly, solely based on tumor cellularity (ratio of epithelial tumor cells over stromal cells) we were able
to roughly distinguish between histological phenotypes and microarray based genotypes with different
prognostic features. In addition, the observations underlined the notion that cancer should be seen as a
multicellular program in which the epithelial tumor cells themselves, the tumor-associated fibroblasts,
and diverse other cells in the tumor micro-environment are active participants.
Secondly, work of our group showed that a condensation of genes localized on the long arm of
chromosome 17q12-25 is, in addition to an association of genes in this region with breast cancer risk in
general, associated with sensitivity to tamoxifen. Especially the genes located in this chromosomal area
with increased expression levels in tamoxifen unresponsive cases were  proposed as promising
candidates for targeted therapy.   
Lastly, it has been shown in this thesis that qRT-PCR is a sensitive, fast, quantitative, and cost-effective
method, extremely suitable to quantify mRNA levels of genes that are differentially expressed in the
primary tumors of breast cancer patients with different prognostic and predictive features. Even when
no antibodies are available to detect protein, qRT-PCR at least enables quantitative assessment of
mRNA levels of candidate markers, nowadays also in formalin-fixed paraffin-embedded (FFPE) tissue.
Therefore, there is no doubt that the single gene or multiplex qRT-PCR approach will remain an
important quantitative method for fast screening of diagnostic markers and therapeutic targets. 
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11.2 SAMENVATTING
Het eerste doel van het in dit proefschrift beschreven onderzoek was inzicht te krijgen in de
wisselwerking tussen borsttumorcellen en de cellen in het omringende stroma. Een tweede doel was om
dit idee van een multitype cellulaire tumor, waarin naast epitheliale tumorcellen ook tumor-
geassocieerde fibroblasten en diverse andere typen cellen een actieve rol spelen, te integreren in onze
zoektocht naar nieuwe prognostische en predicatieve markers. Ten slotte was er het doel om het
concept van biomarkers in een groter geheel te plaatsen door naar de biologische paden te kijken waar
ze onderdeel van zijn, in plaats van naar de individuele biomarkers. Meer specifiek: de onderwerpen die
in dit proefschrift beschreven werden zijn: 1) studies naar de wisselwerking tussen verschillende
biologische systemen, 2) studies met betrekking tot prognose, en 3) studies met betrekking tot het
voorspellen of een patiënt wel of niet zal reageren op tamoxifen therapie.
Algemene inleiding
Om de lezer meer bekend te maken met het basisprincipe van borstkanker en de histologische en
moleculaire technieken die worden gebruikt om borstkanker te bestuderen, is er een algemene
inleiding opgenomen in hoofdstuk 1. Samengevat is in dit hoofdstuk uitgelegd dat borstkanker de bij
vrouwen meest voorkomende soort kanker is, verantwoordelijk voor 30% van alle vrouwelijke
kankerpatiënten. In de westerse wereld is het zelfs de belangrijkste doodsoorzaak voor vrouwen in de
leeftijd van 35 tot 55 jaar. Vroege opsporing en nieuwe behandelingsmethodes, deels gebaseerd op
nieuwe inzichten, hebben tot een verbetering in de behandeling en een daling van sterfte ten gevolge
van borstkanker geleid. Maar het probleem met borstkanker is dat het een heterogene ziekte is die
meerdere vormen omvat, ieder met een eigen specifiek ziekteverloop. Bovendien is er nu groeiend
inzicht dat het weefsel dat de tumorcellen omgeeft (het stroma), signalen kan afgeven die mogelijk
verantwoordelijk zijn voor de genetische veranderingen die voorafgaan aan het ontstaan van een tumor,
tumorgroei en uitzaaiingen bevorderen, sturing geven aan de manier waarop een tumor op therapie
reageert en het uiteindelijke ziekteverloop bepalen. Daarom moet kanker worden gezien als een
multitype cellulair proces waarin de epitheliale tumorcellen zelf, de tumorgeassocieerde fibroblasten en
diverse andere cellen die zich in een tumor in de directe omgeving van de epitheliale tumorcellen
bevinden, allen een actieve rol spelen. Om de dokter te helpen met de behandeling van deze heterogene
en multitype cellulaire ziekte, wordt kanker gekarakteriseerd door histologie, stagering, gradering en
expressie van biomarkers. Biomarkers zijn biologische stoffen die gewoonlijk in kleine hoeveelheid in
tumorweefsel of lichaamsvocht aanwezig zijn en omvatten een grote verscheidenheid aan moleculen
zoals transcriptie factoren, celreceptoren en uitgescheiden eiwitten. Deze biomarkers worden tijdens de
begeleiding van de borstkankerpatiënt om de volgende redenen gemeten: 1) voor vroege opsporing, 2)
ter begeleiding van patiënten met uitgezaaide ziekte, 3) om het ziekteverloop te voorspellen, 4) om te
voorspellen waar de uitzaaiing van de tumor zal plaatsvinden, en 5) om te voorspellen of de patiënt zal
reageren op een therapie. Het is voor dit proefschrift belangrijk het verschil tussen een prognostische
en een predicatieve biomarker te begrijpen: een prognostische biomarker voorspelt de kans op
terugkeer van de ziekte of op tumorgroei, onafhankelijk van toekomstige behandelingseffecten. Een
predicatieve biomarker voorspelt of de patient zal reageren op een specifieke behandeling. Elke
verandering in het verloop van de ziekte moet worden weerspiegeld door een verandering in de
waarden van de biomarker. Verrassend genoeg in deze 'high-throughput' eeuw, zijn de enige algemeen
erkende biomarkers voor borstkanker momenteel de in bloedserum aanwezige antistoffen CA 15-3, CA
125, CA 27-29 en CEA, en de in tumorweefsel gemeten receptoren voor oestrogeen en progesteron,
markers die de hoeveelheid DNA en/of celdelingsnelheid meten, het oncogen ERBB2, het
tumorsuppressor gen p53, de eiwitafbrekende protease uPA en zijn remmer PAI-1, en twee markers om
de gevoeligheid voor erfelijke borstkanker te meten (BRCA1 en BRCA2). Kortom, er is een dringende
vraag naar nieuwe biomarkers.
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Methodes
De technieken om naar nieuwe biomarkers te zoeken, hun bruikbaarheid te testen en om ze een
biologische functie te geven, hebben een grote vooruitgang gemaakt in deze gecomputeriseerde eeuw
van 'proteomics' om eiwitten te bestuderen en 'genomics' om genen te bestuderen. Kwantitatieve
real-time reverse transcriptase polymerase chain reaction (real-time RT-PCR of qRT-PCR) is een van
de methodes die het mogelijk maakt genproducten te kwantificeren als zij zich ophopen in de tijd (''real-
time'') tijdens het PCR amplificatieproces. Wetenschappelijke onderzoekers, die voor nieuwe
diagnostiek- en therapiemethodes hun hoop hebben gevestigd op moleculaire markers, moeten kunnen
beschikken over materialen van een grote verscheidenheid aan patiënten. Hiertoe zijn biobanken met
opgeslagen weefsels, lichaamsvochten en gerelateerde producten zoals DNA, RNA en eiwitextracten
uiterst belangrijk. Een voorbeeld van zo'n goed gekarakteriseerde bank met vers ingevroren
borstkankerweefsel is opgezet door de afdeling Medische Oncologie aan het Erasmus Medisch
Centrum te Rotterdam in Nederland. Deze bank bevat momenteel meer dan 14,000 monsters van
borstkankerweefsel die sinds 1978 zijn verzameld, en direct na de operatie opgeslagen zijn in vloeibare
stikstof. Van 5,500 patiënten is er een geautomatiseerd bestand met bijgewerkte klinische gegevens
beschikbaar. Bovendien is er informatie betreffende de hoge kwaliteitsextracten van DNA uit 3,000
weefsels, van RNA uit 2,000 weefsels, en van eiwit uit 10,000 weefsels opgeslagen in
geautomatiseerde gegevensbestanden. De klinische RNA monsters zijn een zeer belangrijke bron
geweest voor de studies om nieuwe markers te ontdekken zoals deze in dit proefschrift worden
beschreven. 
Resultaten en conclusies
Om de doelstellingen te bereiken die voor dit proefschrift waren opgesteld, is in hoofdstuk 2 de rol van
normale en met tumorweefsel geassocieerde fibroblasten onderzocht in relatie tot expressie van
componenten van het plasminogeenactivator (PA) systeem en het 'insuline-like-groeifactor' (IGF)
systeem, voor en nadat deze fibroblasten aan verschillende groeifactoren voor fibroblasten (FGFs)
waren blootgesteld. De in vitro data die in dit hoofdstuk gegeven worden, suggereerden dat van de
bestudeerde FGFs (FGF-1, -2, -4, 5, en -7), FGF-2 het meest interessante doelwit is voor
therapeutische strategieën die gericht zijn op het verminderen van de bijdrage van de stromale
fibroblasten in het proces van de -door het PA-systeem aangestuurde- eiwitafbraak. 
Door de toenemende vergrijzing van de bevolking is met name de leeftijdsgebonden toename in de
borstkankerincidentie zorgwerkend. In hoofdstuk 3 is de functie van normale en met tumorweefsel
geassocieerde fibroblasten in relatie tot dit belangrijke onderwerp onderzocht. Hiertoe hebben we
bekeken of fibroblasten, die we in het laboratorium in kweek  hebben laten verouderen, veranderingen
gaven in de concentraties van bestanddelen van het PA systeem en van groeifactoren waarvan bekend
is dat ze het PA-systeem beinvloeden. Onze resultaten lieten zien dat veroudering gecombineerd met
verlies van telomeerlengte in alle fibroblastkweken gepaard ging met een toename in de productie van
PAI-1 en FGF-1 mRNA, in een subset van de fibroblastkweken met een toename van uPA en een
afname van IGF-1 mRNA, en alleen in fibroblasten afkomstig uit tumorweefsel met een toename in de
eiwitproductie van matrixmetalloproteinases-2 (MMP-2). Derhalve kunnen de leeftijdsafhankelijke
veranderingen van biomarkers in stromale borstfibroblasten bijdragen aan borstkankerprogressie. 
In hoofdstuk 4 is het belang van het multitype cellulaire concept in een klinische setting ondervonden.
Hier hebben we in patiënten, die met tamoxifen waren behandeld voor uitgezaaide borstkanker,
gekeken naar de predicatieve waarde van de disintegrine en metalloproteinases ADAM-9, ADAM-10,
ADAM-11, en ADAM-12, en de matrixmetalloproteinases MMP-2 en MMP-9. De analyses lieten zien
dat met name voor primaire tumoren die voor een groot deel uit stromale bestanddelen bestaan, het
bepalen van ADAM-9 en ADAM-10 mRNA concentraties bruikbaar zou kunnen zijn om patiënten te
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identificeren die een grotere kans hebben wel of niet te reageren op een behandeling met tamoxifen
voor teruggekeerde borstkanker. 
Een van de toepassingen van qRT-PCR is het in een groter patiëntenbestand valideren van in
microarray-experimenten gevonden vermoedelijke biomarkers. Een voorbeeld van zo'n biomarker is
cycline E2 (CCNE2), een gen dat voorkwam in twee onafhankelijk tot stand gekomen prognostische
genprofielen. In hoofdstuk 5 hebben we beschreven hoe we met deze kwantitatieve methode de
prognostische waarde van cycline E hebben geëvalueerd in een groot bestand van 635 borstkanker
patiënten met negatieve lymfklieren (LNN) die geen systemische aanvullende behandeling hadden
gehad. De studie liet zien dat zowel CCNE1 als CCNE2 kwalificeerden als onafhankelijke
prognostische markers voor LNN borstkankerpatiënten, en dat CCNE1 extra informatie kan geven voor
specifieke subgroepen patiënten met stroma-rijke primaire tumoren. 
Een andere controlestudie, beschreven in hoofdstuk 6, betrof de HOXB13-IL17BR ratio, een ratio die
al eerder was geïdentificeerd als een maat op grond waarvan het ziekteverloop kon worden voorspeld
van borstkankerpatiënten die adjuvant behandeld waren met tamoxifen.  Hier hebben wij aangetoond
dat een hoge HOXB13-IL17BR ratio, bovenop de associatie met het falen van tamoxifen therapie voor
uitgezaaide ziekte, ook geassocieerd is met de intrinsieke agressiviteit van een tumor. 
Nadat wij twee alternatief gesplitste varianten van 'tissue-inhibitor of metalloproteinases-1' (TIMP1)
mRNA hadden ontdekt en deze verder hadden geïdentificeerd in kankercellijnen en
darmkankerweefsel (hoofdstuk 7), hebben wij de prognostische waarde van deze varianten verder
onderzocht in 1301 primaire borstkankermonsters (hoofdstuk 8). Terwijl hoge concentraties TIMP-1
eiwit worden geassocieerd met een slechte prognose, vonden wij dat in de primaire borstkanker
gemeten hoge concentraties TIMP1-v1+2 mRNA zijn geassocieerd met een goede prognose. Een
dergelijke differentiële associatie, mogelijk een aanwijzing voor de aanwezigheid van
posttranscriptionele mechanismes, zou ons kunnen helpen de rol van TIMP-1 ten aanzien van
borstkankerprogressie beter te begrijpen.
Zoals besproken in hoofdstuk 5, hebben gepubliceerde prognostische genprofielen maar een paar
gemeenschappelijke genen. In hoofdstuk 9 hebben we aangetoond dat deze uiteenlopende genensets,
die patiënten voor eenzelfde klinisch eindpunt classificeren, deel uitmaken van overeenkomstige
biologische processen, en dat het daarom beter is om een voorspelling te geven op grond van profielen
die zulke biologische paden beschrijven. Zulke profielen, die tumoren karakteriseren op grond van
biologisch actieve paden, zouden cruciale informatie kunnen verschaffen die nodig is om geschikte
medicijncombinaties te ontwikkelen.
Algemene discussie en toekomstvooruitzichten
In hoofdstuk 10 tenslotte, zijn drie onderdelen verder uitgewerkt die gemeenschappelijk uit de
beschreven studies naar voren kwamen. Dit resulteerde in de volgende conclusies en aanbevelingen:
Ten eerste, enkel en alleen gebaseerd op de samenstelling van de tumor (de verhouding tussen
epitheliale tumorcellen en stromale cellen), zijn we in staat geweest een grof onderscheid te maken
tussen histologische fenotypen en op microarray gebaseerde genotypen met verschillende
prognostische eigenschappen. Bovendien onderstreepten deze waarnemingen het belang van de
opvatting dat kanker gezien moet worden als een proces waarin meerdere celtypen, zoals de epitheliale
tumorcellen zelf, de tumorgeassocieerde fibroblasten en diverse andere cellen die zich in een
tumoromgeving bevinden, actieve deelnemers zijn. 
Ten tweede bleek uit werk van onze groep dat een concentratie van genen op de lange arm van
chromosoom 17q12-25, aanvullend op de associatie van genen in dit gebied met het risico op
borstkanker in het algemeen, geassocieerd is met gevoeligheid voor tamoxifen. Met name de genen in
dit chromosomale gebied die een verhoogde expressie laten zien in tamoxifen ongevoelige tumoren,
werden als veelbelovende kandidaten voor doelgerichte therapie aanbevolen.
Ten slotte is in dit proefschrift aangetoond dat qRT-PCR een gevoelige, snelle, kwantitatieve,
kostenbesparende methode is, die uitermate geschikt is om mRNAconcentraties te meten van genen die
verschillend tot expressie komen in de primaire tumoren van borstkankerpatiënten met verschillende
prognostische en predicatieve kenmerken. Zelfs wanneer er geen antilichamen beschikbaar zijn om
eiwit aan te tonen, is men met qRT-PCR in ieder geval in staat de mRNA concentraties kwantitatief te
meten, vandaag de dag ook in formaline-gefixeerd weefsel dat in paraffine is ingebed. Er bestaat
daarom geen twijfel dat het meten van een enkel gen, of meerdere genen in een multiplex reactie, met
behulp van qRT-PCR een belangrijke kwantitatieve methode zal blijven om snel te screenen op
diagnostische en therapeutische markers.
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(HLO-biochemistry) in Rotterdam to become a technician. She started her scientific career in 1987 in
the department of Medical Oncology at the Dr. Daniel den Hoed Clinic in Rotterdam as a research
technician helping others with their research. A few years later she was given the opportunity to
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En dan nu het dankwoord. Sommige mensen vinden dit het leukste om te schrijven, ik vind het iets
minder leuk, bang als ik ben iemand ten onrechte te vergeten. Mocht dat ondanks mijn beste
bedoelingen toch het geval zijn, bij deze mijn oprechte verontschuldigingen!
In de eerste plaats wil ik mijn ouders bedanken die mij alle ruimte hebben gegeven om een goede
opleiding te volgen. Mede dankzij jullie onvoorwaardelijke ondersteuning heb ik het zover geschopt.
Zonder het vertrouwen en de hulp tot in de late uurtjes van mijn promotor professor Jan Klijn en mijn
copromotor dr. John Foekens had ik het natuurlijk nooit tot dit hoofdstuk kunnen brengen. John, ik heb
niet veel ervaring met leidinggevenden, maar voor mij ben je het beste wat mij had kunnen overkomen.
Ik hoop dat onze toekomst net zo prettig en harmonieus gaat verlopen als ons verleden. Hier wil ik ook
graag de leden van de leescommissie, professor Fred Sweep, professor Lex van Eggermont en dr. Els
Berns, bedanken die, weliswaar voordat ze wisten hoe dik het boekwerk ging worden, zonder aarzeling
hebben toegezegd zich aan deze taak te willen wijden en dat vervolgens ook met verve hebben gedaan.
Mede dankzij de snelle actie van de leescommissie heb ik voldoende tijd gehad om dit boekje een
mooie afwerking te geven, nogmaals dank hiervoor.
Maar zonder Siert Bolt, Joan Bolt en Mieke Timmermans had dit boekje er nooit zo mooi en volledig
uitgezien als nu. Siert, die met een ongekend enthousiasme de taak van DTP-er op zich heeft genomen,
de onderhandelingen met de drukkers heeft gevoerd, mij attent maakte op onregelmatigheden, en tot het
einde toe geduldig bleef als ik toch weer iets anders wilde. Joan en Siert, waar ik 's avonds altijd
welkom was om onder het genot van koffie, sigaretten en een wijntje de stand van zaken door te nemen
waarna ik dan weer enthousiast en vol goede moed met een dik pak papier huiswaarts ging. En mijn
collega’s door dik en dun, Joan en Mieke, wat gaan wij al lang mee zo samen. Mieke, ik zie het echt als
een kroon op mijn werk dat jij de kaft van 'ons' boekje zo'n mooie en toepasselijke vorm hebt kunnen
geven. En alsof dat niet genoeg was, wilde je je ook nog wel als paranimf inzetten voor de promotie.
Zelfs voordat je wist dat je in het zeer goede gezelschap van John Martens zou toeven. John M, het
'jonkie' onder ons die ik echter in de paar jaren dat wij nu samen werken heb leren kennen als een
eerlijke, betrouwbare, rechtdoorzee collega waar je op kan bouwen. Nooit te beroerd voor een praatje
en altijd in voor een goede en open discussie. Een wereldgozer.
Het mag duidelijk zijn, voordat het tot een thesis kan komen, is er een hecht team nodig om resultaten
te krijgen die de moeite van het opschrijven waard zijn. "Als je niet kunt delen, dan kun je ook niet
vermenigvuldigen". Hiertoe wil ik hier eerst alle coauteurs van de publicaties die in deze thesis zijn
opgenomen bedanken: Anita Trapman, Anneke Goedheer, Annette Bartels, Els Berns, Hanne
Offenberg, Hans Jørgen Nielsen, Henk Portengen, Iris van Staveren, Jack Yu, Jan Klijn, Joan Bolt-
de Vries, John Foekens, John Martens, Kirsten Ritstier, Lambert Dorssers, Lars Holten-Andersen,
Marcel Smid, Marion Meijer-van Gelder, Maurice Jansen, Maxime Look, Mieke Timmermans,
Miranda Arnold, Nils Brunner, Pernille Usher, Peter Bosma, Roberto Rodriguez Garcia, Susan
Swiggers, Ulrik Lademann, Vanja de Weerd, Yi Zhang, en Yixin Wang.
Een voorbeeld van zo'n superteam dat hier zeker extra vermelding verdient, is het RDE team dat zich
de afgelopen jaren zo nauwgezet en eensgezind heeft gewijd aan het opwerken van de RNA, DNA en
Eiwit samples. Henk, kamergenoot, stadsgenoot, de laatste der Mohikanen. Dat waren toch leuke tijden
zo 's morgens vroeg samen met jou in de auto op weg naar de Daniel en terug met Tiny die altijd wel
iets leuks had te vertellen. Toen ik uiteindelijk dan toch zelf in het bezit van rijbewijs en eigen auto
kwam, was dat afgelopen, maar nog wel veel contact via de e-mail waar jij altijd zo snel reageerde op
mijn zoveelste verzoek voor database bestanden ten behoeve van de RDE-bank. Ik zal altijd met plezier
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en ondertussen bijna met weemoed terugdenken aan wat ik van jou en Harry heb geleerd: ondanks jullie
gemopper over dat jonge grut dat niet meer kan pipetteren, wat mij betreft niets dan goeds over de oude
garde. Mieke Timmermans, met jouw uitgebreide kennis van alles wat met immunologie en histologie
heeft te maken; zonder jouw expertise had een van de overkoepelende onderwerpen van deze thesis, de
rol van stroma in borstkanker, nooit zo goed uit de verf kunnen komen. Anita Trapman, altijd in om een
nieuwe techniek te leren en daardoor nu degene die als het nodig is overal inzetbaar is, geweldig toch?
Anneke Goedheer, onze vliegende keep die als geen ander orde in de chaos wist te brengen; mens wat
mis ik jouw droge humor en wervende activiteit op ons lab. Miranda Arnolds, nauwgezet en als geen
ander in staat een nieuwe techniek uit te werken, complimenten hoor. Roberto Rodriguez Garcia, onze
onverstoorbare steun en toeverlaat, nooit te beroerd iets aan te pakken. Anneke, Miranda en Roberto, ik
wil jullie hier nogmaals bedanken voor alles wat jullie voor de RDE bank en mij hebben gedaan en kan
alleen maar blij zijn dat jullie uiteindelijke ergens anders een goed plek hebben gevonden. Mensen
komen, mensen gaan. Alhoewel het altijd moeilijk is als mensen weggaan, heb ik daarvoor in de plaats
weer andere collega's gekregen waar ik minstens zoveel goede herinneringen aan heb. Wendy, jij kwam
binnen als een verlegen stagiaire, maar kijk toch eens hoe je gegroeid bent. En Vanja, ik heb je door de
drukte rond dit proefschrift misschien wat in de steek gelaten de afgelopen maanden. Maar als ik kijk
hoe zelfstandig jij nu werkt, denk ik dat dit uiteindelijk alleen maar positief voor ons is geweest. Ik kijk
er naar uit weer samen met jou nieuwe wetenschappelijke uitdagingen aan te gaan. 
Drie andere collega's die hier zeker genoemd moeten worden, ons klinisch statistisch team, de drie M's,
Maxime Look, Marion Meijer-van Gelder, en Marcel Smid. Ik realiseer mij ten volle dat ik enorm
verwend ben met jullie drie die te allen tijden zo snel reageerden op mijn mailtjes met weer een nieuwe
vraag. Maxime, die zelfs vanuit Australië de een na de andere statistische analyse voor mij deed zodat
ik 's morgens vroeg bij het openen van mijn PC weer de nodige stof tot nadenken kon binnenhalen.
Marion, altijd in voor een gezellig kletspraatje 's morgens vroeg, wat overigens meestal uitliep in
discussies hoe we de klinische aspecten van het onderzoek gedegen konden aanpakken. Waarna jij,
altijd met een positieve instelling, weer met lijsten met vragen van mij aan de slag ging. En Marcel met
zijn kennis van de microarray data, die aan een half woord genoeg had om te begrijpen wat ik nu toch
weer graag zou willen bekijken. Zonder jullie drie was dit proefschrift er echt nooit gekomen.
Laat ik hier nu vooral niet vergeten de mensen te bedanken die nog niet genoemd zijn maar met wie ik
de afgelopen jaren zo prettig en collegiaal op het lab heb gewerkt: Antoinette, Arzu, Berthe, Buddy,
Fons, Iris, Jord, Jozien, Kirsten, Maaike, Marijke, Maurice, en Mieke S.
Tenslotte, zeker meer dan een dankwoord voor mijn vriend en levenspartner, die er altijd was als het
even tegenzat, maar waar ik gelukkig ook altijd samen de goede momenten mee heb kunnen delen en
hoop te blijven delen. Albert, dank je wel voor het begrip dat je toonde als ik toch weer net iets langer
bleef doorwerken als was afgesproken en voor de energie die je erin gestoken hebt om mij op gezette
tijden bij die computer weg te halen. Jij maakt mij compleet.
Direct of indirect hebben jullie er allemaal voor gezorgd dat dit boekje er uiteindelijk is gekomen.
Kortom, dit proefschrift ons proefschrift!

